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General Introduction
Kidney transplantation and rejection 
The treatment of choice for patients with organ failure is transplantation [1]. In 1954 the 
first kidney transplantation was performed with acceptable allograft survival rates [2]. 
Without immunosuppression, immune cells of the patient will recognize the transplanted 
organ as foreign leading to rejection of the graft. Discovery of cyclosporine in the late 
seventies; the drug that suppresses this aggressive immune response, largely contributed 
to the success of organ transplantation. Treatment with cyclosporine significantly decreased 
the incidence of acute rejection episodes leading to acceptable graft and patient survival 
rates. In the 1990s, the introduction of more specific drugs further improved the outcomes 
after organ transplantation. Chronic kidney graft failure is the leading cause of transplant 
loss [3]. An important feature of rejection is deterioration of kidney function reflected by 
increased creatinine levels; i.e. decreased levels of estimated glomerular filtration rate 
and proteinuria. Kidney biopsy remains the golden standard diagnostic tool to confirm 
rejection and provide information that guides treatment [4]. Kidney transplant rejection 
can be subdivided into different categories that are based on histomorphology using Banff 
criteria (Figure 1) [5-12]. First, antibody mediated rejection (ABMR) which is mediated by 
antibodies against HLA and non-HLA molecules, endothelial-cell antigens, and ABO blood-
group antigens on endothelial cells and red blood cells [13] of which there is; acute/active 
ABMR and chronic active ABMR. For diagnosis of acute/active or chronic/active ABMR 
three histomorphological features must/should be present; histologic evidence of acute 
tissue injury, evidence of current/recent antibody interaction with vascular endothelium 
and serological evidence of donor specific antibodies (DSAs) [11]. Second, T-cell mediated 
rejection (TCMR) of which there are also different grades; acute TCMR type IA (significant 
interstitial inflammation with foci of moderate tubulitis), acute TCMR type IB (significant 
interstitial inflammation with foci of severe tubulitis), acute TCMR type IIA (mild intimal 
arteritis with or without interstitial inflammation and tubulitis), acute TCMR type IIB (severe 
intimal arteritis with or without interstitial inflammation and tubulitis) and acute TCMR type 
III (transmural arteritis and necrosis of smooth muscle cells with lymphocytic inflammation). 
Chronic TCMR is defined as arterial intimal fibrosis with mononuclear cell infiltration with 
formation of neointima [11].
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Figure 1. In the abovementioned figure a case of acute cellular rejection is displayed showing negative C4d staining 
(A) and high cellular infiltrates (C). In comparison with a case of acute antibody mediated rejection with strong C4d 
positive staining and mononuclear cell infiltrates in peritubular capillaries (D). Picture is adapted from the renal 
pathology education presentation by dr. Marian Clahsen van Groningen (Pathologist, Erasmus MC, Rotterdam, The 
Netherlands).
Heart transplantation and rejection
Also after heart transplantation rejection of the graft limits its long-term survival, to 
which both acute cellular rejection and ABMR (noncellular, vascular, humoral) significantly 
contribute [14-17]. For the diagnosis of rejection, heart transplant patients receive 
surveillance endomyocardial biopsies that are most frequently performed in the first 
months after transplantation. The International Society of Heart and Lung transplantation 
has a standardized nomenclature grading system for cardiac biopsies, which was introduced 
first in 1990 and revised in 2004. However, sampling error leads to underestimation of the 
severity of rejection [18-21]. The diagnosis of ABMR is based on the following histologic 
features; myocardial capillary with intravascular macrophage accumulation and positive 
immunofluorescence within the capillaries for immunoglobulins (IgG, IgM and/or IgA), 
complement (C4d, C3d, and or C1q), and CD68 macrophage staining [22]. For acute rejection 
three grades are defined; Grade 1R (mild, interstitial and/or perivascular infiltrate with up 
to one focus of myocyte damage), Grade 2R (moderate, two or more foci of infiltrate with 
associated myocyte damage and Grade 3R (severe, diffuse infiltrate with multifocal myocyte 
damage, with or without edema, hemorrhage, or vasculitis) (Figure 2) [21]. 
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Figure 2: The illustrations are adapted from Stewart et al. JHLT, 2005.
Novel mechanisms involved in allograft rejection: The role of monocytes/macrophages 
The contribution of monocytic cells to organ graft rejection has been attracting increasing 
attention. This cell population has been recognized as important players in both acute 
and chronic rejection responses. Monocytes arise from myeloid precursor cells in primary 
and secondary lymphoid organs such as the bone marrow and execute functions in innate 
immunity [23, 24]. These cells are the precursors of macrophages and essential for the first 
line of defense against pathogens. Monocytes can be distinguished into 3 subsets based 
upon CD14 (LPS co-receptor) and CD16 (Fcγ receptor III) expression. Three circulating 
monocyte subtypes can be identified: the CD14++CD16- (classical monocytes), CD14++CD16+ 
(intermediate monocytes) or CD14+CD16++ (non-classical monocytes) [25, 26]. Classical 
monocytes are able to migrate in response to infection or tissue damage, and are released 
in blood in a CCR2-depended manner [27]. Intermediate and non-classical monocytes are 
considered as inflammatory cells, and the non-classical monocytes, specially, are known for 
their patrolling and crawling patterns [28]. CD16+ monocytes can produce pro-inflammatory 
cytokines such as TNF-α and IL-1β. CD16+ monocytes are also associated with development 
of atherosclerosis in chronic kidney disease patients [29]. In the transplantation setting, we 
documented a shift towards proinflammatory CD16+ monocytes in stable kidney transplant 
recipients that was already present at the time of transplantation and remained during the 
first 6 months, despite immunosuppressive regime and improvement of kidney function [30]. 
Macrophages have the capability of differentiating into a variety of phenotypes in response 
to the microenvironment [31]. In transplantation, macrophages are involved in allograft 
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damage, tissue remodeling, and have immunoregulatory and/or immunosuppressive 
effects [32]. Macrophages can also be subdivided into classically (M1) and the alternatively-
activated (M2) subtypes. In response to IFN-γ and after engagement of toll-like receptors 
(TLRs), M1 macrophages display a pro-inflammatory phenotype by expressing high levels of 
the co-stimulatory molecules CD80 and CD86, inducible nitric oxide synthase (iNOS), and by 
production of many pro-inflammatory cytokines like TNF-α, IL-1 and IL-6. M2 macrophages 
display an anti-inflammatory phenotype and are activated in response to IL-4 or IL-13. 
These M2 cells express cell surface markers such as the mannose receptor CD206, the high 
affinity scavenger receptor for the hemoglobin-haptoglobin complex CD163, arginase-1 and 
the anti-inflammatory cytokine IL-10. This macrophage subset is mainly involved in wound 
healing and tissue remodeling [33-36]. 
The first report about the presence of macrophages in rejecting kidney allografts was 
published in 1958 [37]. Macrophage infiltration has been associated with both acute 
antibody mediated rejection and acute cellular rejection [38, 39]. It is also been described 
that infiltration of CD68+ macrophages is associated with acute rejection in human kidney 
and heart allografts [40, 41]. Importantly, intravascular macrophage accumulation in the 
endomyocardial capillaries is now one of the most important diagnostic criteria for antibody 
mediated rejection [21]. The study of Grimm et al. showed that infiltration level of activated 
macrophages discriminates between clinical and subclinical rejection in kidney allograft 
patients [42]. Presence of abundant numbers of macrophages are associated with poor 
graft outcome in kidney and in heart transplantation. Intragraft presence of macrophages 
is also associated with the development of fibrosis [41, 43] in which M2 macrophages 
play a dominant role [44, 45]. Currently, immunosuppressive drugs; i.e. agents that inhibit 
the anti-donor response, can induce CD163+ M2 macrophages that express high levels of 
mRNA coding for pro-fibrotic cytokines such as TGF-β1[46, 47]. CD163+ overexpression 
also correlates with kidney function as measured by serum creatinine levels at 1 year 
after transplantation [48]. Finally, CD16+ monocyte infiltration with smooth muscle like 
characteristics was described during chronic allograft dysfunction, which suggests the 
important role of monocytes in remodeling including neointima formation and formation of 
profibrotic matrix through TGF-β expression [49]. 
Novel mechanisms involved in allograft rejection: microRNAs 
The expression of many genes including those coding for genes involved in rejection 
responses are controlled by microRNAs (miRNAs) which are endogenous, short non-coding 
RNAs [50]Antisense. As a consequence, miRNAs have been widely investigated in transplant 
patients to determine if by the measurement of these small molecules rejection can be 
diagnosed or even predicted. Particularly, because the early and non-invasive detection 
of rejection in transplant patients is warranted. Sui et al. was the first who identified 20 
miRNAs in tissue, which were associated with acute rejection in kidney transplant recipients. 
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This first potential use of miRNA analysis as a diagnostics tool boosted the field and led to 
multiple studies reporting about the outcomes of miRNA studies [51]. A next article reported 
that 10 miRNAs were under expressed and 7 miRNAs overexpressed in acute rejection 
biopsy samples compared to allograft tissue without histological signs of rejection. This 
observation showed that miRNAs studies can be used as a tool to better diagnose rejection 
and to determine the mechanisms involved [52]. In a biomarker discovery study, miR-210 
and miR-10b were identified as specific urinary biomarkers of acute cellular rejection. 
Compared to the urine from stable kidney transplant patients, miR-210 was expressed at 
lower levels, while miR-10b was highly expressed during acute rejection [53]. Scian et al. 
were the first to report on a miRNA signature for chronic allograft dysfunction (CAD) with 
interstitial fibrosis/tubular atrophy (IF/TA). Five miRNAs (miRNA-142-3p, miR-204, miR-107, 
miR-211 and miR-32) were differentially expressed and correlations between tissue samples 
and subsequent urine samples were found [54]. In a small cohort of IF/TA biopsies obtained 
from transplant patients and normal transplant tissue, differential miRNA expression was 
analyzed. In this study, miR-21, miR-142-3p/5p and miR-223 were expressed higher in IF/
TA biopsies whereas miR-30 family members were higher expressed in normal biopsies 
[55]. More recently, Wilflingseder et al. performed a large miRNA profiling study with 65 
renal allograft biopsies and described 4 other miRNAs being associated with acute cellular 
rejection: miR-150, miR155, miR-663a and miR-638. In antibody mediated rejection, six 
upregulated miRNAs were identified including miR-21 and miR-182 [56]. Note that miR-
150 is critical in regulation of B cell development and lymphopoiesis, whereas miR-155 is 
important in CD8+ T cells effecting the regulation of CD8+ T cell responses [57]. Controlled 
and mechanistical studies need to be performed in order to further unravel the role of these 
molecules in the pathogenesis of rejection.
Aims and outline of this thesis
It only has been recently appreciated that cells of the innate immune system such as 
monocytes and macrophages are major players in acute and chronic immunity in organ 
transplantation. These cells contribute to antigen processing, antigen presentation, 
costimulation, production of pro- and anti-inflammatory cytokines, and tissue repair or 
remodeling. The overarching objective of this thesis is to shed light on the role of monocytes 
and macrophages in various types of rejection in both kidney and heart transplantation. 
More explicitly, we aimed to provide evidence that the balance between pro- and anti-
inflammatory monocytes/macrophages can influence the outcome of the anti-donor 
immune response in terms of fibrosis and long-term graft function. We aimed to characterize 
the local distribution of divers monocyte and macrophage subsets in different types of 
rejections in order to search for specific features that could signify the type of rejection. 
Furthermore, the impact of the currently given immunosuppressive drugs on myeloid 
lineage is largely unknown. Therefore, a literature study was performed to gain an overview 
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on the current knowledge and new immunotherapeutic challenges. To better understand 
the mechanisms of rejection, we performed a miRNA study. To these ends, we analyzed 
both biopsy and blood specimens. In detail, the following aims were investigated: 
 3 To determine and correlate monocyte-macrophage profiles in endomyocardial tissue 
with corresponding serial blood samples in heart transplant recipients undergoing 
acute cellular rejection and the relationship with fibrosis– Chapter 2
 3 To determine whether compartmental differences in distribution of monocyte-
macrophage subsets between different types of rejection are present. Infiltration of 
subsets were correlated to serum creatinine and eGFR at the time of biopsy, 3, 6 and 12 
months pre and post-rejection – Chapter 3 
 3 To investigate whether there are essential differences in pretransplant monocyte subset 
composition and whether monocytes could serve as a biomarker to predict kidney 
allograft rejection – Chapter 4
 3 To determine if microRNAs could discriminate between different histopathological 
subtypes of kidney allograft rejection – Chapter 5
 3 To investigate whether human monocytes obtained from renal transplant recipients 
and healthy individuals possess the capacity to produce IFN-γ – Chapter 6
 3 To discuss the effects of currently prescribed immunosuppressive drugs on monocyte - 
macrophage features and the future challenges – Chapter 7
In Chapter 8 and Chapter 9 the above mentioned research will be summarized and discussed.
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CD16+ monocytes and M2 macrophages in heart transplantation
19
2BackgroundDuring acute heart transplant rejection, infiltration of lymphocytes and monocytes is followed by endothelial injury and eventually myocardial fibrosis. To date, no information is available on monocyte-macrophage related cellular shifts and their polarization status during rejection. Here, we aimed to define and correlate monocyte-macrophage endomyocardial tissue profiles obtained at rejection and time-points prior to rejection, with corresponding serial blood samples in 25 heart transplant recipients experiencing acute cellular rejection. Additionally, 33 healthy individuals served as control.Material and MethodsUsing histology, immunohistochemistry, confocal laser scan microscopy and digital imaging expression of CD14, CD16, CD56, CD68, CD80 and CD163 was explored to define monocyte and macrophage tissue profiles during rejection. Fibrosis was investigated using Sirius Red stainings of rejection, non-rejection and one-year biopsies. Expression of co-stimulatory and migration-related molecules on circulating monocytes, and production potential for pro- and anti-inflammatory cytokines were studied using flowcytometry.ResultsAt tissue level, striking CD16+ monocyte infiltration was observed during rejection 
(p<0.001). Significantly more CD68+CD163+ M2 macrophages were documented 
during rejection compared to barely present CD68+CD80+ M1 macrophages. 
Rejection was associated with severe fibrosis in 1-year biopsies (p<0.001). 
Irrespective of rejection status, decreased frequencies of circulating CD16+ 
monocytes were found in patients compared to healthy individuals. Rejection 
was reflected by significantly increased CD54 and HLA-DR expression on CD16+ 
monocytes with retained cytokine production potential.      
Conclusions
CD16+ monocytes and M2- macrophages hallmark the correlates of heart 
transplant acute cellular rejection on tissue level, and seem to be associated with 
fibrosis on the long-term. 
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st
ra
ct
CD16+ monocytes and M2 macrophages in heart transplantation
19
22
Introduction 
During acute cellular heart transplant rejection, infiltration of lymphocytes and monocytes 
is followed by endothelial injury, structural tissue damage and eventually myocardial fibrosis 
[1]. Not only T-cells but also monocyte-/macrophage-lineage cells are abundantly present 
in the rejecting heart [2, 3]. To date, the rejection related monocyte–macrophage subset 
profiles in both tissue and blood compartment are not yet defined in heart transplant 
recipients. It is also unclear whether rejection-related changes of monocyte-macrophage 
subsets on tissue level are reflected in circulation. 
Expression of CD14 (LPS co-receptor) and CD16 (Fcγ receptor III) define three phenotypically 
and functionally distinct human monocyte subsets: CD14++CD16- (classical), CD14++CD16+ 
(intermediate), and CD14+CD16++ (non-classical) monocytes [4]. The CD16+ monocytes are 
considered pro-inflammatory due to production of pro-inflammatory cytokines, like TNF-α 
and IL-1β compared to classical monocytes [4, 5]. Higher expression of HLA-DR, CD86 and 
CD54 (ICAM-1) distinguish CD16+ monocytes from the classical ones. 
Monocytes are important in many inflammatory diseases. Coronary artery disease 
patients have higher numbers of monocytes compared to healthy cohorts [6, 7]. Local 
biphasic monocyte accumulation was observed following acute myocardial infarction [8, 
9]. The monocytes, located in the infarct border zone during the inflammatory phase after 
infarction, consisted mainly of CD14+CD16- cells, whereas during the proliferative phase 
the monocytes in the infarct core showed comparable percentages of CD14+CD16- and 
CD14+CD16+. Different macrophage populations are also observed following myocardial 
infarction with pro-inflammatory cells early on followed by reparative macrophages [8].
Related to the state of activation, macrophages can be functionally grouped into two main 
classes: the M1 (pro-inflammatory) and the M2 (anti-inflammatory), although an increasing 
number of different phenotypes with intermediate and contrasting features have been 
described recently [10]. Classically, the M1 macrophages can be induced after stimulation 
of monocytes with IFN-γ, and mainly have phagocytic, anti-microbial and pro-inflammatory 
functions [11]. On the other hand, M2 macrophages are induced after monocyte-stimulation 
with modulating factors such as IL-4/IL-13, immune complexes, or glucocorticoids, and 
are phenotypically characterized by expression of CD163, CD206, and/or CD204. These 
macrophages exert anti-inflammatory functions by production of IL-10 and TGF-β [12]. M2 
macrophages can also produce matrix metalloproteinases contributing to extra cellular 
matrix turnover and fibrosis [13].
As different monocyte and macrophage subset phenotypes are functionally different in 
induction and/or maintenance of inflammation or fibrosis, it is important to investigate their 
role in relation to heart transplant rejection. This information will eventually help identifying 
key cell types, molecules and markers, which can serve as diagnostic biomarkers of rejection, 
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and/or as targets for rejection treatment. Here, we aimed to define and correlate monocyte/
macrophage profiles in tissue and circulation using endomyocardial biopsies obtained at 
rejection and time points prior to rejection, and their corresponding serial blood samples 
in 25 heart transplant recipients experiencing acute cellular rejection. Next, we wondered 
whether these cellular shifts were associated with structural graft damage and fibrosis. 
Additionally, blood profiles of non-rejecting heart transplant recipients were compared with 
33 healthy individuals using a cross-sectional approach.
Material and Methods
Patient characteristics
Twenty-five heart transplant recipients underwent protocol surveillance biopsies within the 
first year after transplantation at the Erasmus University Medical Center (Rotterdam, The 
Netherlands). Peripheral blood mononuclear cells (PBMC) were collected serially in time: at 
a time point that the protocol biopsy showed no rejection, and subsequently at a time point 
of biopsy-proven rejection (Median time±SEM between both time points: 3±1.4 weeks). 
Additionally, biopsies obtained at 1 year post rejection were used for Sirius Red staining 
(Median time±SEM between rejection and post rejection time points: 56±12.5 weeks). Of 
note, no rejection episodes occurred between the rejection time point and 1 year post-
rejection. Histopathological features were scored according to 2011 and 2005 International 
Society for Heart and Lung Transplantation guidelines in order to diagnose acute antibody 
mediated rejection and acute cellular rejection, and to grade endomyocardial biopsies as 
non-rejection (0R) or rejection (2R) [14, 15]. 
All studied endomycardial biospies (n=50) showed acute cellular rejection (2R according to 
2005 ISHLT classification system) with no signs of histopathologic and immunopathologic 
evidence of acute antibody mediated rejection. All biopsies were C4d negative. Intravascular 
macrophages and neutrophils as well as signs of endothelial injury like swelling and 
denudation with congestion and/or hemorrhage were absent. No serologic evidence of 
anti-HLA antibodies could be detected using Luminex technique. 
This study was performed according to the tenets of the Declaration of Helsinki and approved 
by the Medical Ethical Committee of the Erasmus MC. All patients signed written informed 
consent. Table 1 lists the transplantation characteristics, and the clinical and immunological 
features of this cohort. In addition, blood samples were collected from 33 healthy individuals 
(age: median + range: 51 (25-73); male: 42%) and used as control.
All patients were treated with horse or rabbit anti-thymocyte globulin (hATG or rATG) as 
induction therapy in combination with maintenance calcineurin inhibition (Prograft® or 
Neoral®), mycophenolate mofetil (Cellcept®), and steroids; the dose schedule was adjusted 
according to the local standard protocol. 
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Table 1. Clinical and immunological characteristics of heart transplant recipients
Characteristics Recipients (n=25) 
Age (median (year), range) 46 (15-64)
Gender (% male) 64%
Primary disease (number of patients, %)
Cardiomyopathy 16 (64%)
Ischemic heart disease 9 (36%)
Induction therapy
Horse-antithymocyte globulin 68%
Rabbit-antithymocyte globulin 32%
Maintenance therapy
Cyclosporine/prednisone/mycophenolate mofetil 56%
Tacrolimus/prednisone/mycophenolate mofetil 44%
HLA mismatches total (median, range)
Class I mismatches 3 (2-4)
Class II mismatches 2 (1-2)
Ischemia (median (min), range) 170 (137-250)
Phenotype, activation and co-stimulatory molecule status of monocytes
In order to investigate monocyte phenotype, activation status and co-stimulatory molecules 
(HLA-DR and CD54), PBMC were collected from whole blood using Ficol gradient. Labeling 
and flow cytometric assessment were performed as described before [16, 17]. Monocytes 
were identified based on forward/sideward scatter, lack of expression of CD3, CD20 and 
CD56 and expression of CD14 and CD16 (Figure 1A). 
Intracellular cytokine production
PBMC were incubated overnight with 10 ng/ml LPS (Sigma-Aldrich) in the presence of 
golgiplug (1:1000, Becton Dickinson) after pre-stimulation with IFN-γ for 2 hours. The cells 
were then incubated with conjugated primary antibodies in phosphate buffered saline 
containing 0.5% bovine serum albumine for 30 minutes. The antibodies used were CD3-
PE, CD14-Pacfic Blue, CD16-PE-Cy7, CD20-PE, CD56-PE (all Biolegend) at 4˚C and were 
incubated with EDTA for 15 min followed by incubation with FACS permeabilizing solution 2 
(BD Biosciences) for 15 min. Next, conjugated antibodies to TNF-α-Percp-Cy5.5, IFN-γ-APC-
Cy7, IL-1β-FITC, IL-6-APC, and IL-10-APC and their respective isotype controls (all Biolegend) 
were added to determine intracellular cytokine production. The cells were washed and 
analyzed using flow cytometry (FACSCanto II, BD Biosciences) and FACSDiva software [17].
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Immunohistochemical staining
Immunohistochemistry was performed by an automated staining system (Ventana Benchmark 
ULTRA, Ventana Medical Systems, USA) using horseradish peroxidase (HRP) with brown 
chromogen (3,3'-Diaminobenzidine) as enzymatic label. Tissue sections were incubated with 
antibodies against CD14 (clone 7, mouse-monoclonal IgG2a, 1:100, Leica Biosystems, Newcastle), 
CD16 (clone sc-20052, mouse-monoclonal IgG1, 1:400, Santa Cruz Biotechnology, Dallas, Texas, 
USA), CD56 (clone 123C3, mouse-monoclonal, Ventana, ready to use, Tucson, AZ, USA), CD68 
(clone KP1, mouse-monoclonal, ready to use, DAKO, Carpentaria, CA, USA), CD80 (clone 37711, 
mouse-monoclonal IgG1, 1:50, R&D systems, Minneapolis, USA) or CD163 (clone EDHu-1, 
mouse-monoclonal, IgG1, 1:400, AbD Serotec, Raleigh, USA). Two pathologists independently 
scored these endomyocardial biopsies (EBMs). 
Immunofluorescence staining
Tissue sections were incubated with primary mouse-monoclonal CD14 IgG2a antibody overnight 
at 4° C. Secondary goat-anti-mouse IgG2a Alexa Fluor 488 (Invitrogen) was applied and incubated 
for 1 hour at room temperature (RT). After washing steps, the second primary antibody mouse-
monoclonal CD16 IgG1 was added for one hour. Next the secondary goat-anti-mouse IgG1 Alexa 
Fluor 555 (Invitrogen) was applied for another one hour at RT. Slides were covered with anti-
fading mounting medium containing DAPI (Vectashield, UK) and stored at 4°C until evaluation. 
To distinguish CD16 expressing monocytes from the infiltrating CD16+ NK-cells and CD68+ 
macrophages, CD14/CD16, CD56/CD16 and CD68/CD16 double stainings were performed as 
described above. Double staining with CD68 (1:1600, clone KP1, mouse-monoclonal, DAKO, 
Carpentaria, CA, USA) and CD80 (clone 37711, mouse-monoclonal IgG1, 1:50, R&D systems, 
Minneapolis, USA) were used to characterize M1-type macrophages. For M2 macrophages, 
double stainings were performed with CD68 and CD163 (clone EDHu-1, mouse-monoclonal, 
IgG1, 1:400, AbD Serotec, Raleigh, USA) mAbs. Specific controls are used as displayed in 
supplementary figure 2.
Sirius Red staining
In brief, following deparaffinization slides were rehydrated by passage through decreasing 
ethanol series, 5 minutes predifferentation step using 0,2% fosformolybdeen-acid followed by 
45 minutes incubation with 0,1% Sirius Red solution. Slides were analyzed using polarization 
method. Representative pictures were made under polarized light and positive stained area was 
analyzed by ImageJ software.
Image analyses and Laser Scanning Confocal Microscopy
EMB samples were scored using ImageJ IHC analysis software [18]. Analyses were performed 
blinded to the clinical source using scanned Nanozoomer Digital Pathology files. Images of the 
entire biopsy sample (mean size range: 3,4-3,6 mm) were analyzed at 10x objective magnification. 
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Confocal microscopy was performed using LSM-700 laser scanning confocal microscope 
(Carl Zeiss). The entire biopsy samples were scored counting the absolute number of cells 
as for CD16+CD56-, CD16+CD56+, CD16-CD56+, CD14+CD16-, CD14+CD16+ or CD14-CD16+ 
using 40x magnification. 
Statistical analysis 
Statistical analysis was performed using Graphpad Prism 6. Statistical significance was 
evaluated by Mann-Whitney-U test, t-test, and one-way ANOVA. A p-value of <0.05 was 
considered statistically significant. 
Results 
CD16+monocytes are significantly decreased and CD16- monocytes are significantly 
increased in peripheral blood in heart transplant recipients independent of rejection 
status
We first aimed to investigate how the monocyte subset composition in heart transplant 
recipients would relate to that of healthy individuals. Although the absolute numbers 
of monocytes were similair, the percentages of classical CD14++CD16- monocytes (NR: 
%92±7,5, R: %90±4,5 (median±IQR)) were significantly higher (p<0.05, p<0.001), and the 
percentages of intermediate CD14++CD16+ (NR: %4±1,5, R: %4±3,5 (median±IQR)) and non-
classical CD14+CD16++ monocytes (NR: %3±3,5, R: %3±3,5 (median±IQR)) were significantly 
lower in heart transplant recipients than healthy controls (%83±5,25, %5,5±3,5, %9±4,75 
(median±IQR)) (p<0.001) (Figure 1B-D). Moreover, no subset differences could be detected 
between non-rejection and rejection time points.
Circulating CD3+T cell frequencies were significantly increased during rejection as compared 
with non-rejection time points which is consistent with previous findings [19] (p<0.001) 
(Supplementary Figure 1). 
CD16+ monocytes are significantly increased in rejecting endomyocardial biopsies 
Serial EMBs were stained using double immunofluorescence labeling with CD14 and CD16. 
Co-localization and membranous staining of CD14 and CD16 is shown in rejected tissue 
(Figure 1H). Absolute numbers of stained cells were counted using 20x magnification field 
by confocal microscopy. Considering the fact that mean surface area of the total biopsies 
ranged between 3.4-3.6 mm2, there was no need to correct the data for the size of biopsies. 
Absolute numbers of CD14+CD16- monocytes were significantly higher during rejection 
compared to non-rejection biopsies (p<0.05). Although usually minor subsets in peripheral 
blood, both CD14+CD16+ and CD14-CD16+ subsets were prominantly increased during 
rejection in tissue compared to the prior non-rejection time point (p<0.001, Figure 1E-G). 
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Figure 1. Contrasting monocyte subsets in blood and tissue during heart transplant rejection. 
Representative monocyte subset FACS gating strategy is depicted (A). Blood: The percentage of (B) classical 
CD14++CD16-, (C) intermediate CD14++CD16+ and (D) non-classical CD14+CD16++ monocytes in healthy 
individuals (HI; n=33) and heart transplant recipients (n=25) at time points no rejection (NR) and rejection (R) are 
presented as median±IQR. Tissue: The absolute numbers of (E) CD14+CD16-, (F) CD14+CD16+ and (G) CD14-CD16+ 
monocytes in heart transplant biopsies at time points non-rejection (NR; n=25) and rejection (R; n=25) are given. A 
representative overview of double immunofluorescence stainings of rejected endomyocardial tissue is shown; (H) 
CD14 (green) and CD16 (red) at 10x magnification. Detailed co-localization (H) of CD14 (green) and CD16 (red) is 
shown at 63x magnification. Absolute numbers of cells are depicted. * p<0.05, ** p<0.01, *** p<0.001.
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Figure 2. CD16+ cells in graft tissue are monocytes and accumulate upon rejection. 
The expression of CD14 and CD16 was analyzed in biopsies at two time points; non-rejection (NR; n=25) and 
rejection (R; n=25) and compared intra-individually. The absolute number of cells is depicted for (A) CD14+CD16-, 
(B) CD14+CD16+ and (C) CD14-CD16+. The expression of (D) CD56 was measured using immunohistochemistry, 
analyzed by ImageJ and depicted as mean % positive stained area. The absolute numbers of cells of (E and F) 
CD56+CD16- and CD56+16+ were determined. A representative overview of rejecting endomyocardial tissue 
stained for (G) CD56 (green) and CD16 (red) at 20x magnification is shown. A representative overview of rejecting 
endomyocardial tissue stained for (H) CD14 (green), (I) CD16 (green) and CD68 (red) at 20x magnification is given. 
* p<0.05, *** p<0.001.
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To verify whether CD16+ cells were either CD14+monocyte or CD56+NK-cell or CD68+ 
macrophage, double immunofluorescence stainings were performed using CD16/CD56, 
CD14/CD68 and CD16/CD68 labeling (Figure 2G-I). Individual biopsy analyses showed hardly 
any co-localization between CD56 and CD16 staining (Figure 2G). Intra-individual analysis of 
the monocyte subsets showed high numbers of CD16+ expressing cells at rejection (Figure 
2A-C). Although the simultaneously present CD56+NK cells were very low in absolute 
numbers at rejection compared to non-rejection time points, this difference appeared to 
be statistically significant between these two time points (Figure 2D). The absolute numbers 
of infiltrating CD56-CD16+ cells were significantly higher compared to CD56+CD16- within 
rejecting tissue (p<0.001, Figure 2D-F). Similarly, representative confocal images could hardly 
show co-localization between CD14 and CD16 positive cells with CD68 surface-expression 
using CD14/CD68 and CD16/CD68 double stainings of all biopsies (Figure 2 H-I). Based on 
these data, the CD14-CD16+ tissue pool can be considered as monocytes.
Rejection is reflected by increased expression of HLA-DR and CD54 by CD16+ 
peripheral blood monocytes 
To compare monocyte subsets at functional level, expression of co-stimulatory and 
migration-related molecules by CD16- and CD16+ blood monocyte populations were 
studied in ten patients at non-rejection and rejection time points. The HLA-DR expression 
level was significantly increased on CD16+ monocytes compared with CD16- monocytes 
at both non-rejection and rejection time points (Figure 3A). During rejection, HLA-DR 
expression by CD16+ monocytes was even significantly higher as compared to non-rejection 
time point before. CD16+ monocytes express CD54 at a higher degree compared to CD16- 
monocytes and this CD54 expression was, although statistically not significant, enhanced 
during rejection (Figure 3B). 
Pro-inflammatory cytokine production potential of monocytes in heart transplant 
recipients is preserved and independent of rejection status 
To explore the cytokine production capacity of monocytes in ten heart transplant recipients, 
we preferred to investigate production of pro-inflammatory cytokines IL-1β, IL-6, TNF-α and 
IFN-γ and anti-inflammatory cytokine IL-10 by in vitro experiments after LPS stimulation, and 
compared this with healthy individuals (Figure 3C) because localizing cytokine expression on 
tissue level is generally considered to be associated with a high rate of false positive and false-
negative results. The percentage of IFN-γ producing cells was higher in healthy individuals 
compared with heart transplant recipients (P:0.112), whereas the production potential of 
IL-1β, IL-6, TNF-α and IL-10 was similar between heart transplant recipients and healthy 
individuals. These findings indicate that, despite the use of potent immunosuppressive 
drugs in heart transplant recipients, monocytes still remain capable of cytokine production, 
oftentimes at a similar level as in healthy individuals. 
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Figure 3. Phenotypic and functional characteristics of circulating monocytes in heart transplant recipients 
compared with healthy individuals 
Expression levels of (A) HLA-DR, (B) CD54 (ICAM-1) are increased in CD16+ monocyte pool during rejection 
compared to non-rejection. The percentages of IL-1β, IL-6, TNF-α, IFN-γ, IL-12, and IL-10 -producing monocytes 
of both healthy individual group (n=9-14) and heart transplant recipients (n=10) are shown at both NR and R time 
points after LPS stimulation (C) (Mean±SEM) * p<0.05, ** p<0.01, *** p<0.001.
M2 macrophages increase in rejecting endomyocardial tissue compared to non-
rejection time-point
To explore the type of tissue-infiltrating macrophages, CD68, CD80 and CD163 expression 
was tested using immunohistochemistry, and quantified using ImageJ analysis. A significantly 
increased presence of CD68+ macrophages was detected in rejected tissue compared 
to non-rejected tissue in both grouped and intra-individual analysis (p<0.001, Figure 
4A and D). To investigate whether these macrophages are of M1 or M2 origin, adjacent 
immunohistochemical and double immunofluorescence staining were performed using 
CD68+CD80 (M1) and CD68+CD163 (M2) combinations. Confocal microscopy was used to 
show co-localization (Figure 4K). CD80 was hardly expressed by CD68+ macrophages in the 
endomyocardial tissue (Figure 4B and I). Expression increased, albeit not significantly, with 
rejection, but levels of CD80-expressing cells remained low. In contrast, the vast majority 
of CD68+ macrophages co-expressed CD163 in biopsies of both rejecting and non-rejecting 
tissue (Figure 4C, -F, and -K) showing a significant increase upon rejection.
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Figure 4. M2-type macrophages predominate in transplanted endomyocardial tissue and increase upon rejection.
The expression of (A) CD68, (B) CD80 and (C) CD163 was measured using immunohistochemistry, analyzed by ImageJ 
and depicted as mean % positive stained area. The expression of (D) CD68, (E) CD80 and (F) CD163 was analyzed 
intra-individually at rejection and non-rejection time points. Representative histological and immunohistochemical 
images are shown at 20x magnification (G) HE, (H), CD68, (I) CD80 and (J) CD163. Co-localization of (K) CD68 and 
CD80 (M1 macrophage), and CD68 with CD163 (M2 macrophages) is shown at 40x magnification *** p<0.001.
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Severe persistent fibrosis at rejection which is irreversible over time
To investigate the association between the detected cellular shifts and the degree of fibrosis, 
the positive Sirius Red stained area at non-rejection, rejection and approximately one year 
post-rejection was measured. A significantly increased degree of fibrosis was found at 
rejection compared to non-rejection time point persisting at 1-year post rejection (p<0.001: 
Figure 5B). Fibrosis was mainly localized in interstitium and the perivascular areas showing 
focal collagen accumulation (Figure 5A). 
Figure 5. Severe fibrosis at rejection which is irreversible over time.
Sirius Red staining was used to assess fibrosis. Representative histological images for non-rejection time point (NR; 
1st time point), Rejection time point (R; 2nd time point) and one year post-rejection time point (1-year post rejection, 
3rd time point) are shown at 20x magnification (A). Fibrosis is quantified as mean%positive stained Sirius Red area 
(B) (Mean±SEM) *** p<0.001.
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Discussion 
Here, we present an in-depth analysis of peripheral blood and tissue monocyte/macrophage 
profiles of 25 heart transplant recipients experiencing acute cellular rejection. We found 
contrasting monocyte subset profile in blood and tissue during rejection with prominent 
presence of CD16+ monocytes and M2 macrophages at the tissue level. Increased 
classical monocytes and simultaneously decreased fractions of CD16+ monocytes signify 
the monocyte subset composition in heart transplant recipients compared to healthy 
individuals. No numerical differences were noted between rejection and non-rejection 
conditions. However, rejection was reflected by a significantly increased expression of 
HLA-DR and CD54 within the circulating CD16+ monocyte pool pointing towards a higher 
activation grade, antigen presentation potential, and increased migratory capacity of the 
activated monocytes towards the graft. In line, at tissue level, significantly more CD16+ 
monocytes, especially of CD14-negative phenotype were detected. Also significantly more 
CD68+CD163+ M2 macrophages were documented during rejection. CD68+CD80+ M1 
subtype remained a minute subset. The finding of significantly increased fibrosis at rejection, 
which was also persistently detectable in one year biopsies together with the accumulation 
of CD16+ monocytes and M2 macrophages, indicates an association between these cellular 
shifts in induction of the prolonged damage to the heart transplant tissue.
On tissue level, we detected significantly higher frequencies of CD16+ monocytes in the 
rejecting heart tissue. We showed that CD16+ tissue-infiltrating cells are monocytes as 
hardly co-localization with CD68 and CD56 could be detected ruling out macrophage or 
NK cell phenotype as the cell source. M2 macrophages accumulate increasingly in tissue 
during rejection suggesting that the presence of CD16+ monocytes, with a presumed pro-
inflammatory nature, and anti-inflammatory IL-10 producing M2 macrophages are parts of a 
micro-environmental balance within the endomyocardial tissue. Higher tissue macrophage 
frequencies are known to predict worse graft outcome [20]. Future research is needed to 
investigate monocyte-macrophage profiles during acute antibody mediated rejection.
In figure 6 we attempt to visualize a model based on our data. It is tempting to think that 
preferentially CD16+ monocytes will leave circulation and enter the graft at transplantation, 
causing vasculopathy in due time [21]. Rejection results in an even higher influx of 
activated CD16+ monocytes producing pro-inflammatory cytokines. At the same time, a 
counterbalanced predominance of anti-inflammatory M2 macrophages contribute to the 
remodeling and fibrosis of the damaged heart tissue [22]. 
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In conclusion, although the numbers of included patients in this explorative study are 
limited, fibrosis is investigated by Serius Red stainings and not by cardiac MRI with delayed 
gadolinium pre- and post-rejection, to our knowledge, this is the first report on matched 
serial blood samples and endomyocardial biopsies at time points prior to rejection and 
at rejection. Here, we showed that CD16+ monocytes and M2- macrophages hallmark 
the correlates of acute cellular rejection on tissue level and seem to be associated with 
fibrosis after heart transplant rejection on the long-term. The elucidation of the molecular 
mechanisms underlying these cellular shifts may lead to discovery of new molecular 
biomarkers indicating the immunological graft status, and may help finding new molecular 
targets for specific immunotherapy. 
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Supplementary Materials
Supplementary Figure 1. Peripheral blood 
leukocyte profiles in heart transplant 
recipients compared to healthy individuals 
Percentages of CD3+, CD20+, and CD56+ in 
circulation showed a significantly increased 
number of CD3+ T cells during rejection. *** 
p<0.001.
Supplementary Figure 2. Control tissue stainings. 
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Supplementary Figure 2. Control tissue stainings (continued)
Tonsil and liver tissue: positive controls for CD68, CD80 and CD163 immunohistochemical stainings (A) Tonsil and 
spleen: positive controls for CD14+CD16 immunofluorescence stainings (B). The replacement of the secondary 
antibody by PBS was used as negative control.
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3Monocytes-macrophages have crucial roles in kidney transplant rejection. In this study, compartmental differences in the distribution of monocyte-macrophage subsets between different types of rejection were investigated. 46 kidney transplant biopsies were studied with Banff 2015 diagnosis of chronic, active, antibody-mediated rejection (c-aABMR, n=9), acute, active ABMR (a-aABMR, n=8), acute T cell-mediated rejection type I and II (aATCMRI: n=6, aATCMRII: n=8), and 15 protocol biopsies from recipients with stable kidney allograft function. Infiltrating monocytes were characterized by double immunofluorescent staining with CD14 and CD16. Type 1 and 2 macrophages were identified using immunohistochemistry as follows: CD68+CD80+ (M1) and CD68+CD163+ (M2). Results of immunohistochemistry were correlated to renal function at the time of biopsy and 3, 6 and 12 months post-rejection. The presence of CD68+CD163+ 
macrophages was significantly associated with both the occurrence of rejection 
and worse transplant function after rejection (p=<0.002, p<0.010). With 
regard to compartmental infiltration, glomerular monocyte infiltration and 
CD14+ perivascular monocyte distribution signified c-aABMR in comparison to 
a-aABMR, whereas perivascular infiltration by CD68+CD163+ macrophages was 
correlated to a-aABMR. Comparing a/a ABMR and aATCMRI and II, we found 
significantly more glomerular CD68+CD163+ macrophage infiltration in a-aABMR 
(p=<0.001), perivascular infiltration of mainly CD16+ monocytes (p=<0.001) and 
CD68+CD163+ macrophages (p=<0.001) in aATCMR II, and abundant glomerular 
CD16+ monocyte infiltration in aATCMR I (p=<0.01). Altogether, the presence of 
glomerular and perivascular monocytes and CD68+CD163+ macrophages in the 
tissue is a hallmark of clinical rejection independent of histopathological Banff 
assignment. Ab
st
ra
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Introduction
As early as in 1958 monocytes and macrophages were next to the T cells recognized as the 
dominant cell types infiltrating acutely rejecting grafts, however, this cell lineage was further 
neglected in transplantation research [1-4]. Emerging evidence reveals a crucial role for 
monocyte-macrophage lineage in the pathogenesis of acute and chronic (antibody) rejection. 
Immune regulation, antigen processing and presentation, inflammation, cytotoxicity, 
phagocytosis, response to injury and tissue remodeling comprises the broad spectrum of 
monocyte-related functions [5, 6]. CD68+ mononuclear cells is also associated with the 
degree of kidney transplant dysfunction [7]. Futhermore, glomerular and peritubular 
monocyte infiltration in acute rejection kidney biopsies could predict worse graft outcome 
[8-10]. It is shown that interstitial infiltration including macrophages is regarded as an 
independent predictor of worse graft outcome during acute cellular rejection [8, 11]. Recent 
studies showed that more macrophages are present in biopsies with positive C4d staining in 
peritubular capillaries compared to those with no C4d positivity [12-14]{Mannon, 2012 #44}. 
Another study analysed the renal function of 78 kidney transplant recipients experiencing 
T-cell mediated rejection (TCMR) and found that monocyte infiltration was associated with 
deterioratation of kidney transplant function [7]. 
We previously showed that there is a skewed shift towards circulating pro-inflammatory 
CD16+ monocytes in stable kidney transplant recipients, and that this was still so during 
the first 6 months post-transplant [15]. These monocytes were capable of IFNγ production 
[5]. Furthermore, we have shown that pre-transplant numbers of CD16 + monocytes can 
serve as an early biomarker to predict acute rejection. Also, rejection-related shifts in CD16+ 
monocyte composition between circulation and the rejecting kidney tissue were observed. 
An increased number of pretransplant CD16+ monocytes in blood was associated with a 
significantly higher risk of acute rejection [16].
Diagnosis of rejection relies upon histopathological lesions of an active alloimmune response 
consisting of immune cell infiltration of different renal tissue compartments. These lesions 
are non-specific [17-20]. Banff consensus guidelines have led to a clear improvement of 
diagnostic accuracy [21-23]. However, medical management of clinical rejection depends 
on both clinical judgment and histopathological assessment (24-26). Treatment decisions in 
case of discrepant biopsies are often made based on solely clinical presentations [24]. In 
line, the heterogeneity of clinical expression of ABMR has been a matter of debate sinds 
many years [21]. To reduce these disagreements between clinical and histopathological 
assignments, our field can benefit from incorporation of molecular classifiers into the Banff 
grading system. At the same time the question arises whether our evaluation steps take into 
account the different immune cell types dominating the plethora of tissue damage. As long as 
other immune cells like monocytes and macrophages are not considered, we will still face an 
incomplete evaluation of rejection and may miss diagnostic and therapeutic opportunities.
3
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Based on our previous findings, we hypothesized that there are significant compartmental 
differences in the distribution of monocyte-macrophage subsets between different types 
of rejection which may influence the functional outcome of kidney transplants, and may 
signify distinctive histopathological features specific for different rejection types. We aimed 
to study monocyte-macrophage compartmental infiltration in renal allograft biopsies 
showing different Banff categories. We used double immunofluorescent staining and 
immunohistochemistry techniques to identify monocyte and macrophage subsets on a 
single cell level in the renal allograft and relate these to serum creatinine and eGFR at the 
time of biopsy and 3, 6 and 12 months post indication biopsy.
Materials & Methods
Study population
The compartmental infiltration by monocytes-macrophages was studied in 46 for cause 
kidney transplant biopsies with Banff 2015 categories [21] of either acute T cell mediated 
rejection type I or II (aTCMRI: n=6, aTCMRII: n=8), acute, active ABMR (a-aABMR, n=8), 
chronic, active antibody-mediated rejection (c-aABMR, n=9) and in 15 protocol biopsies 
from recipients with a Banff catergory I and stable kidney allograft function. The biopsies 
were evaluted by a renal pathologist according to the Banff 2015 classification [21]. Clinical 
and transplantation related characteristics were collected, including serum creatinine 
concentrations and corresponding eGFRs according to MDRD formula [25] at the time of 
biopsy and 3, 6 and 12 months post-biopsy (Table 1). Stable biopsies were obtained from the 
study of Shuker et al. with approved medical ethical review board number 2010-080 [26]. All 
patients signed written informed consent. Tissue samples are used according to the Dutch 
Code of Conduct 2011 and according to the decleration of Helsinki. 
Immunohistochemistry, Sirius Red staining and Double-immunofluorescence
These techniques were performed as previously described (29).
Image analysis
Detailed compartmental analyses of kidney biopsy samples stained for CD68, CD80, CD163 
was performed using ImageJ IHC software [27]. Slides were investigated in a blinded fashion 
to the clinical information using scanned Nanozoomer Digital Pathology files. Images of 
the entire biopsy sample (mean size range: 8.5-10.5 mm) were studied at 20x objective 
magnification for mean area precentage positively stained. Selections were made to analyze 
all glomeruli and the average area percentage positively stained was calculated. Perivascular 
compartment analysis was done by selection of all arteries excluding peritubular capillaries. 
Tubulointersitial compartment surface percentage was calculated by excluding glomeruli 
and arteries of the cortical tissue.
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Table 1. Baseline characteristics
Baseline Characteristics Stable grafts (N=15) Rejection (N=31) P-value
Age, mean±SEM, years 53.47±3,6 46.55±2,8 0.154
Gender Recipient: Male, N (%) 11 (73,3) 20 (64,5) 0.560
Ethnicity:  N (%) 0.623
Caucasian 12 (80) 24 (77,4)
Black 2 (13,3) 4 (12,9)
Asian 1 (6,7) 1 (3,2)
Other 0 (0) 2 (6,5)
Primairy kidney disease: N (%) 0.166
Hypertensive nephropathy 8 (53,3) 16 (51,8)
Diabetic nephropathy 2 (13,3) 2 (6,5)
Polycystic kidney disease 3 (20) 1 (3,2)
IgA nephropathy 1 (6,7) 2 (6,5)
Other 1 (6,7) 10 (32)
Creatinine level (µmol/l), mean±SEM
12 months before biopsy 252,66 ± 26,23 239,58 ± 42,73 0.840
6 months before biopsy 290,86 ± 29,02 345,77 ± 57,58 0.525
3 months before biopsy 306,53 ± 36,90 351,09 ± 57,74 0.612
at the time of biopsy (protocol/indication) 131,81 ± 8,86 402,38 ± 58,05 0.002
3 months after biopsy 125,42 ± 7,69 272,16 ± 34,00 0.005
6 months after biopsy 125,85 ± 6,71 294,32 ± 43,90 0.011
12 months after biopsy 127,41 ± 8,5 230,25 ± 22,38 0.003
eGFR (ml/min), mean±SEM
12 months before biopsy 11,80 ± 0,81 37,93 ± 3,73 <0.001
6 months before biopsy 11,93 ± 0,88 28,06 ± 3,73 0.005
3 months before biopsy 9,80 ± 0,65 27,87 ± 3,84 0.002
at the time of biopsy (protocol/indication) 50,26 ± 4,31 21,16 ± 2,54 <0.001
3 months after biopsy 52,66 ± 4,13 30,70 ± 3,56 0.001
6 months after biopsy 51,53 ± 3,89 29,70 ± 3,55 0.001
12 months after biopsy 51,2 ± 3,90 32,70 ± 3,43 0.002
CMV seropositive: N (%) 13 (86,7) 20 (64,5) 0.123
EBV seropositive: N (%) 15 (100) 28 (90,3) 0.222
VZV seropositive: N (%) 14 (93,9) 31 (100) 0.153
HCV seropositive: N (%) 0 (0) 1 (3,2) 0.493
Time on dialysis: mean±SEM 0,53±0,165  2,77±0,395 <0.001
Type of dialysis prior to transplantation: N (%) 0.014
No dialysis 8 (53,3) 3 (9,7)
Hemodialysis 3 (20) 15 (48,4)
Peritoneal dialysis 4 (26,7) 13 (41,9)
Previous kidney transplantation: N (%) 0 (0) 13 (41,9) 0.002
Living kidney donation: N (%) 15 (100) 25 (80,6) 0.070
Delayed Graft function: N (%) 1 (6,7) 7 (22,6) 0.190
Maintenance Therapy: N (%) 0.109
tacrolimus/prednison/cellcept 15 (100) 31 (100)
Basiliximab Induction therapy: N (%) 12 (80) 25 (80,6) 0.594
Peak current PRA %, median (IQR) 0 (0-17) 0 (0-54) 0.707
Peak historical PRA %, median (IQR) 4 (0-57) 2 (0-98) 0.324
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Baseline Characteristics Stable grafts (N=15) Rejection (N=31) P-value
Total number of HLA mismatches: mean±SEM
A 1,13±0,165 0,94±0,139 0.395
B 1,20±0,175 1,23±0,129 0.908
DR 1,27±0,206 1,16±0,115 0.631
Total 3,60±0,412 3,32±0,247 0.546
Return to dialysis after 1 year: N (%) 1 (3,22) 15 (48,4) 0.008
Abbreviations: SEM (standard error of the mean), eGFR (estimated glomerular filtration rate), CMV 
(cytomegalovirus), EBV (Epstein-Barr virus), VZV (Varicella-zoster virus), HCV (Hepatitis C virus), PRA (Panel Reactive 
Antibody) and HLA (human leukocyte antigen).
Laser Scanning Confocal Microscopy
Confocal microscopy was performed using LSM-700 laser scanning confocal microscope 
(Carl Zeiss). The entire biopsy samples (mean size range: 8.5-10.5 mm) were evaluated 
for CD14+CD16-, CD14+CD16+ or CD14-CD16+ cells using 40x magnification. Absolute 
number of CD14+CD16-, CD14+CD16+ or CD14-CD16+ cells were double blind counted. 
Immunohistochemical stainings for overall macrophages, M1 and M2 macrophages were 
analyzed using ImageJ software [27, 28]. 
Statistical analysis
Differences between means were analyzed using either Student’s t-test or the Mann-Whitney 
U test. Univariate analyses was used when multiple groups were compared with Bonferroni 
correction for multiple comparisons. Multivariable analyses were performed to examine 
the relation of monocytes and macrophages with different Banff categories of rejection in 
a multinomial logistic regression. Covariates included donor age, the number of previous 
transplantations, the presence of HLA-DSA, current PRA and the total number of HLA 
mismatches. Two-sided p-values <0.05 were considered statistically significant. Statistical 
testing was performed using RStudio software version 0.99.441 as well as graphpad prism 
software version 5.01.
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Results
Patient and histopathological baseline characteristics 
The clinical characteristics of the renal transplant recipients are shown in table 1. The median 
post-transplantation follow up for stable, a-aABMR, aTCMR I and aTCMR II was 9 months 
(IQR 0.2-13). All indication biopsies were obtained within the first year after transplantation 
except for those showing c-aABMR (median: 61 months, IQR range: 44-91). Banff 2015 
classification of indication biopsies and donor specific antibody (DSA) status at the time of 
rejection are given in table 2. Clinical analyses based on Banff categories showed significant 
inferior transplant function as measured by serum creatinine and eGFR at the time of 
biopsy and 3 , 6 and 12 months post-biopsy in the rejection groups as compared to stable 
controls (p=<0.01, supplementary table 1). Compared to patients with stable graft function, 
patients with biopsy proven rejection had a longer pretransplant dialysis time (p=<0.001) 
and included a higher percentage of patients with multiple previous kidney transplantations 
(p=0.004). Percentage current or historical PRA and the number of HLA mismatches were 
similair between the groups. Graft outcome as defined by return to dialysis one year 
posttransplant was significantly inferior in rejection group compared to those with stable 
grafts (p=0.008). 
Table 2. Banff 2015 categories
In suspicious for c-aABMR group : one of the patients had a c-aABMR (this patient had DSAs and C4d positivity). In 
the suspicious for a-aABMR group the patient with positive DSA showed no C4d positivity in the biopsy. 
Histomorphology C4d positivity DSA
Suspicious for c-aABMR (N=8) 1/8 1/8 (DQ7 and CDC)
Suspicious for a-aABMR (N=9) 5/9 1/9 (DR3 and DR14)
aTCMR grade I (N=6) 0/6 1/6 (DR11)
aTCMR grade II (N=8) 0/8 2/8 (A29,B45,DR6 and B44 DR11)
No abnormalities (protocol biopsies: N=15) 0/15 1/15 (DQ9)
Abbreviations: c-aABMR (chronic active antibody mediated rejection), a/aABMR (acute active antibody mediated 
rejection), aATCMR(acute T cell mediated rejection), DSA (donor specific antibodies). 
The overall presence of monocytes and CD68+CD163+macrophages is significantly 
associated with clinical rejection regardless of Banff category, an univariate analysis
The compartmental distribution of CD14+CD16- (classical), CD14+CD16+ (intermediate) and 
CD14-CD16+ (non-classical) monocytes was analysed by counting the absolute number of 
cells using confocal microscopy. Correction for biopsy size variation was applied according to 
international standard formula [28]. The compartmental distribution of CD68+, CD68+CD80+ 
and CD68+CD163+ macrophages was investigated by calculating the percentage area staining 
using ImageJ analysis (Figure 1A-D, Figure 2A-C). 
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We found significantly more area % staining of classical (median±SEM: 26 ± 4.4 cells), 
intermediate (10 ± 1.5 cells) and non-classical monocytes (31± 4.5 cells) in all biopsies 
demonstrating rejection as compared to stable grafts (6.4 ± 0.6, 3.0 ± 0.8, 1.5± 0.3 cells for 
classical, intermediate and non-classical monocytes, respectively). Intermediate monocytes 
were shown to be the preffered monocyte subset infiltrating the perivascular area (Figure 1D, 
arrows). As no colocalization of CD16+ cell surface expression with CD56 and/or CD68 could 
be found, we exclude the NK cells and macrophages as possible cell source of CD16+ cells and 
regard these CD16+ cells as monocytes [29]. 
With respect to macrophages, a significantly higher precentage of positive stained infiltration 
area by CD68+ (5.4% ± 0.9%) and CD163+ (5.1% ± 0.65%) macrophages was detected in all Banff 
catagories compared to protocol biopies of stable patients (0.74% ± 0.07%, 0.92% ± 0.02%) with 
a trend towards higher numbers of CD68+CD163+ macrophages in TCMRI/II (Figure 2A-B). Of 
note, CD80+ (0.07 %± 0.02%) macrophages were barely present (data not shown).
The overall presence of monocytes and CD68+ CD163+ macrophage infiltration is 
associated with clinical rejection regardless of Banff catagory; a multivariate analysis 
Odds ratios of infiltrating classical (CD14+CD16-), intermediate (CD14+CD16+), and non-
classical monocytes (CD14-CD16+) in different Banff catagories are shown in table 3. All 
monocyte subsets were present in rejection regardless of Banff catagory but not in stable 
grafts. This is in sharp contrast to graft infiltrating T-cells known to be present in protocol 
biopsies of patients with stable kidney function [30]. Other variables included: donor age, 
total number of HLA mismatches, number of previous transplantations, pretransplant donor-
specific HLA antibodies (HLA-DSA), and historical peak panel reactive antibodies (PRAs).
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Figure 2. CD68+CD163+ macrophage infiltration is significantly associated with rejection regardless of Banff 
category.
CD68+ (A) and CD163+ (B) macrophages are analysed using ImageJ and expressed as percentage of positive stained 
area. Individual rejection grades are compared tostable kidney grafts. (C) represents a 5x magnification overview 
example of a ATCMRgrade II showing severe CD68+ infiltration mainly located perivascularly. CD68+ macrophages 
harboured mainly the M2 CD68+CD163+ subset as indicated by immunofluorescent double staining of CD68+ with 
CD163 showing a complete perivascular overlap (magnification 63x). Data are presented as Mean±SEM. * p<0.05, 
** p<0.01, *** p<0.001. 
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The overall presence of CD68+CD163+ macrophages is independently associated with 
rejection regardles of Banff catagory compared to stable grafts (c-aABMR: OR: 21.34 (CI: 
1.57, 289.16), p=0.021), (a-aABMR: OR: 25.20 (CI: 1.84, 344.19), p=0.016), (aATCMR I: 
OR: 27.66 (CI: 2.01, 381.15), p=0.013), (aATCMR II: OR: 29.13 (CI: 2.12, 400.64), p=0.012), 
showing that the CD68+ CD163+ macrophages are a hallmark of clinical rejection (Table 3).
Table 3. Monocytes and CD68+ CD163+ macrophage kidney graft infiltration is independently associated with 
rejection 
Odds ratios of infiltrating classical (CD14+CD16-), intermediate (CD14+CD16+), non-classical monocytes (CD14-
CD16+), macrophages (CD68+) and M2-macrophages (CD163+) in different Banff catagories show significant 
associations with rejection regardless of Banff category compared to stable grafts. Univariate analysis was used 
when multiple groups were compared with Bonferroni correction for multiple comparisons. Multivariable analyses 
were performed to examine the relation of monocytes and macrophages with different Banff categories of rejection 
in a multinomial logistic regression. Covariates included donor age, the number of previous transplantations, the 
presence of HLA-DSA, current PRA and the total number of HLA mismatches. 
c-aABMR HR (CI) P value
Classical monocytes 1.21 (1.06, 1.38) p=0.004
Intermediate monocytes 1.22 (1.03, 1.45) p=0.023
Non-classical monocytes 1.74 (0.98, 3.09) p=0.058
CD68 21.34 (1.57, 289.16) p=0.021
CD163 1.87 (0.93, 3.73) p=0.077
a-aABMR HR (CI) P value
Classical monocytes 1.17 (1.03, 1.33) p=0.018
Intermediate monocytes 1.23 (1.03, 1.45) p=0.019
Non-classical monocytes 1.77 (1.00, 3.15) p=0.050
CD68 25.20 (1.84, 344.19) p=0.016
CD163 2.42 (1.21, 4.86) p=0.013
TCMR I HR (CI) P value
Classical monocytes 1.19 (1.04, 1.35) p=0.010
Intermediate monocytes 1.30 (1.08, 1.55) p=0.004
Non-classical monocytes 1.74 (0.98, 3.08) p=0.059
CD68 27.66 (2.01, 381.15) p=0.013
CD163 2.23 (1.10, 4.51) p=0.026
TCMR II HR (CI) P value
Classical monocytes 1.21 (1.06, 1.37) p=0.005
Intermediate monocytes 1.35 (1.13, 1.61) p<0.001
Non-classical monocytes 1.78 (1.00, 3.16) p=0.049
CD68 29.13 (2.12, 400.64) p=0.012
CD163 3.20 (1.52, 6.75) p=0.002
Abbreviations: OR (Odds Ratio), CI (Confidence Interval 95%)
HR: Hazard ratio, Covariates included: donor age, the number of previous transplantations, the presence of HLA-
DSA, current PRA and the total number of HLA mismatches.
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Glomerular and perivascular infiltration of all monocyte subsets and tubulointerstitial 
infiltration of CD16+ non-classical monocytes are associated with rejection, a 
compartmental analysis
Glomerular, perivascular and tubulointerstitial infiltration of monocytes was analysed 
manually by confocal microscopy. Higher numbers of all monocyte subsets were seen in the 
glomeruli of all Banff categories compared to stable grafts, in particularly during c-aABMR 
compared to a-aABMR and aATCMR I and aATCMR II (p<0.01, p<0.001) (Figure 3 A-D). 
Perivascular infiltration was more pronaounced in all rejection subtypes compared to 
stable garfts, whereas increased amounts of classical monocytes were particularly seen in 
c-aABMR. Perivascular CD16+ monocytes were abundantly present during the aATCMR II 
subtype compared to stable (p=<0.001), and to other rejection subtypes (p=<0.05, p=<0.01) 
(Figure 3 E-H). 
Tubulointerstitial infiltration showed higher counts of CD16+ monocytes in rejection 
catagories compared to stable grafts (p<0.05, p<0.01, p<0.001) (Figure 3 I-L). Nevertheless, 
monocytes were also present in tubulointerstitial compartments of stable grafts while no 
perivascular and glomerular monocyte infiltration was seen.
Monocyte and macrophage infiltration is associated with fibrosis 
Kidney graft infiltration by classical monocytes (OR: 0.01 (CI: 0.01, 0.02), p=0.001), 
intermediate monocytes (OR: 0.02 (CI: 0.01, 0.02), p<0.001) and non-classical monocytes 
(OR: 0.03 (CI: 0.00, 0.05), p=0.030) is significantly associated with % area staining of Sirius 
Red in all Banff rejection catagories compared to stable grafts. In line, CD68+ macrophage 
(OR: 0.12 (CI: 0.03, 0.20), p=0.006) and CD163+ monocytes (OR: 0.08 (CI: 0.01, 0.16), 
p=0.032) tissue infiltration is also significantly associated with % area staining of Sirius Red 
in the rejection groups (Figure 4A-C). 
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Coeﬃcient (95%CI) p-value
Classical Monocytes 0.01 (0.01, 0.02) p=0.001
Intermediate Monocytes 0.02 (0.01, 0.02) p<0.001
Non-classical Monocytes 0.03 (0.00, 0.05) p=0.030
CD68 0.12 (0.03, 0.20) p=0.006
CD80 3.25 (0.51, 6.00) p=0.020
CD163 0.08 (0.01, 0.16) p=0.032
Figure 4
A B
C
Glomerular
Perivascular
Tubulointerstitial
Figure 4. Monocyte and macrophage infiltration is associated with fibrosis 
The presence of different monocyte and macrophage subsets were analysed in different Banff cataegories and 
correlated to the degree of fibrosis as measured by the percentage of positive stained Sirus Red area in these 
biopsies (A-B). (C) represents a 5x magnification overview example of a ATCMRgrade II showing moderate fibrosis. 
Fibrosis was strongly expressed in perivascular or tubulointerstitial area as shown with 20x magnification. Data are 
presented as Mean±SEM. * p<0.05, ** p<0.01, *** p<0.001.
c-a ABMR versus a-a ABMR , a compartmental subset analysis
Glomerular infiltration of all monocyte subsets was significantly higher in c-aABMR compared 
to a-aABMR (p<0.05, p<0.01) (Figure 3A-C and Supplementary figure 1A). Perivascular 
and tubulointerstital infiltration of all monocyte subsets showed no significant difference 
between c-aABMR and a-aABMR (Figure 3E-L and Supplementary figure 1B-C). No significant 
differences was found in glomerular and tubulointerstitial infiltration of macrophages, 
whereas perivascular infiltration of CD68+ CD163+ macrophages predominated in a-aABMR 
(p=<0.01) (Figure 5A-C). 
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Figure 5. Perivascular infi ltrati on of CD68+CD163+ macrophages signifi es a-aABMR and not c-a ABMR
Percentage positi ve stained areas for glomerular CD68+ and CD163+ (A), perivascular CD68+ and CD163+ (B) and 
tubulointersti ti al CD68+ and CD163+ (C) macrophages are analysed using ImageJ. Rejecti on groups are compared 
individually and with stable kidney graft s. (A-C) CD163+ staining represents a 40x magnifi cati on example of 
glomerular, perivascular and tubulointersti ti al infi ltrati on. Data are presented as Mean±SEM. * p<0.05, ** p<0.01, 
*** p<0.001.
a-a ABMR versus ATCMRI &ATCMRII , a compartmental subset analysis
Glomerular infi ltrati on of CD16+ monocytes was signifi cantly higher in aTCMR I compared 
to either aTCMR II or a-aABMR (p=<0.05) (Figure 3A-C and Supplementary fi gure 2A). 
Perivascular infi ltrati on of CD16+ monocytes was signifi cantly higher in aATCMR II compared 
to aATCMR I (p=<0.05) (Figure 3E-G and Supplementary fi gure 2B).Tubulointersti ti al 
infi ltrati on showed no signifi cant diff erence between a-a ABMR and aATCMRI & aATCMRII 
(Figure 3I-K and Supplementary fi gure 2C). Glomerular infi ltrati on of macrophages was 
highly present during a-aABMR compared to stable and aATCMRI/II (Figure 6A). Prominent 
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perivascular infi ltrati on of CD68+CD163+ macrophages hallmarked aATCMRII (p=<0.001) 
(Figure 6B). Strikingly, signifi cantly more infi ltrati ng CD163+ macrophages were found in 
tubulointersti ti al area during aATCMR II (p=<0.05) (Figure 6C). Glomerular CD16+ monocyte 
infi ltrati on hallmarked aATCMR I as perivascular infi ltrati on of CD16+ monocytes and 
CD68+CD163+ macrophages was pronounced in aATCMR II.
Figure 6. Perivascular CD68+CD163+ macrophages hallmarks aATCMRII 
Area percentage positi vely stained for glomerular CD68+ and CD163+ (A), perivascular CD68+ and CD163+ (B) 
and tubulointersti ti al CD68+ and CD163+ (C) macrophages are analysed using ImageJ. Individual rejecti on grades 
compared tostable kidney graft s. Data are presented as Mean±SEM. * p<0.05, ** p<0.01, *** p<0.001.
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CD68+CD163+ macrophage infiltration is significantly associated with loss of 
kidney graft function in the long term     
Classical, intermediate, and non-classical monocytes are not related to a decline in eGFR 
within the fi rst 12 months aft er rejecti on (p>0.05). In contrast, CD68+ macrophage and 
CD163+ macrophage infi ltrati on is signifi cantly associated with an eGFR decline 12 months 
aft er biopsy proven rejecti on (-2.49 (-4.03, -0.95), p=0.002) (Figure 7A).
Figure 7. CD68+CD163+ macrophages are signifi cantly associated with loss of long term renal allograft  functi on 
Classical, intermediate, and non-classical monocytes are not associated with a decline in eGFR 12 months aft er 
rejecti on, whereas CD68+ and CD163+ macrophage infi ltrati on is (A). Graft  outcome was analyzed by dividing the 
rejecti on group into CD68+ or CD163+ low group consisti ng of pati ents with a low CD68+ or CD163+ macrophage 
infi ltrati on (below the median of 2.8 precentage positi ve area) and a CD68+ or CD163+ high group consisti ng of 
high presence of CD68+ or CD163+ macrophages (above the median of 2.8 precentage positi ve area) (B-C).
Rejecti on group was divided into subgroups based on precentage area positi ve staining by 
macrophage subsets: CD68+ low group consisti ng of pati ents with a low CD68+ macrophage 
infi ltrati on (below the median of 2.8 precentage positi ve area) and a CD68+ high group consisti ng 
of high presence of CD68+ macrophages (above the median of 2.8 precentage positi ve area). 
The same strategy was used to subdivide the rejecti on group based on CD163+ macrophage 
infi ltrati on (Figure 7B and C). Higher graft  infi ltrati on of CD68+CD163+ macrohages is signifi cantly 
associated with loss of renal allograft  functi on over ti me in all Banff  rejecti on catagories.
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Discussion
The overall presence of CD68+CD163+ macrophage is significantly associated with clinical 
rejection regardless of type of rejection. Importantly, we observed that the amount of 
CD68+CD163+ macrophages is clearly associated with significantly inferior graft function 
over time. As such, CD68+CD163+ macrophage can be regarded as an independent 
histopathological risk factor for rejection indicating inferior graft survival. Larger validations 
studies also including other changes not considered to be caused by rejection(for example 
BK nephropathy or recurrence of disease) are needed to confirm the clinical relevance of our 
findings. Furthermore, we show significant compartmental differences in the distribution 
of different macrophage and monocyte subsets between c/a ABMR vs. a-aABMR, and a/a 
ABMR vs. aTCMR I and II. These findings may have possible clinical implementation in typing 
and grading of rejection in relation to graft outcome. To date, the Banff grading system 
still needs to refine the diagnostic categories in a more specific way. Our compartmental 
analysis show that glomerular and perivascular infiltration of all monocyte subsets and 
tubulointerstitial infiltration of mainly CD16+ non-classical monocytes are associated with 
rejection. Considering the fact that monocyte lineage cells are also frequently present in 
interstitial compartment of protocol biopsies of stable cohort, we find that the interstitial 
compartmental is not discriminative for rejection. Compartemental infiltration showed 
specific patterns as for example glomerular monocyte infiltration during c-aABMR, prominent 
perivascular presence of CD68+ CD163+ in a/a ABMR and TCRII, and high perivascular CD16+ 
monocyte infiltration in aATCMRII. 
The presence of a T cell infiltrate doesn’t necessarily imply clinical rejection [31-35]. Here, we 
found that the presence of CD68+CD163+ macrophages is associated with clinical rejection 
regardless of Banff rejection category. At the moment, it is not routine standard practice 
to treat sublicincal rejection in all centers. Controversial results are published on benefitial 
outcomes of subclinical rejection treatment with steroids [32, 34, 36]. One can envision that 
a histopathological feature, such as CD68+CD163+ macrophage, which is directly linked to 
clinical rejection and worse graft outcome, would help to answer these questions. 
Several findings of this explorative study are in line with previously reported research 
results. As we found high numbers of M2 type macrophages in aTCMR II, increased numbers 
of CX3CR1+ CD68+ macrophages were detected in acute tubuointerstitial and acute vascular 
rejection biopsies in comparison to normal protocol kidney graft biopsies. CX3CR1+CD68+ 
macrophage infiltrates were associated with an inferior graft outcome one year post-
transplantation. CX3CR1 is a chemokine receptor which is mainly expressed on monocytes 
and macrophages [37]. Glomerular presence of monocytes and macrophages has been 
related to severe histopathological kidney graft injury with deleterious consequences for 
the graft function. Tinckam et al. described that a close correlation between peritubular 
C4d staining and glomerular monocyte infiltrates [38]. Moreover, cases of severe glomerular 
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endothelial injury associated with monocyte/macrophage-rich infiltrate in patients receiving 
alemtuzumab as induction therapy have been described [39-41]. A recent study showed that 
CD68+ macrophages are strongly linked to ABMR and T-cell mediated rejection. In this study, 
glomerular CD68 expression was reported as a surrogate marker for ABMR accompanied 
by higher Ki67 expression which is a cell proliferation marker, indicating that infiltrating 
macrophages act as ongoing triggers of alloimmune inflammation and subsequent graft 
injury [42].
Limitation of the presented proof of concept study is small numbers, but results are intriguing 
with a potential for clinical implementation in typing and grading rejection in relation to 
graft outcome. Addition of monocyte and macrophage markers to recently discovered and 
applied molecular microscope diagnostic system has the potential to assist in précising 
Banff histopathological categories (15). Further research on underlying mechanisms and 
compartmental specific distribution patterns of macrophages and monocytes will allow 
us to develop new therapeutic targets and specific treatments options in order to combat 
acute and chronic allograft injury. 
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Supplementary Figure 1. Glomerular infi ltrati on of all monocyte subsets and perivascular infi ltrati on of mainly 
CD14+ monocytes denotes c-aABMR 
Classical (A), intermediate (B) and non-classical (C) monocytes are manually counted in the glomeruli, perivascular 
or tubulointersti ti ti al compartement using confocal laser microscopy. Individual rejecti on grades are compared to 
stable kidney graft s. Data are presented as Mean±SEM. * p<0.05, ** p<0.01, *** p<0.001.
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Supplementary Figure 2. Glomerular CD16+ monocyte infi ltrati on hallmarks ATCMRI and perivascular infi ltrati on 
of CD16+ monocytes hallmarks ATCMRII
Classical (A), intermediate (B) and non-classical (C) monocytes are manually counted in the glomeruli, perivascular 
or tubulointersti ti ti al areas using confocal laser microscopy. Individual rejecti on grades are compared to stable 
kidney graft s. Data are presented as Mean±SEM. * p<0.05, ** p<0.01, *** p<0.001.
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4Acute rejection is one of the major immunological determinants of kidney graft function and survival. Early biomarkers to predict rejection are lacking. Emerging evidence reveals a crucial role for the monocyte-macrophage lineage cells in the pathogenesis of rejection. We hypothesized that higher pre-transplant numbers 
of proinflammatory CD16+ monocytes can predict rejection. The study cohort 
consisted of 104 kidney transplant recipients (58 no-rejections and 46 biopsy-
proven rejections), and 33 healthy individuals. Posttransplant median±IQR follow 
up time was 14.7 (0.3-34) months. Pretransplantation blood samples were analyzed 
by flow cytometry for monocyte immunophenotypes. Groups were compared by 
Cox regression models for the occurrence of acute rejection. We documented 
a significantly increased absolute number of pretransplant CD16+ monocytes in 
patients who developed biopsy proven rejection after transplantation compared 
to no-rejections and healthy individuals (Hazard Ratio [HR], 1.60; 95% Confidential 
Interval [CI], 1.28 to 2.00; p<0,001 and HR, 1.47; CI, 1.18 to 1.82, p<0,001). In 
parallel, significantly less absolute numbers of CD16- monocytes were observed 
at pretransplant time point in rejectors vs non-rejectors (HR, 0.74; CI, 0.58 to 0.94; 
p<0,014). A higher pre-transplant number of CD16+ monocytes is significantly 
associated with a higher risk of acute rejection after kidney transplantation. Ab
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Introduction 
Extensive research on short and long-term kidney graft fate has repeatedly shown that the 
occurence of rejection, regardless of the type and timing, significantly worsens the graft 
survival and function [1-3]. The golden standard diagnostic proof for acute rejection is renal 
biopsy which is an invasive, time consuming technique comprising a risk of bleeding and 
even graft loss [2]. At present, no clinically applicable biomarkers are available to predict 
rejection. As T cells are directly involved in the pathogenesis of rejection, a large body of 
data on T cell related biomarker research exists. Unfortunately, none of them could find their 
way to clinical practice as yet [4-6]. The low specificity of current diagnostic factors remain 
a major hurdle to be routinely used to discriminate differential diagnostic possibilities like 
rejection or infection.
Recenst advances in the field of molecular biology extending from genomics to proteomics 
and metabolomics have opened new possibilities to search for early rejection biomarkers 
in solid organ transplantation [7-9]. mRNA encoding cytotoxic proteins like granzyme B, and 
FOXP3 in urinary cells have been extensively investigated in prospective clinical trials [10-
14]. Reversal of acute rejection could be predicted with 90% sensitivity and 73% specifity 
using urinary FOXP3 mRNA [12]. Urinary chemokines CXCL-9 and CXCL-10 were markedly 
elevated during acute rejection or BK infection [15, 16]. Sui et al. identified 12 upregulated 
and 8 downregulated miRNAs which are differentially expressed in acute rejection compared 
to normal kidney tissue [17]. Anglicheau et al. reported 10 upregulated miRNAs and 7 
downregulated miRNAs in acute rejection biopsies compared to stable kidney graft tissue 
[18]. Increased levels of donor-derived cell-free DNA were found during acute rejection at 
a very early stage [19]. Suhre et al. found a composite mRNA signature consisting of 18S 
ribosomal RNA, CD3ε mRNA, and interferon-inducible protein-10 with a specificity of 84% 
and a sensitivity of 90% in diagnosing acute rejection [20]. Using micro-arrays, a five gene-
set was classified to diagnose acute rejection with 91% sensitivity and 94% specificity which 
needs further validtion [21, 22]. A top-20 gene signature involving proliferation of B and CD4 
T cells, and inhibition of CD14 monocyte related functions was shown to identify tolerant 
patients with almost 92% accuracy [23, 24]. 
Although, as early as in 1958 monocyte-macrophages were next to T cells recognized as 
the dominant cell types infiltrating acutely rejecting grafts, biomarker research in this area 
has lagged behind [25]. The heterogeneity and plasticity of the monocyte-macrophage-
dendritic cell lineage have been obstacles to translate the functional relevance to 
diagnostic and prognostic clinical biomarkers. A new approach is to focus on the monocyte/
macrophage lineage cells as emerging evidence reveals a crucial role for this cell line in the 
pathogenesis of rejection associated with worse outcome [26-28]. Monocyte-macrophage 
lieange cells have a number of roles in the rejection process: Immune regulation, antigen 
processing and presentation, inflammation, cytotoxicity, phagocytosis, response to injury 
4
Chapter 4 Pre-transplant CD16+ monocytes as a novel biomarker
6564
4
and tissue remodelling [29-31]. Glomerular and peritubular monocyte infiltration in acute 
rejection kidney biopsies could predict worse graft outcome [32-34]. In another study, 
increased infiltration of an activated population of macrophages could discriminate between 
clinical and subclinical kidney transplant rejection [35]. Furthermore, monocyte infiltration 
has been positively associated with the degree of kidney transplant dysfunction [36]. 
Circulating monocyte subsets can be characterized as classical (CD14++CD16-), intermediate 
(CD14++CD16+) and non-classical (CD14+CD16++). CD16+ monocytes are known to produce 
high amounts of TNF-α and IL-1β, and therefore are considered as highly pro-inflammatory 
[37-39]. CD16+ monocytes have unique functions in angiogenesis, production of reactive 
oxygen species and patrolling behaviour [37, 40-42]. Moreover, the intermediate CD16+ 
monocytes have been associated with the development of atherosclerosis in patients with 
chronic kidney disease [43-46]. 
We hypothesized that there are essential differences in pretransplant monocyte subset 
composition between patients with allograft rejection and with no rejection, in particular 
with regard to pretransplant proinflammatory CD16+ monocyte numbers. In that case, 
pretransplant numbers of CD16 + monocytes could serve as an early biomarker for acute 
rejection after kidney transplantation. To this end, we investigated the pretransplant monocyte 
immunophenotypes in a study cohort consisting of 104 kidney transplant recipients. Of the 
included patients, 58 developed biopsy proven rejection within the first 24 months after 
transplantation, and 46 patients remained free of any rejection episodes with a median±IQR 
follow up time of 14.7 (0.3-34) months. 33 healthy individuals served as control. 
Methods
Population information
One hundred and four patients who had undergone renal transplantation between 2007 
and 2012 were studied. Peripheral blood mononuclear cells (PBMC) were isolated from 
heparinized blood using Ficoll-Hypaque density gradient (Lymphoprep™) and stored at −150°C 
until analysis. From this cohort 58 patients were selected who remained free of rejection 
and 46 patients who developed biopsy-proven acute rejection. 33 healthy individuals served 
as control. Additionally, we performed a pilot case-control study to investigate monocyte 
subset composition in blood, and to relate these findings to the same variables at tissue 
level in case of an acute rejection compared to 6 patients with stable graft function were 
served as control. To this end, the PBMC were serially obtained from 6 rejecting kidney 
transplant recipients at the time of transplantation and at the time of biopsy proven acute 
rejection (T-cell mediated rejecton type IA) . Six stable kidney transplant recipients served as 
control with blood samples obtained at exactly the same corresponding time points. Table 
1 lists the transplantation characteristics and the clinical and immunological features of the 
cohort. 20% of no acute rejection group and 13% of rejection group received basiliximab 
Chapter 4 Pre-transplant CD16+ monocytes as a novel biomarker
6564
4
induction therapy No induction treatment is given in all other cases. All patients received 
same maintenance immunosuppressive regimen consisting of a calcineurin inhibitor; 
tacrolimus (Prograft®), Mycophenolate Mofetil (Cellcept®), and prednisolone. Prednisolone 
was tapered to zero according to local standard protocol during the first four months after 
transplantation if no rejection was detected. Delayed graft function post transplantation 
was defined as the need for continuing dialysis due to insufficient kidney transplant 
function. Rejection was diagnosed by for cause biopsies. No rejection was defined by a 
stable transplant function. We don’t perform protocol biopsies at our centre. Biopsy proven 
acute rejection was defined according to the Banff criteria 2015. All patients signed written 
informed consent. The Medical Ethical Committee approved the study (Blood samples: MEC 
number 2010-080, MEC-2007-228, and patients with 6 rejecting biopsy samples: EudraCT 
2010-018917-30). 
Table 1. Baseline Characteristics of Kidney Transplant Recipients 
No Acute Rejection (N = 58) Acute Rejection (N = 46) P Value
Gender Recipient 0.828
     Male (%) 75.5 70.83
Age, mean±SEM, years 50±1,87 53±2,14 0.245
Ethnicity -- no. (%) 0.635
     Caucasian 47/58 (81) 40/46 (87)
     Black 11/58 (19) 5/46 (11)
     Asian 0/58 (0) 1/46 (2)
Primary kidney disease -- no. (%) 0.636
     Diabetic nephropathy 10/58 (17) 7/46 (15)
     Polycystic kidney disease 10/58 (17) 6/46 (13)
     Glomerolonephritis 5/58 (9) 7/46 (15)
     Hypertensive nephropathy 17/58 (29) 16/46 (35)
     Reflux disease/chronic 1/58 (3) 4/46 (9)
     Other 15/58 (25) 6/46 (13)
CMV seropositive -- no. (%) 37/58 (63) 24/46 (52) 0.155
Previous Kidney Transplantation -- no. (%) 5/58 (8) 11/46 (24) 0.053
Patients not on dialysis -- no. (%) 18/58 (31) 12/46 (26) 0.668
Time on dialysis -- mean (range) -- yr 1.0 (0-9) 1.0 (0-17) 0.068
Living kidney donation -- no. (%) 45/58 (77) 38/46 (82) 0.877
Delayed graft function -- no. (%) 5/58 (8) 10/46 (21) 0.075
Basiliximab Induction therapy -- no. (%) 12/58 (20) 6/46 (13) 0.403
Percent current PRA %, median (IQR) 0 (0-4) 0 (0-4) 0.395
Percent historical PRA %, median (IQR) 0 (0-0) 0 (0-48) 0.013
Positive DSA  -- no. (%) 1/58 (1) 2/46 (1) 0.429
Total no. HLA mismatches -- mean±SEM 2.5±0.20 2.80±0.18 0.526
     HLA class I mismatches  1.44±0.15 1.59±0.17 0.998
     HLA class II mismatches  1.10±0.14 1.10±0.09 0.412
Outcome after 1 year -- no. (%) 0.012
     Functional graft 55/58 (94) 39/46 (84)
     Back to RRT 2/58 (3) 9/46 (19)
CMV: cytomegalovirus, RRT: renal replacement therapy,  PRA: panel reactive antibody, IQR: interquartile range, 
HLA: human leucocyte antigen, DSA: Donor Specific Antibodies
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Monocyte phenotype
Monocytes were identified based on forward/sideward scatter, lack of expression of CD3, 
and lack of expression of CD20 and CD56. Subsequently, they were characterized by the 
expression of CD14 and CD16 as described before (Supplementary Figure 1) [47]. 
CD14 and CD16 double immunofluorescence stainings of rejection-biopsies
Immunofluorescence stainings were performed using double indirect labeling. In brief, 
following fixation with acetone, slides were blocked with normal goat serum 10% (Jackson 
ImmunoResearch). Primary mouse-monoclonal CD14 IgG2a antibody was incubated 
overnight at 4°C. Secondary goat-anti-mouse IgG2a Alexa Fluor 488 (Invitrogen) was applied 
for 1 hour at room temperature (RT). To minimize non-specific binding, goat-anti-mouse Fab 
fragment (Jackson ImmunoResearch) was applied for 30 minutes at RT. After washing steps, 
the second primary antibody mouse-monoclonal CD16 IgG1 was added for one hour. Next, 
the secondary goat-anti-mouse IgG1 Alexa Fluor 555 (Invitrogen) was applied for another 
one hour at RT. Following washing steps, the slides were covered with anti-fading mounting 
medium containing DAPI (Vectashield, UK) and stored at 4°C until evaluation. 
Confocal microscopy was performed using LSM-700 laser scanning confocal microscope 
(Carl Zeiss). The entire biopsy samples (size range: 4-5 cm) were evaluated for presence of 
CD14+CD16-, CD14+CD16+ or CD14-CD16+ cells using 40x magnification. 
Statistical analysis
Differences between means were analyzed using the Student’s t-test or Mann-whitney 
U test as appropriate. Both univariate and multivariate analysis were performed to study 
the relation between the absolute numbers of different monocyte immunophenotypes at 
pretransplant time point and the occurrence of biopsy proven acute rejection (Table 2). 
Univariate analysis was performed when multiple groups were compared, and corrected 
using Bonferroni test for multiple comparisons. Multivariate analysis was performed using 
other immunological variables and covariates to examine the relation with acute rejection 
in Cox proportional hazards regression analysis. Covariates used include donor age, total 
number of HLA mismatches, number of previous transplantations, pre-transplant donor-
specific HLA-antibodies (HLA-DSA), and historical peak PRA. Crude and adjusted hazard ratios 
(HRs) for rejection-free time were calculated using Cox proportional hazards regression. 
Two sided P values <0.05 were considered statisitically significant. Statistical analysis was 
performed using the RStudio software version 0.99.441. 
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Table 2. Hazard Ratios for the absolute number of monocytes in relation to acute rejection
Univariable OR (95% CI) P value  Multivariable OR (95% CI)α P Value
Absolute number of Classical 
Monocytes (per 150/µl) 0.74 (0.58, 0.94) 0.014 0.73 (0.57, 0.94) 0.016
Absolute number of Intermediate 
Monocytes (per 50/µl) 1.60 (1.28, 2.00) <0.001 1.63 (1.28, 2.07) <0.001
Absolute number of Non-classical 
Monocytes (per 50/µl) 1.47 (1.18, 1.82) <0.001 1.46 (1.16, 1.85) 0.002
Absolute number of CD16+ 
Monocytes (per 50/µl) 1.27 (1.03, 1.57) 0.013 1.26 (1.01, 1.57) 0.038
α Multivariable Cox Regression analysis with covariates included were number of HLA mismatches, age, delayed 
graft function, previous transplantation, and current PRA percentage. OR: Odds Ratio, CI: Conficence Interval, HLA: 
human leucocyte antigen, DSA (donor specific antibodies), PRA: panel reactive antibody
Results 
Kidney transplant recipient characteristics
The clinical and immunological characteristics of the kidney transplant recipients are 
shown in Table 1. Posttransplant median±IQR follow up time was 14.7 (0.3-34) months. The 
median age for the group with no rejection or the group with rejection was 50 or 53 years, 
respectively. 77% were living donor kidneys while in the rejector group 82% of kidneys were 
from living donors (p=0.87). Total numbers of human leukocyte antigen (HLA) mismatches 
were not different between both groups (p=0.52). Both groups showed no significant 
difference in the numbers of previous transplantions (p=0.05). No statistically significant 
difference was noted with regard to the occurrence of delayed graft function between two 
groups (p=0.07). Historical peak percent panel reactive antibody (PRA) was significantly 
higher in rejectors (p=0.01). All observed acute rejection episodes occurred within the first 
24 months after transplantation with the majority of rejection incidence within the first 
year posttransplant (44/46). Rejection were classified according to the latest Banff 2015 
classification (Supplementary Table 1.). Patients with loss of graft function were returned to 
dialysis (p=0.03). 
High pretransplant numbers of CD16+ monocytes are associated with biopsy 
proven acute rejection 
At pretransplantation, significantly higher absolute numbers (Figure 1A) and precentages 
(Figure 1B) of both intermediate CD14++CD16+ and non-classical CD14+CD16++ monocyte 
subsets were detected in the rejector group compared to non-rejectors and healthy 
individuals (p=<0.05). Concordantly, the absolute numbers of classical (CD14++CD16-) 
monocytes were significantly lower in rejectors compared to non-rejectors (p=<0.001) and 
healthy controls (p=<0.01). These findings may refer to a higher pro-inflammatory set point 
in the monocytic system at pretransplant time point in kidney transplant recipients who 
develop acute rejection after transplantation during the follow up time.
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The hazard ratios of absolute numbers of intermediate (1.60, CI: 1.28 to 2.00; p<0.001) 
and non-classical monocyte subsets (1.47, CI: 1.18 to 1.82, p<0.001) indicate that higher 
pretransplant absolute numbers of CD16+ monocytes significantly increase the risk of 
rejection, and is associated with significantly shorter rejection-free survival time (p=<0.001). 
Conversely, classical monocytes showed a hazard ratio of 0.74 (CI: 0.58 to 0.94; p<0.014) 
pointing towards an inverse relationship between the absolute number of classical monocytes 
and the rejection-free survival time; the higher the number of classical monocytes the lower 
the risk of acute rejection.
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Figure 1. Higher absolute numbers of pretransplant intermediate and non-classical CD16+ monocytes are 
significantly associated with rejection 
(A) Absolute pretransplant numbers of monocyte subsets in rejectors, non-rejectors and healthy individuals. (B) 
FACS percentages of pretransplant monocyte subsets in rejectors, non-rejectors and healthy controls. Posttransplant 
median±IQR follow up time of 14.7 (0.3-34) months. *p<0.05, **p<0.01, ***p<0.001.
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Higher absolute pretransplant numbers of CD16+ monocytes are associated 
with shorter rejection free survival while higher absolute numbers of classical 
monocytes are associated with longer rejection free survival 
Kaplan-Meier acute rejection free survival curves were extracted for tertiles of classical 
(Figure 2A), intermediate (Figure 2B) and non-classical monocytes (Figure 2C). Differences 
between survival curves were analyzed using log-rank test between the highest and the 
lowest tertile. A higher cumulative rejection incidence was associated with the lowest tertile 
of absolute numbers of classical monocytes in pretransplant patient’s sample, while higher 
tertiles relate were associated with a lower rejection risk (Chisq=6.1, p=<0.05). In contrary, 
higher tertiles of absolute numbers of both intermediate (Chisq=9.6, p=<0.01) and non-
classical (Chisq=6.4, p=<0.05) CD16+ monocytes in pretransplant patient samples were 
associated with a significantly higher rejection risk.
Transplant tissue infiltration by CD16+ monocytes at rejection; a pilot case-control 
study 
We studied subset composition of circulating monocytes in patients experiencing biopsy 
proven acute cellular rejection at two time points; i.e. at the time of transplantation and at 
the time of biopsy (before start of treatment). As controls, blood samples were obtained from 
age and sex matched non-rejecting stable patients at the same corresponding time points. 
Figure 3A representative demonstration of monocytes subsets in patients with rejection 
(n=6) and patients with no-rejection (n=6) at pretransplantation and rejection-matched time 
points. In the group with no rejection, no numerical differences were detected in monocyte 
subsets between these two time points. Whereas, in the group with rejection the CD16+ 
monocytes were significantly increased in pretransplant specimens as compared with 
monocytes from patients with no rejection. Intriguingly, frequencies of CD16+ monocytes 
were significanly decreased in peripheral blood at the time of rejection (p=<0.05) pointing 
towards the possibility of migration of pro-inflammatory CD16+ monocytes to the rejecting 
kidney. In line, extensive tubulo-interstitial infiltration of CD14+CD16+ monocytes was 
detected in graft tissue during rejection (Figure 3B). 
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Figure 2. Higher absolute pretransplant numbers of CD16+ monocytes are associated with higher rejecti on risk 
while higher absolute numbers of classical monocytes are associated with lower rejecti on risk 
Kaplan Meier survival curves for acute rejecti on free survival and the incidence of acute rejecti on aft er kidney 
transplantati on on strati fi cati on for the absolute numbers of classical (Chisq=6.1 p=<0.05), intermediate (Chisq=9.6 
p=<0.01) and non-classical monocytes (Chisq=6.4 p=<0.05). Absolute numbers of classical monocyte subsets were 
subdivided into terti les (high [479-947/µl], intermediate [341-479/µl] and low [52-341/µl]). Absolute numbers of 
intermediate monocyte subsets were subdivided into terti les (high 6.02-8.13/µl], intermediate [5.0-6.02/µl] and 
low [2,3-5,0/µl]). Absolute numbers of non-classical monocyte subsets were subdivided into terti les (high [5.64-
8.10/µl], intermediate [4.81-5.64/µl] and low [2.32-4.81/µl]). Diff erences between survival curves were analyzed 
using log-rank test between the highest and the lowest terti le.
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Pre-transplant Matched time point
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88,7%
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11,3%
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Figure 3. Transplant ti ssue infi ltrati on by CD16+ monocytes at rejecti on; a pilot case-control study 
(A) Representi ve FACS fi gure showing the diff erence in CD16+ monocyte subsets between non-rejectors and 
rejectors at pretransplantati on and at rejecti on-matched ti me points. (B) Overview of double immunofl uorescency 
stainings analyzed with confocal laser scan microscopy showing large tubulo-intersti ti al infi ltrates of CD14+CD16+ 
monocytes at respecti vely 10x and 40x magnifi cati on. 
Chapter 4 Pre-transplant CD16+ monocytes as a novel biomarker
7372
4
Discussion
A major clinical challenge is the lack of biomarkers to predict rejection in kidney 
transplantation. In this study, we tested the hypothesis whether pretransplant numbers 
of proinflammatory CD16+ monocytes could predict acute rejection risk after kidney 
transplantation. We found that patients who developed acute rejection after transplantation 
possesed higher absolute numbers of CD16+ monocytes at the time of transplantation 
as compared to patients with no rejection. On the other hand, high numbers of classical 
monocytes pretransplant were significantly associated with lower rejection risk. In a pilot 
case-control study, we showed abundant accumulation of CD16+ monocytes at rejection 
in kidney graft tissue with a concomitant decrease of the absolute number of circulating 
CD16+ monocytes in peripheral blood. These findings indicate a migratory shift of CD16+ 
monocytes from the circulation towards the rejecting tissue.
Monocytes/macrophages have shown their potential value as biomarkers in several 
diseases [26, 31, 48-52]. Recently, we documented a skewed shift towards pro-inflammatory 
CD16+ monocytes in stable kidney transplant recipients which was already present at the 
time of transplantation and retained during the first 6 months posttransplant despite 
immunosuppressive therapy and a significant improvement of kidney function [47]. These 
monocytes were capable of IFNγ production [53]. Many studies have tried to identify the 
type and the function of injury-related monocytes in kidney transplant recipients and 
also in patientes with chronic renal failure undergoing dialysis. CD163 overexpression on 
circulating monocytes was shown to be useful in prediction of transplant function after 
kidney transplantation. CD163 over-expression seemed to significantly correlate with serum 
creatinine values 1 year after transplantation [54]. This subpopulation is involved in regulating 
the production of anti-inflammatory cytokines by macrophages. Recently, graft infiltration 
by CD16+ monocytes with smooth muscle cell like characteristics was documented during 
chronic transplant dysfunction, which suggests tissue remodeling including neointima 
formation in transplant arteries and formation of a pro-fibrotic matrix via TGF-β expression 
[55]. Patients with chronic renal failure undergoing dialysis have been shown to possess 
expanded CD14+CD16+ monocyte pools with production of proinflammatory cytokines like 
IL-1β, TNFα and IL-6 [56, 57]. Other studies showed that haemodialysis leads to temporary 
removal of monocytes in the pheripheral blood followed by the reappearance of activated 
CD14+CD16+ monocytes [58]. Although more detailed knowledge is now available with 
regard to phenotype and function of different subtypes of monocytes, no information 
regarding the molecular signature and functional roles of the monocyte subsets in relation 
to distinct acute and chronic rejection types is known as yet. Advances in genomics and 
proteomics will help to answer these open questions, to define the nature of monocyte 
subset in the context of disease, and to move the diagnostic, prognostic, and therapeutic 
biomarker discovery field forward. 
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This report describes a proof of principal study indicating the feasibility of CD16+ monocytes 
pretransplant number as a predictive marker for rejection. Here, we report on a novel concept 
of (CD16+) monocyte as a crucial immune cell type participating in the pathogenesis of 
rejection showing measurable subset differences before transplantation between patients 
who will develop rejection and patients who will remain free of rejection. Interestingly, at 
the time of rejection a measurable decrease in circulating CD16+ monocyte subset was 
paralleled by an increase in tissue infiltrating CD16+ monocytes implying a migration towards 
inflamed graft. On the other hand, these results should be confirmed in a larger prospective 
blinded validation fashion, as there are limitations and cautions. The studied population 
was selected based on available blood samples. Although almost equally distributed, a part 
of study population [4/5 (80%) of no rejection group and 8/11 (72%) of rejection group 
was re-transplanted, had a graft in situ and used immunosuppressive medication. All these 
parameters could have an effect on circulating monocyte subsets and numbers, which 
need to be taken into account in a future validation study. Next, we want to investigate 
the specificity of this finding by including more diagnostic groups in the future like patients 
with BK nephropathy, DGF, CMV infection, and urinary tract infections. Altogether, our 
data point out that higher pretransplant numbers of CD16+ monocytes are associated with 
significantly higher rejection risk, shorter rejection free survival, and may serve as an early 
biomarker to predict acute rejection after kidney transplantation. A calculated cut-off value 
of 23.5/µl CD16+ monocyte numbers pretransplant could have a sensitivity of 90% to detect 
the population at risk for rejection. Conversely, higher numbers of CD14+CD16- monocytes 
are significantly associated with no-rejection outcome. Interestingly, the absolute numbers 
of CD14+ monocytes can be measured using CD14+ beads offering a simpel, cheap and fast 
immunological monitoring tool for future validation studies. 
Furthermore, next-step research is warranted to investigate the value of monocyte subset 
monitoring in risk stratification and personalized optimization of immunosuppressive 
treatment as one of the cornerstones of posttransplant clinical work-up of kidney transplant 
recipients.
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Supplementary Table 1. Banff 2015 classification of biopsy proven rejections
Rejection type No. (%) 
aABMR I  3/46 (6,52)
aABMR II  1/46 (2,17)
aABMR III  1/46 (2,17)
TCMR IA  12/46 (26,08)
TCMR IIA  14/46 (30,43)
TCMR IB  4/46 (8,69)
TCMR IIB  5/46 (10,86)
TCMR III  1/46 (2,17)
C4d+ Status 6/46 (13,08)
Other  5/46 (10,86)
Other: Bordeline TCMR (2/46), acute tubular necrosis (3/46) 
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5MicroRNAs are important regulators of gene expression. The dysregulation of some microRNAs in kidney tissue has been associated with kidney transplant rejection. Here, we aimed to investigate whether kidney microRNA expression profiles could discriminate between the different histopathological rejection types. The microRNA expression levels were determined in total RNA isolated from 31 fresh 
frozen kidney biopsies derived from kidney transplant patients suffering from 
different forms of rejection. 8 patients displayed chronic active antibody-mediated 
rejection (c-aABMR), 9 presented with acute active antibody-mediated rejection 
(a-aABMR), 6 with T cell-mediated rejection type 1 (aTCMR I), and 8 with T cell-
mediated rejection type 2 (aTCMR II). To investigate related pathways microRNA 
data was analyzed using Ingenuity software. Patients with a-aABMR could be 
distinguished from patients experiencing aTCMR by 55 differentially expressed 
microRNAs (p=<0.01), while patients with a-aABMR could be discriminated from 
c-aABMR by 5 differentially expressed microRNAs (p=<0.01). Pathway analyses 
indicated associations between these microRNAs and the inflammatory response 
network. Our exploratory study identifies microRNA signatures discriminating 
a-aABMR from aTCMR, and a-aABMR from c-aABMR. Further validation studies 
are needed to confirm these data in larger clinically and histopathologically well-
defined patient cohorts. Ab
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Introduction
The use of microRNAs (miRNAs) as diagnostic biomarkers for rejection processes after 
kidney transplantation receives increasing attention. There is a clear unmet clinical need 
for the development of minimally invasive biomarkers that not only signal rejection but are 
also capable to distinguish between the different forms of rejection. The latter is particularly 
important as renal transplant recipients with different rejection types have a different 
prognosis and require different treatment modalities. Acute and chronic rejection are still 
one of the strongest negative prognostic factors associated with worse kidney transplant 
survival and function[1-3]. Currently, the diagnosis of rejection relies on a kidney transplant 
biopsy which comes with a potential risk of bleeding[4]. Molecular biology advances 
extending from genomics to proteomics and metabolomics have led to new possibilities 
to search for early surrogate markers for rejection in solid organ transplantation[5-8]. 
Urinary mRNA encoding cytotoxic proteins like granzymes, and other markers like FOXP3, 
OX-4, OX40L, PD1, PD-L1 or PD-L2 have been extensively investigated in clinical trials with 
promising results[9-18]. Unfortunately, none of these biomarkers has yet found its way into 
clinical practice. One of the reasons is the low biomarker specificity to discriminate rejection 
processes from infection which forms a major hurdle in their routine clinical use.
MiRNAs are small, noncoding RNAs with a length of 18 to 24 nucleotides. They fulfill an 
important role in gene expression regulation by binding in the context of the RNA induced 
silencing complex (RISC) to the 3’UTR of target mRNAs. MiRNA binding results in mRNA 
degradation and/or translation inhibition[19]. miRNAs display a tissue specific expression 
that can be severely deregulated in disease. This and the fact that they are stable present and 
easily detectable, not only in tissue but in body fluids like blood, urine and saliva make them 
highly suited as biomarker[20, 21]. MiRNAs affect most – if not all – cellular biochemical 
processes and play critical roles in the modulation of innate and adaptive immune responses. 
In the field of transplantation, Sui et al. were the first to identify 20 kidney tissue miRNAs 
which were differentially expressed during acute rejection after transplantation as compared 
to biopsies from transplanted kidneys that show no rejection[22]. Another study reported 
on 10 miRNAs to be underexpressed and 7 miRNAs overexpressed in acute rejection tissue 
samples compared to normal kidney transplant tissue. Their potential utility as rejection 
biomarkers was emphasized by miR-142-5p and miR-155 as ROC analyses indicated 100% 
sensitivity and 95% specificity for both of these miRNAs[23]. Urinary miR-210 downregulation 
and miR-10b upregulation were identified as specific urinary biomarkers for acute cellular 
kidney transplant rejection[24]. Scian et al. reported on a specific miRNA signature for 
chronic allograft dysfunction with interstitial fibrosis/tubular atrophy (IF/TA) compared to 
normal allograft tissue; five miRNAs were shown to be differentially expressed including 
miRNA-142-3p and miRNA-32 which were upregulated, and the downregulated miRNA-107, 
miRNA-211 and miRNA-204. A characteristic miRNA signature for IF/TA that correlates with 
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paired urine samples was identified[25]. miRNA profiles were studied in IF/TA biopsies of 
transplant patients and compared to normal surveillance biopsies showing that higher 
expression levels of miRNA-21, miRNA-142-3p/5p and miRNA-223 could be detected in IF/
TA biopsies whereas miRNA-30 family members were expressed more abundantly in normal 
surveillance biopsies[26]. Of note, miRNA-21 is also found upregulated in a wide variety 
of oncological and cardiovascular disorders[27, 28]. MiRNA-21 promotes cell proliferation, 
migration, invasion and also apoptosis. Danger et al. showed miRNA-142-5p to be a specific 
biomarker for chronic antibody mediated rejection in PBMCs and biopsy samples of renal 
transplant patients as well as for the state of immunological tolerance[29],[30]. More 
recently, Wilflingseder et al. performed a large miRNA profiling study involving 65 renal 
allograft biopsies and identified seven significantly upregulated miRNAs in patients with 
delayed graft function including miRNA-21. In acute cellular rejection, 4 miRNAs (miRNA-150, 
miRNA-155, miRNA-663a and miRNA-638) where shown to be significantly upregulated. In 
antibody mediated rejection, six upregulated miRNAs were identified including miRNA-21 
and miRNA-182[31]. Note that miR-150 is critical in regulation of B cell development and 
lymphopoiesis, whereas miRNA-155 is an important mediator of T-cell proliferation and 
CD8+ T cells cell responses[30].     
In the present study, we aimed to investigate whether microRNAs can discriminate 
between different histopathological types of kidney allograft rejection. To this end we used 
a microarray profiling platform to determine miRNA expression profiles in 31 fresh frozen 
kidney biopsies (8 chronic active antibody mediated rejection, 9 acute active antibody 
mediated rejection, 6 acute T-cell mediated rejection type I, and 8 acute T-cell mediated 
rejection type II). Furthermore, using bioinformatic approaches we mapped biochemical 
pathways that are affected by selected miRNAs to identify potential biomarkers and new 
therapeutic targets.
Materials & Methods
Study population                 
Standard clinical and transplantation related characteristics were collected, as well as serum 
creatinine concentrations and corresponding eGFRs according to MDRD formula[32] at the 
time of biopsy (Table 1). Tissue samples are used according to the Dutch Code of Conduct 
2011 and according to the declaration of Helsinki. For-cause kidney transplant fresh 
frozen biopsies with Banff 2015 categories of chronic, active antibody-mediated rejection 
(c-aABMR, n=8), acute, active ABMR (a-aABMR, n=9), acute T cell mediated rejection type I 
and II (aTCMR I: n=6, aTCMR II: n=8) were used for microarray experiments[33],[34]. 
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Table 1. Clinical characteristics 
c-aABMR a-aABMR TCMR I TCMR II
Number of patients 8 9 6 8
Age, mean±SEM, years 50 ± 6,6 39 ± 3,2 53 ± 8,0 50 ± 4,2
Ethnicity -- n (%)
Caucasian 7 (87,5%) 6 (66,7%) 5 (83,3%) 6 (75%)
Black 0 (0%) 3 (33,3%) 0 (0%) 1 (12,5%)
Asian 1 (12,5%) 0 (0%) 1 (16,7%) 1 (12,5%)
Other 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Gender Recipient: Male, n (%) 6 (75%) 5 (55,55%) 3 (50%) 6 (75%)
Living kidney donation -- n (%) 7 (87,5%) 8 (88,8%) 5 (83,33%) 5 (62,5%)
Primairy kidney disease -- n (%)
Hypertensive nephropathy 4 (50%) 6 (66,7%) 3 (50%) 3 (37,5%)
Diabetic nephropathy 0 (0%) 1 (11,1%) 0 (0%) 1 (12,5%)
Polycystic kidney disease 1 (12,5%) 0 (0%) 0 (0%) 0 (0%)
IgA nephropathy 0 (0%) 1 (11,1%) 0 (0%) 1 (12,5%)
Other 3 (37,5%) 1 (11,1%) 3 (50%) 3 (37,5%)
Type of dialysis prior to transplantation -- n (%)
Pre-emptive 2 (25%) 0 (0%) 1 (16,7%) 0 (0%)
Hemodialysis 3 (37,5%) 7 (77,8%) 2 (33,3%) 3 (37,5%)
Peritoneal dialysis 3 (37,5%) 2 (22,2%) 4 (66,6%) 5 (62,5%)
Time on dialysis -- years, mean±SEM 0,87 ± 0,32 4,33 ± 0,81 2,00 ± 0,43 3,00 ± 0,19
Total no. HLA mismatches -- mean±SEM 2,75 ± 0,59 3,56 ± 0,29 3,83 ± 0,65 3,25 ± 0,49
Peak current PRA %, median (IQR) 0 (0-0) 0 (0-33) 0 (0-0) 0 (0-54)
Peak historical PRA %, median (IQR) 0 (0-13) 4 (0-96) 0 (0-10) 4 (0-98)
Maintenance Therapy  -- n (%)
prograft/prednison/cellcept 6 (75%) 6 (66,7%) 3 (50%) 7 (87,5%)
tacrolimus/prednison/cellcept 2 (25%) 3 (33,3%) 3 (50%) 1 (12,5%)
Basiliximab Induction therapy -- n (%) 4 (50%) 7 (77,8%) 2 (33,3%) 2 (25%)
Previous kidney transplantation -- n (%) 3 (37,5%) 6 (66,7%) 1 (16,7%) 3 (37,5%)
Delayed Graft function -- n (%) 2 (25%) 2 (22%) 1 (16%) 3 (38%)
Time point of biopsy postTX in days (mean±SEM) 1975 ± 505 284 ± 259 111 ± 62 357 ± 128 
Creatinine level (µmol/l, mean±SEM
       Time of biopsy (protocol/indication) 212 ± 25 548 ± 131 297 ± 76 506 ± 137 
eGFR (ml/min), mean±SEM
       Time of biopsy (protocol/indication) 30 ± 3 18 ± 6 17 ±  4 17 ± 4
Creatinine/Protein Ratio (mg/mmol), mean±SEM
       Time of biopsy (protocol/indication) 581 ± 362 2541 ± 1542 129 ± 86 114 ± 61 
Return to dialysis after 1 year -- n (%) 2 (25%) 2 (22,2%) 3 (50%) 3 (37,5%)
Abbreviations: c-aABMR (chronic active antibody mediated rejection), a-aABMR (acute active antibody mediated 
rejection), aTCMR (acute T-cell mediated rejection type I or II), HLA (human leucocyte antigen), PRA (percent 
reactive antibody), SEM (standard error of the mean), IQR (interquartile range), postTX (post-transplantation), 
eGFR (estimated glomerular filtration rate).
MicroRNA profiling
RNA isolation from fresh frozen biopsy specimens was performed at Exiqon Services, 
Denmark. The quality of the total RNA was verified by an Agilent 2100 Bioanalyzer profile. 
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400 ng total RNA from both sample and reference (snoRNAs and snRNAs including U6) 
was labeled with Hy3™ and Hy5™ fluorescent tags, respectively, using the miRCURY LNA™ 
microRNA Hi-Power Labeling Kit, Hy3™/Hy5™ (Exiqon, Denmark) following the procedure 
described by the manufacturer. The Hy3™-labeled samples and a Hy5™-labeled reference 
RNA sample were mixed pair-wise and hybridized to the miRCURY LNA™ microRNA Array 
7'th GEN (Exiqon, Denmark), which contains capture probes targeting all microRNAs for 
human registered in miRBASE version18.0. The hybridization was performed according to 
the miRCURY LNA™ microRNA Array Instruction manual using a Tecan HS4800™ hybridization 
station (Tecan, Austria). After hybridization the microarray slides were scanned and stored 
in an ozone free environment (ozone level below 2.0 ppb) in order to prevent potential 
bleaching of the fluorescent dyes. The miRCURY LNA™ microRNA Array slides were scanned 
using the Agilent G2565BA Microarray Scanner System (Agilent Technologies, Inc., USA) 
and the image analysis was carried out using the ImaGene 9.0 software (BioDiscovery, Inc., 
USA). The quantified signals were background corrected (Normexp with offset value 10, see 
Ritchie et al. 2007 [35]) and normalized using the quantile normalization method.
MicroRNA target and pathway analysis: 
Targeted genes of differentially regulated miRNAs were further analyzed using Ingenuity 
Pathway analyses (Ingenuity, USA), with respect to their molecular function, associated 
biological processes, and subcellular location. 
Statistical analysis
Statistical analysis of microArray data was performed using R version 3.2.2 and BRB-
ArrayTools Version 4.4.1. Data were analyzed by univariate- and Two-sample T-test. Nominal 
significance level of each univariate test was set at 0.01. Since the nature of this study is 
exploratory we did not run extensive multiple testing corrections.
Results
Baseline characteristics of rejecting kidney transplants   
Standard clinical and transplantation related characteristics were collected as well as the 
serum creatinine concentrations and eGFR according to MDRD formula (Table 1)[36]. The 
median follow up time for a-aABMR, TCMR I and TCMR II was 9 months (IQR 0.2-13). All 
rejections were diagnosed within the first year after kidney transplantation with exemption 
of c-aABMR (median: 61 months, IQR: 44-91). MicroRNA expression profiles were studied in 
31 for-cause kidney transplant biopsies with Banff 2015 categories[33] of either acute T cell 
mediated rejection type I or II (aTCMRI: n=6, aTCMRII: n=8), acute, active ABMR (a-aABMR, 
n=9), or chronic, active antibody-mediated rejection (c-aABMR, n=8). As we do not perform 
standard protocol biopsies for patients with stable kidney transplant function in our center, 
we were unable to investigate those microRNA profiles.
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MicroRNA profiling of different Banff rejection categories 
Figure 1 shows the unsupervised clustering of the top 50 most variable expressed microRNAs. 
Here, it is clear that the different subtypes already show some different expression patterns. 
Next, we analyzed the differences in microRNA expression profiles between a-aABMR vs. 
aTCMRI and aTCMRII, and between a-aABMR vs. c-aABMR.
Figure 1. MicroRNA profiling of different histopathological subtypes of rejection
The heatmap was produced using the top 50 variably expressed microRNAs. The color scale illustrates the relative 
expression level of the indicated microRNA across all the samples, (red) expression <0.28, (green) expression >0.28.
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Significantly differentially expressed microRNAs between a-aABMR and aTCMR I/II
Microarray analysis identified 55 significantly differentially expressed microRNAs between 
a-aABMR and aTCMRI/aTCMRII; p-values <0.01 (Figure 2A, B and Table 2). Among the top 
5 differentially expressed microRNAs we observed an upregulation of hsa-miR-99a-5p (Fold 
Change (FC): 2.2, p=0.00094) and downregulation of hsa-miR-4756-3p (Fold Change: -2.1, 
p=0.0001944), hsa-miR-4290 (FC: -1.6, p=0.000524), hsa-miR-1284 (FC: -1.6, p=0.0011) 
and hsa-miR-4303 (FC: -1.3, p=0.0012) in a-aABMR compared to aTCMRI/aTCMRII. These 
55 differentially expressed microRNAs between aTCMR and a-aABMR were analyzed using 
Ingenuity Pathway analysis, and were characterized as genomic mediators in pathways 
involved in inflammatory diseases, inflammatory responses, protein synthesis, cellular growth 
and proliferation processes. One network is displayed in Figure 3 and molecules identified in 
this network are linked to their microRNAs (Figure 3 and Supplementary Table 1).
Table 2. Significantly differentially expressed microRNAs between a-aABMR and aTCMR I/II
miRNA Fold Change adjusted P-value
hsa-miR-4756-3p -2.165 0.0001944
hsa-miR-4290 -1.606 0.000524
hsa-miR-99a-5p 2.219 0.0009458
hsa-miR-1284 -1.606 0.0011456
hsa-miR-4303 -1.333 0.001228
hsa-miR-4778-3p -1.29 0.0013518
hsa-miR-1972 -1.273 0.0013659
hsa-miR-3184-3p -1.442 0.0014167
hsa-miR-877-3p -1.659 0.0015449
hsa-miR-4300 -1.315 0.0018098
hsa-miR-4646-3p -1.471 0.0019378
hsa-miR-320a 1.722 0.002107
hsa-miR-550b-3p -1.327 0.0024474
hsa-miR-320b 1.581 0.0024878
hsa-miR-4538 -1.54 0.0026582
hsa-miR-4454 1.734 0.0026636
hsa-miR-22-3p 2.049 0.0026906
hsa-miR-3183 -1.621 0.0029419
hsa-miR-5002-5p -1.406 0.0034821
hsa-miR-1976 -1.42 0.0037172
hsa-miR-3920 -1.248 0.0037711
hsa-miR-214-3p 1.814 0.0039018
hsa-miR-210 1.564 0.0039767
hsa-miR-4326 -1.193 0.004058
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miRNA Fold Change adjusted P-value
hsa-miR-320c 1.599 0.0043812
hsa-miR-4728-3p -1.607 0.0045045
hsa-miR-4286 3.004 0.0049026
hsa-miR-3124-3p -1.548 0.0050548
hsa-miR-1285-5p -1.633 0.0053395
hsa-miR-138-2-3p 1.847 0.0054998
hsa-miR-144-3p 4.03 0.0057715
hsa-miR-4743 -1.461 0.005934
hsa-miR-151a-3p 1.469 0.0060134
hsa-miR-5096 -1.46 0.0060656
hsa-miR-2114-5p -1.294 0.0063726
hsa-miR-4328 2.153 0.006618
hsa-miR-145-5p 2.143 0.0073292
hsa-miR-100-5p 1.68 0.007891
hsa-miR-17-3p 1.311 0.0082762
hsa-miR-139-5p 1.489 0.0082949
hsa-miR-4451 -1.765 0.0083672
hsa-miR-654-5p -1.402 0.008576
hsa-miR-4722-3p -1.223 0.0087056
hsa-miR-23b-3p 2.512 0.0087352
hsa-miR-4797-5p 2.1 0.0088696
hsa-miR-1236 -1.824 0.0090253
hsa-miR-650 -1.3 0.0094688
hsa-miR-377-3p 1.408 0.0095252
hsa-miR-4804-3p -1.459 0.0095933
hsa-miR-144-5p 1.231 0.0096551
hsa-miR-423-3p 1.533 0.0097147
hsa-miR-28-3p 1.224 0.0097947
hsa-miR-644b-3p -1.313 0.0099017
hsa-miR-584-5p -1.391 0.0099344
hsa-miR-191-5p 1.879 0.0099896
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Figure 2. Differentially expressed miRNAs in acute active antibody mediated rejection versus acute T 
cell mediated rejection type I/II
(A) represents heatmap of expression values of significant miRNAs. Centered and scaled values are 
indicated as light blue expression <-0.8 and dark blue expression >0.7. Yellow line indicates different 
histomorphological group; a-aABMR (left) and aTCMR (right). (B) Volcano plot showing FC (log
2
 values) 
and p-value (log
10
 values) for the 55 microRNAs of interest comparing a-aABMR and aTCMR I/II.
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Significantly differentially expressed genes between a-aABMR and c-aABMR.  
Microarray analysis identified 5 significantly differentially regulated microRNAs between 
a-aABMR and c-aABMR as tested by univariate testing and p-values <0.01 (Figure 4A, B and 
Table 3). Among the 5 differentially expressed microRNAs, we detected an upregulation of 
hsa-let-7f-1-3p (FC: 1.1, p=0.0038), hsa-miR-3679-3p (FC: 1.4, p=0.0099) and downregulation 
of hsa-miR-664-5p (FC: -1.2, p=0.0013), hsa-miR-3591-5p (FC: -1.5, p=0.0058) and hsa-
miR-4268 (FC: -1.5, p=0.0072) in a-aABMR biopsies compared to c-aABMR biopsies.
Figure 4. Differentially expressed miRNAs in acute active antibody mediated rejection versus chronic active 
antibody mediated rejection
(A) represents heatmap of expression values of significant miRNAs. . Centered and scaled values are indicated as 
light blue expression <-0.9 and dark blue expression >0.8. Yellow line indicates different histomorphological group 
a-aABMR (left) and aTCMR (right). (B) Volcano plot showing FC (log
2
 values) and p-value (log
10
 values) for the 5 
microRNAs comparing a-aABMR and aTCMR.
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Table 3. Significantly differentially expressed genes between a-aABMR and c-aABMR
miRNA Fold Change adjusted P-value
hsa-miR-664-5p -1.272 0.0013678
hsa-let-7f-1-3p 1.182 0.0038045
hsa-miR-3591-5p -1.597 0.0058369
hsa-miR-4268 -1.582 0.0072596
hsa-miR-3679-3p 1.484 0.0099494
Discussion
In this study, we compared miRNA expression profiles detected in biopsies from transplanted 
kidneys displaying different types of rejection (a-aABMR vs. aTCMR and between a-aABMR 
vs. c-aABMR). Furthermore, pathway analyses were performed to search for the target 
genes, and to elucidate the contributions of specific miRNAs in the rejection process. We 
identified 55 differentially expressed miRNAs between a-aABMR and aTCMR. The microRNAs 
found in this study are all part of immune and inflammation pathways which again shows 
the dominant role of these pathways in the anti-donor response. These pathways are 
particularly active in immune cells such as lymphocytes, monocytes – macrophages, NK 
cells and dendritic cells. These cells are all involved during rejection of the allograft. Clearly, 
larger cohorts including samples showing no signs of rejection are needed to validate these 
findings, and to determine the association of specific miRNAs with either rejection type, i.e. 
antibody mediated rejection or T cell mediated rejection.
The rapid technological advances enabling in depth investigations of the human genome 
and particularly microRNAs, also affects the field of transplantation immunology[22, 23, 
25, 26, 37]. In order to better define differences in alloimmune inflammatory responses 
underlying different types of rejection, a molecular approach should be used. Here, we 
found large differences in miRNA expression profiles between a-aABMR and aTCMR related 
kidney biopsies, whereas less pronounced differences were found between a-aABMR and 
c-aABMR biopsies. Particularly the expression of microRNA-100-5p was different between 
a-aABMR and aTCMR. miRNA-100-5p reached one of the highest fold change expression 
levels abundantly present in kidney transplant tissue showing acute active antibody 
mediated rejection compared to acute cellular rejection. It is known that this miRNA is 
involved in the regulation of adhesion molecule CD209 (DC-SIGN). The functional interaction 
between miRNAs-100-5p and CD209 should be investigated in future studies[38, 39]. The 
majority of the infiltrated myeloid dendritic cells express CD209 leading to activation of the 
T-cells[39]. Woltman et al. tested the reliability of DC-SIGN as a rejection marker performing 
double immunostaining experiments for DC-SIGN/BDCA-1 on fresh frozen kidney transplant 
samples. Although the effect of kidney DCs on allograft survival has not been defined 
completely, a prior study has shown that DCs density in rejecting allograft biopsies could 
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predict kidney transplant dysfunction[38]. DCs density was also able to predict poor allograft 
survival independent of clinical variables[40]. Given these findings, one can envision that 
manipulation of miRNA-100-5p expression and/or function can potentially be used to affect 
DC-SIGN function in rejecting kidney transplants.
Also miRNA-145-5p interacts with many cellular functions such as cell growth, cell 
proliferation, cell differentiation and apoptosis[41-43]. MiRNA-145-5p is expressed by 
different types of immune cells such as CD4+ and CD8+T-cells, and CD19+ B-cells[44]. 
MiRNA-145-5p has been directly related to the synthesis of TGF-B1 (transforming growth 
factor beta 1), VASN (vasorin), DDR1 (discoidin domain receptor tyrosine kinase 1), PADI1 
(peptidyl arginine deiminase 1) and TP53 (tumor protein p53, and regulates the production 
of SMA (smooth muscle actin), TAGLN (transgelin) and ACTG2 (acta gamma 2). TGF-B1 has 
been demonstrated to affect kidney transplant survival in many ways. TGF-B1 is not only 
involved in tissue regeneration but can also act as an immunosuppressive factor repressing 
anti donor cellular immune responses[45, 46]. DDR1 is found to be one of the new mediators 
in chronic kidney disease as it modulates inflammatory cell recruitment, and is indirectly 
linked to smooth muscle actin, ECM deposition and fibrosis in renal disease in general[47, 
48]. Vasorin together with lumican have been identified in plasma of patients with diabetic 
nephropathy. Soluble lumican protein core can bind LPS-mediated proinflammatory effects 
in macrophages[49]. 
As in many gene expression and in particular miRNA studies, the cell source of the detected 
discriminating miRNAs cannot be defined as yet unless in situ hybridization studies on 
formaline fixated parrafine imbedded corresponding kidney biopsies from the same patients 
are performed. Clearly, different kidney resident cell types contain a broad range of miRNAs, 
all with their unique targets and functions. Therefore, specificity and interpretation of kidney 
biopsy derived miRNAs is still a hurdle to be taken. Studies are ongoing at the moment to 
determine the cell source of the identified microRNAs of interest by in situ hybrydization. 
In order to understand the full biological impact of particular miRNAs, further identification 
of their mRNA targets in necessary as well as the cellular pathways in which they function. 
Without any doubt, this knowledge will be essential to point out the discriminating 
checkpoints during different rejection type processes. Clinically, this information is very 
useful as the treatment modalities and prognosis differ between various rejection types. 
Nevertheless, the clear differentially expressed microRNA profiles between different types 
of rejection, as demonstrated in this study, emphasize again the high potential of these 
small RNAs as biomarkers for post-transplant immunological injury and kidney transplant 
outcome.
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6Representing a crucial T-helper 1 cytokine, IFN-γ acts as an important bridge between innate and adaptive immunity and is involved in many acute and chronic pathologic states, such as autoimmune diseases and solid organ transplant rejection. At present, debate still prevails about the ability of human monocytes to produce IFN-γ. We aimed to investigate whether human monocytes possess 
the capacity to produce IFN-γ at mRNA and protein level. Using real time PCR, 
flow cytometric analysis and ELISA, we investigated the capacity of freshly 
isolated CD14+ monocytes of healthy individuals and kidney transplant recipients 
to produce IFN-γ after stimulation with IFN-γ and LPS or LPS alone. We observed 
increased IFN-γ mRNA levels in CD14+ monocytes after stimulation as compared 
to the unstimulated controls in both populations. In addition, stimulation with 
IFN-γ and LPS or LPS alone led to a significant increase in the percentage of CD14+ 
monocytes producing TNF-α and IFN-γ at protein level (p<0.05). A trend towards 
increased secreted IFN-γ production in supernatants was also observed after 
LPS stimulation using ELISA. We conclude that human monocytes from healthy 
individuals and kidney transplant recipients possess the capacity to produce IFN-γ.
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Introduction 
Interferon-gamma (IFN-γ) is a pleiotropic cytokine with pivotal roles in innate and 
adaptive immunity. It affects many biological functions primarily related to host defense 
and immune regulation, such as antiviral and antibacterial defense, cell cycle, apoptosis, 
and inflammation [1]. IFN-γ stimulation leads to up-regulation of MHC class I and class II 
molecules and increases antigen presentation by professional antigen-presenting cells (APCs) 
[2]. Activation of macrophages (Mph) by IFN-γ leads to cytokine secretion, upregulation of 
antigen processing and presenting pathways, and activation of antimicrobial and antitumor 
mechanisms [1]. In addition, IFN-γ attracts, matures and differentiates leukocytes [3]. It 
also enhances natural killer cell activity and regulates B-cell function [3-5]. In early host 
defense the production of IFN-γ by natural killer (NK) cells and possibly professional APCs is 
important, while T cells become the main producers of IFN-γ during the adaptive immune 
response [6]. Moreover, IFN-γ is critically important in the development of a type 1 T-helper 
cell response, by regulating differentiation, activation and homeostasis of T cells and 
inhibiting Th2 cell development. 
Clinically, IFN-γ plays a major role in auto-immunity and solid organ transplant rejection. 
In multiple sclerosis (MS) increased IFN-γ and Interleukin-(IL)12 expression in the central 
nervous system and cerebrospinal fluid were correlated with increased disease activity [7]. 
In serum of MS patients the concentration of IFN-γ was significantly increased compared 
to healthy individuals [8]. In addition, administration of IFN-γ to patients with MS markedly 
exacerbated the disease [9]. In a mouse model, induced by transfer of myelin protein-
specific CD8+ T cells neutralization of IFN-γ ameliorated the disease [10]. In a mouse model 
for rheumatoid arthritis, administration of IFN-γ exacerbated the severity of disease [11, 
12]. Next to its role in auto-immunity, IFN-γ is also a key cytokine in transplant immunity. 
In mouse models for solid organ transplantation, high IFN-γ gene expression levels were 
associated with rejection [13]. Furthermore, IFN-γ-/- mice were unable to reject MHC class 
II-incompatible grafts whilst still rejecting MHC class I-incompatible grafts [14], probably 
due to the fact that IFN-γ up-regulates MHC class II expression by professional and non-
professional APCs [15, 16]. In humans, early acute rejection episodes [17, 18] and poor 
long term kidney graft function [19] were predicted by high IFN-γ plasma levels and IFN-γ 
production during mixed lymphocyte reactions pre-transplantation. Finally, patients with 
pronounced clinical glomerulitis had significantly higher intrarenal IFN-γ mRNA compared 
to patients with subclinical glomerulitis and patients without any histological abnormalities 
[20]. In addition to the major role of IFN-γ in immune activation, it is also involved in 
down-regulation of adaptive immunity. This is particularly mediated via IFN-γ-induced 
expression of indoleamine 2,3-dioxygenase in APCs, which in turn stimulates differentiation 
of regulatory T cells [21].
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In the field of solid organ transplantation, T-cells are the predominant cell types infiltrating 
acutely rejecting kidney transplants [22, 23]. T-cells are known to be required for acute 
rejection [24-26] Other immune cell types such as monocytes and NK cells compose up 
to now neglected immune cells, gaining more attention due to their nowadays recognized 
contribution to acute and chronic antibody mediated rejection [27-29]. Monocyte infiltration 
and specifically glomerular monocytes were associated with graft dysfunction and poor graft 
outcome [30, 31]. Furthermore, monocytic infiltrates seemed to drive the acute rejection in 
T-cell-depleted, alemtuzumab-treated kidney transplant recipients [32]. Moreover, one of 
the cardinal histopathological hallmarks of antibody mediated rejection is accumulation of 
monocytes and Mph in peritubular capillaries leading to acute, overt and often irreversible 
graft damage. IFN-γ is one of major pro-inflammatory cytokines driving rejection of the 
kidney graft [33, 34]. Whether monocytes contribute to rejection by IFN-γ production 
remains an important question for further investigations. At present, the production of 
IFN-γ by monocytes is debated in the literature. Most of the research has focused on the 
production of IFN-γ by Mph, but contrasting reports in this regard have been published in 
recent years. Schleicher et al. reported that RAG2-/- γ-chain-/- Mph did not produce IFN-γ 
after stimulation with IL-12, IL-18, lipopolysaccharide (LPS) alone or in combination with 
IFN-γ. They related the observed production of IFN-γ by Mph to the contamination of these 
Mph with other cell types [35]. However, Choudhry et al. found that RAG2-/- γ-chain-/- mice 
did retain control over C. parvum reproduction which was IFN-γ dependent [36]. In addition, 
they showed that the secretion of IFN-γ by Mph was stimulated by IL-18 and IL-12. 
To further elucidate the possibility of IFN-γ production by monocytes, we aimed to investigate 
whether human monocytes obtained from healthy individuals and renal transplant recipients 
(Tx recipients) possess the capacity to produce IFN-γ at mRNA and protein level. 
Materials & Methods
Patient characteristics
Whole blood was collected from kidney Tx recipients either at time of transplantation or 3 
months after transplantation and from healthy individuals. All patients were treated with 
basiliximab (Simulect®) as induction therapy and the maintenance immunosuppressive 
regimen consisted of mycophenolate mofetil (cellcept®), tacrolimus (prograft®) and 
corticosteroids. Following the guidelines of the Ethical Committee of the ErasmusMC, all 
patients signed written informed consent. 
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Monocyte isolation and stimulation
Using a Ficoll-Hypaque density gradient (LymphoprepTM), PBMCs were isolated from anti-
coagulated blood collected in sodium-heparin coated tubes. CD14+ beads (Miltenyi) were 
applied to purify the monocytes using magnetic activated cell sorting on an AutoMACS 
according to the manufacturers instruction. Cell purity was checked by flow cytometric 
analysis and was always higher than 95%.
Freshly isolated CD14+ monocytes were used to determine intracellular cytokine 
production. The cells were cultured in RPMI medium supplemented with 10% fetal calf 
serum and stimulated using either 100 ng/ml E. coli LPS (Sigma-Aldrich) and golgiplug (BD 
Biosciences) overnight or pre-treated for 2 hours with 20 ng/ml IFN-γ (U-Cytech) and then 
with a combination of 100 ng/ml LPS and golgiplug overnight. The optimal time for priming 
of monocytes with IFN-γ was determined by performing time-course experiments. Pre-
stimulation with IFN-γ was done for 2, 4 or 6 hours before overnight stimulation with LPS. 
As no difference in the cytokine producing capacity of monocytes at different IFN-γ pre-
stimulation time points could be observed, a 2 hour priming period with IFN-γ was used 
(data not shown).
Flow cytometric analysis of intracellular cytokine production
After overnight stimulation, cells were incubated with EDTA for 15 min and washed. Cells were 
exposed to CD14-Pacific Blue (Biolegend) in PBS containing 10% BSA for 30 minutes at 4°C. 
The cells were incubated with FACS lysing solution at room temperature for 10 min and with 
FACS permeabilizing solution 2 (BD Biosciences) for 15 min. Next, conjugated antibodies to 
TNF-α-Percp-Cy5.5 and IFN-γ-APC-Cy7 and their respective isotype controls (Supplementary 
Figures 1 and 2) (all Biolegend) were added to determine intracellular cytokine production. 
The cells were washed and analyzed using flow cytometry (FACSCanto II, BD Biosciences) and 
FACSDiva software. Gating was done on living cells and monocytes were identified based on 
CD14 expression. To study the shift of monocytes to Mph, cells were stained for CD68 using 
as a primary antibody mouse-anti-CD68 antibody (DakoCytomation) and a FITC-conjugated 
anti-mouse IgG1 secondary antibody (Biolegend). To study the amount of cell death after 
overnight incubation of the monocytes, cells were stained for 7-AAD (Biolegend).
ELISA
CD14+ monocytes were stimulated overnight with 100 ng/ml LPS. Supernatants were 
harvested the next day and frozen until use. The IFN-γ ELISA was performed according to 
manufacturers instructions (U-CyTech).
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mRNA analysis 
After stimulation of CD14+ monocytes with LPS alone for 2 hours or with IFN-γ for 2 hours 
followed by 2 hours with LPS cells were fixed in RNAlater (Ambion). RNA was isolated by 
RNA isolation kit according to manufacturer’s protocol (Roche). 
cDNA was generated using random primers and 275 ng RNA. To verify target gene mRNA 
expression the StepOnePlus™ Real-Time PCR system, taqman universal PCR master mix 
and the primer/probes for IFN-γ (Hs00174143.m1), TNF-α (Hs99999905.m1) and GAPDH 
(Hs9999043.m1) (all Applied Biosciences) were used to perform quantitative real-time PCR. 
Gene expression levels were normalized to GAPDH mRNA levels and presented as a ratio 
relative to the unstimulated controls.
Statistical analysis
Significant differences were determined using either the t-test, or one-way ANOVA. The 
results are presented as mean ± SEM. A p-value <0.05 was considered significant.
Results
Intracellular cytokine production by monocytes
Freshly isolated monocytes from healthy individuals and Tx recipients were used to 
stimulate with IFN-γ and LPS or LPS alone. Overnight incubation of the monocytes caused 
approximately 15% cell death as was observed by 7-AAD staining (Supplementary Figure 
3). To determine the effectiveness of the stimulation protocols in activating monocytes, 
we investigated TNF-α production as a positive control in our system. No differences were 
observed between healthy individuals and Tx recipients for the unstimulated condition as well 
as for both stimulation protocols (Figure 1A). TNF-α was produced by 3% of the monocytes 
by both healthy individuals and Tx recipients in the unstimulated condition. Stimulation with 
both IFN-γ and LPS and LPS alone induced a significant increase in the percentage of TNF-α 
producing monocytes compared to unstimulated cells, both in healthy individuals and Tx 
recipients (mean ± SEM: 32.7% ± 5.6 and 26.7% ± 9.8 for healthy individuals and 20.6% ± 4.1 
and 28.2% ± 5.7 for Tx recipients respectively) (Figure 1A,C). 
Interestingly, both types of stimulation protocols increased the percentage of IFN-γ positive 
monocytes comparably (Figure 1B). The percentage of unstimulated monocytes producing 
IFN-γ was 1.1% and 1.3% for healthy individuals and Tx recipients. Stimulation with both IFN-γ 
and LPS or LPS alone significantly increased the percentage of IFN-γ-producing monocytes, 
with no difference between the two groups (mean ± SEM: 10.5% ± 2.2 and 11.6% ± 7.7 for 
healthy individuals and 7.3% ± 2.8 and 10.6% ± 4 for Tx recipients respectively) (Figure 1B,D). 
In addition, no significant difference was observed comparing IFN-γ and LPS and LPS alone 
for both healthy individuals and Tx recipients. Thus stimulation with LPS alone induces IFN-γ 
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production by monocytes and priming with IFN-γ prior to LPS exposure did not alter this 
response. 
In addition, we investigated the monocyte-derived IFN-γ production by means of ELISA. 
We observed that unstimulated monocytes produced IFN-γ at background level (5 pg/
ml), whereas increased IFN-γ concentration levels were detected in supernatants of LPS-
stimulated monocytes confirming more enhanced production and secretion of IFN-γ by 
monocytes after LPS stimulation (mean ± SEM: 27.6 pg/ml ± 12.2) (data not shown).
IFN-γ production by CD68+ and CD68- monocytes 
Cell surface expression of CD68 was determined to check whether a switch towards Mph 
phenotype had taken place during the procedure. Stimulation did not lead to a significant 
increase in cell surface expression of CD68, indicating that monocytes did not shift towards 
a Mph-like phenotype (Figure 2A-D). Importantly, production of IFN-γ did not reside 
specifically within monocytes with CD68 cell surface expression, since a large proportion 
of IFN-γ-positive monocytes did not express CD68 (Figure 2D). This indicates that IFN-γ 
production was not associated with a shift towards a more Mph-like phenotype. 
IFN-γ mRNA expression by monocytes upon stimulation
A clear trend towards increased mRNA expression levels of IFN-γ was observed, indicating 
that stimulation with IFN-γ and LPS or LPS alone is potent in activating monocytes to produce 
IFN-γ (Figure 3A) underlying our findings at the protein level. Accordingly, we observed that 
the mRNA expression of TNF-α by monocytes was significantly increased with both types 
of stimulation compared to the unstimulated state (Figure 3B). The IFN-γ mRNA expression 
is more pronounced after 2 hours priming with IFN-γ itself followed by LPS stimulation, 
indicating that the priming and/or longer stimulation period may lead to more detectable 
production of IFN-γ mRNA probably due to differences in cytokine production kinetic. 
Although statistically not significant, the IFN-γ mRNA expression was more enhanced by 
monocytes obtained from healthy individuals than kidney transplant recipients which may 
be explained by the uremic condition of our patients (Supplementary Figure 4). 
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Figure 1. Human monocytes produce IFN-γ
Freshly isolated CD14+ monocytes from healthy individuals (HI) and renal transplant recipients (Tx) were used to 
test the production capacity of IFN-γ and TNF-α. Cells were stimulated overnight in the presence of golgiplug with 
either LPS alone or in combination with IFN-γ. (A) Both stimulation protocols led to a significant increase in the 
percentage of TNF-α-producing monocytes with equal efficacy (HI: mean ± SEM: 32.7% ± 5.6 for IFN-γ + LPS and 
26.7% ± 9.8 for LPS alone, n=5; Tx: mean ± SEM 20.6% ± 4.1 for IFN-γ + LPS and 28.2% ± 5.7 for LPS alone, n=8). (B) 
Both stimulation protocols led to a significant increase in the percentage of IFN-γ-producing monocytes with equal 
efficacy (HI: mean ± SEM: 10.5% ± 2.2 for IFN-γ + LPS and 11.6% ± 7.7 for LPS alone, n=5; Tx: mean ± SEM 7.3% ± 2.8 
for IFN-γ + LPS and 10.6% ± 4 for LPS alone, n=8). Representative flow cytometric plots of TNF-α (C) and IFN-γ (D) 
production are shown with unstimulated (upper panel), IFN-γ + LPS-stimulated (middle panel) or LPS-stimulated 
(lower panel) monocytes from a transplant recipient. *p<0.05, **p<0.01, ***p<0.001.
Figure 2. IFN-γ production not associated with a shift towards a Mph-like phenotype
Freshly isolated CD14+ monocytes from Tx recipients were used to test whether a shift towards Mph-like phenotype 
occurs. Cells were stimulated overnight in the presence of golgiplug with either LPS alone or in combination with 
IFN-γ and stained for IFN-γ and CD68 the next day. Representative flow cytometric plots showing CD68 versus IFN-γ 
are depicted in A-C. (D) Percentage of monocytes expressing CD68 versus IFN-γ (n=4). 
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Figure 3. IFN-γ mRNA expression by monocytes upon stimulation 
Freshly isolated CD14+ monocytes from Tx recipients were used to test the production capacity of TNF-α and IFN-γ 
mRNA. Cells were stimulated with either LPS for 2 hours or pre-stimulated with IFN-γ for 2 hours followed by 2 
hours stimulation with LPS. Subsequently mRNA was isolated and qPCR performed. Target gene expression levels 
were normalized to GAPDH mRNA levels and presented as a ratio relative to the unstimulated control. Stimulation 
of monocytes with both stimulation protocols increased the mRNA expression of (A) IFN-γ and (B) TNF-α (n=5-8).
Discussion
Here, we show that human monocytes produce IFN-γ upon stimulation with LPS. We 
observed that stimulation of freshly isolated CD14+ human monocytes derived from healthy 
individuals and Tx recipients with LPS alone or combined stimulation with IFN-γ and LPS lead 
to a significant increase in the percentage of TNF-α- and IFN-γ-producing monocytes. 
Although IFN-γ is mostly regarded as a T cell associated cytokine, it is also produced by other 
immune cell types like Mph and NK cells. No direct observations on human monocytes have 
been available so far. Several studies have shown that human monocyte-derived Mph and 
dendritic cells have the capacity to produce IFN-γ. Fenton et al. observed that infection 
of alveolar Mph with M. tuberculosis in vitro stimulated the release of IFN-γ protein and 
transiently induced an increase in IFN-γ mRNA levels using RT-in situ PCR [37]. Furthermore, 
human monocyte-derived dendritic cells are able to produce IFN-γ upon stimulation with 
either IL-12 or Salmonella infection [38, 39]. Recently, it was shown that monocytes produce 
high levels of IFN-γ in the presence of IL-2 and the bisphosphonate zoledronic acid [40]. 
These zoledronic acid-treated monocytes augmented, through the release of IFN-γ, TNF-
related apoptosis-inducing ligand-mediated cytotoxicity of human NK cells. Although IFN-γ 
is well-known to activate a variety of signaling pathways in monocytes, we were interested 
in the potential of the monocytes to produce IFN-γ in response to the well-known stimuli 
such as LPS and/or IFN-γ/LPS. The effects of IFN-γ itself on monocytes are therefore not 
discussed here.
Recently, we documented the production of IFN-γ by monocyte subsets obtained from 
kidney transplant recipients after combined stimulation with IFN-γ and LPS or LPS alone 
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[41]. We observed that the percentage of both CD16+ monocyte subsets was significantly 
increased in transplant recipients compared to healthy individuals retaining for at least 6 
months after transplantation, indicative of triggered innate immunity. Enhanced production 
capacity of TNF-α, IFN-γ and IL-1β by monocytes was observed at time of transplantation 
compared to healthy individuals. Remarkably, three months post-transplant, in presence 
of potent immunosuppressive drugs and despite improved kidney function, IFN-γ, TNF-α 
and IL-10 production capacity still remained significantly increased. We concluded that 
this shift could be one of the important drivers of early post-transplant cellular immunity. 
Uptake of IFN-γ from the extracellular medium after pre-stimulation with IFN-γ does not 
likely contribute significantly to the elevated percentage of IFN-γ+ monocytes, since results 
after stimulation with LPS alone were similar. These findings prompted us to investigate the 
IFN-γ production in both healthy individuals and Tx recipients more in detail using freshly 
isolated monocytes.
In this study, we demonstrate that monocytes express IFN-γ protein after stimulation by two 
different methods, namely flow cytometric evaluation representing the intracellular IFN-γ 
production and ELISA showing IFN-γ production and secretion by stimulated monocytes in 
supernatants. To be complete, IFN-γ mRNA production was also documented. Of note, the 
IFN-γ production by the monocytes was not associated with a shift towards CD68 positivity, 
indicating that these cells did not change in type towards a more Mph-like phenotype. Our 
data confirm that monocyte is a cell type capable of IFN-γ production. Whereas the IFN-γ 
production by macrophages and dendritic cells is believed to take place in tissue, T cells and 
monocytes could be designated as IFN-γ producing immune cells in circulation.  
The immunosuppressive maintenance treatment received by the kidney transplant 
recipients had clearly no inhibitory effect on cytokine producing capacity of monocytes as 
there was no difference between the percentage of TNF-α and IFN-γ producing monocytes 
at pre-transplant and post-transplant time points. Of note, the release of TNF-α, IL-1β and 
IL-8, from monocytes isolated from cord blood was not inhibited by therapeutic levels of 
dexamethasone [42]. In addition, the inhibition of cytokine production was significantly 
lower in monocytes compared to T cells, indicating that monocytes are less sensitive to 
glucocorticoids as T-cells [43].
Taken together, our data show clearly that human monocytes possess the capacity to produce 
IFN-γ, shedding more light at their role in both linking innate and adaptive immunity, and 
the pathogenesis of kidney transplant related immunity. 
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Supplementary Materials
Supplementary Figure 1. Isotype control for TNF-α 
Freshly isolated CD14+ monocytes were used to test the production capacity of TNF-α. Cells were stimulated 
overnight in the presence of golgiplug with either LPS alone or in combination with IFN-γ. Representative flow 
cytometric plots of (A) isotype control and (B) TNF-α are shown with unstimulated (upper panel), IFN-γ + LPS-
stimulated (middle panel) or LPS-stimulated (lower panel) monocytes. 
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Supplementary Figure 2. Isotype control for IFN-γ 
Freshly isolated CD14+ monocytes were used to test the production capacity of IFN-γ. Cells were stimulated 
overnight in the presence of golgiplug with either LPS alone or in combination with IFN-γ. Representative flow 
cytometric plots of (A) isotype control and (B) INF-γ are shown with unstimulated (upper panel), IFN-γ + LPS-
stimulated (middle panel) or LPS-stimulated (lower panel) monocytes. 
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Supplementary Figure 3. 7-AAD staining of monocytes
Freshly isolated CD14+ monocytes from healthy 
individuals and Tx recipients were stimulated 
overnight in the presence of golgiplug with either LPS 
alone or in combination with IFN-γ and stained for 
7-AAD the next day. A representative flow cytometric 
plot of 7-AAD staining is shown for unstimulated 
(upper panel), IFN-γ + LPS-stimulated (middle panel) 
or LPS-stimulated (lower panel) monocytes from a 
healthy individual.
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Supplementary Figure 4. 
Freshly isolated CD14+ monocytes from healthy individuals (HI) and Tx recipients (preTx) were used to test the 
production capacity of (A) IFN-γ and (B) TNF-α mRNA. Cells were stimulated either with LPS for 2 hours or pre-
stimulated with IFN-γ for 2 hours followed by 2 hours stimulation with LPS. Subsequently mRNA was isolated and 
qPCR performed. Target gene expression levels were normalized to GAPDH mRNA levels and presented as a ratio 
relative to the unstimulated control (n=3-8).
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7There is an unmet clinical need for immunotherapeutic strategies which specifically target the active immune cells participating in the process of rejection after solid organ transplantation. The monocyte-macrophage cell lineage is increasingly recognized as a major player in acute and chronic allograft immunopathology. The dominant presence of cells of this lineage in rejecting allograft tissue is associated with worse graft function and survival. Monocytes and macrophages contribute to alloimmunity via diverse pathways: antigen processing and presentation, co-stimulation, pro-inflammatory cytokine production and tissue repair. Cross talk with other recipient immune competent cells and donor endothelial cells leads to amplification of inflammation and a cytolytic response in the graft.Surprisingly little is known about therapeutic manipulation of the function of cells of the monocyte-macrophage lineage in transplantation by immunosuppressive agents. Although not primarily designed to target monocyte-macrophage lineage cells, multiple categories of currently prescribed immunosuppressive drugs, such 
as mycophenolate mofetil, mTOR inhibitors and calcineurin inhibitors, do have 
limited inhibitory effects. These effects include diminishing the degree of cytokine 
production, blocking co-stimulation and inhibiting the migration of monocytes to 
the site of rejection. Outside the field of transplantation, some clinical studies have 
shown that the monoclonal antibodies canakinumab, tocilizumab and infliximab 
are effective in inhibiting monocyte functions. Indirect effects have also been 
shown for simvastatin, a lipid lowering drug, and BET (Bromodomain and Extra-
Terminal motif) inhibitors that reduce the cytokine production by monocytes-
macrophages in patients with diabetes mellitus and rheumatoid arthritis. 
To date, detailed knowledge concerning the origin, the developmental 
requirements and functions of diverse specialized monocyte-macrophage subsets 
justifies research for therapeutic manipulation. Here, we will discuss the effects 
of currently prescribed immunosuppressive drugs on monocytes/macrophages 
features and the future challenges.Ab
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Non-standardized abbreviation list
ATG  anti-thymocyte globulin
BET  bromodomain and extra terminal
CNI  calcineurin inhibitor
CTLA-4 Ig  cytotoxic T-lymphocyte-associated protein 4 immunoglobulin
ERK  extracellular regulated kinase
GRE  glucocorticoids response element
ICAM  intercellular adhesion molecule
MAPK  mitogen-activated protein kinase
MCP  monocyte chemoattractant protein
MHC  major histocompatibility complex
MMF  mycophenolate mofetil
MPA  mycophenolic acid
NFκB   nuclear factor kappa B
NFAT  nuclear factor of activated T-cells
NOD  nucleotide-binding oligomerization domain
RA  rheumatoid arthritis
SEB  staphylococcal enterotoxin B
TAT  tyrosine aminotransferase
TLR  toll like receptor
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Introduction
Solid organ transplantation (SOT) is the preferred method to treat organ failure. Over the 
past decades, transplantation has become the preferred approach to treat solid organ 
failure. Striking improvement in short-term allograft survival, in particular of kidney 
allograft, has been achieved while long-term survival has lagged behind [1]. Intriguingly, this 
improvement is seen mainly in recipients who have never experienced a rejection episode, 
emphasizing the recipient’s alloimmunity; in particular chronic antibody mediated rejection 
(cABMR) as a major determinant of overall transplant outcome [2, 3]. At present, there is an 
unmet clinical need to apply immunotherapeutic strategies to specifically target the active 
immune cells crucially participating in the process of rejection after SOT.
However, treatment with immunosuppressive drugs has exchanged the morbidity and 
mortality of organ failure for the risks of infection, cancer and increased mortality from 
cardiovascular disease. Although acute and chronic rejection, regardless of the type and the 
time of occurrence, are still major contributors leading to graft failure [1, 4, 5], cABMR is the 
main concern for the long term graft survival. Chronic antibody mediated rejection arises, 
at least in part, because immunosuppressive strategies do not completely inhibit rejection-
related alloimmune responses specifically, resulting in slow progressive deterioration of 
graft function. 
The monocyte-macrophage cell lineage is increasingly recognized as a major player in acute 
and chronic allograft immunopathology [6, 7]. The clinically used immunosuppressive drugs 
are not specifically directed against monocyte-macrophage lineage cells but still have some 
inhibitory effects. These cells contribute to alloimmunity via diverse pathways; antigen 
processing and antigen presentation, co-stimulation, pro-inflammatory cytokine production 
and tissue repair. Cross talk with other recipient immune competent cells and donor 
endothelial cells underlies amplification of inflammation at the graft site [8-10]. Interestingly, 
acute and chronic antibody mediated rejection are characterized amongst others by 
accumulation of monocyte-macrophage cells. Kidney graft infiltrating macrophages have 
been described to be a predictor of death-censored graft failure [11-21]. Macrophages are 
present in both acute antibody mediated rejection (ABMR) and acute cellular rejection (ACR) 
of solid organ transplants [19, 22]. In rejecting cardiac tissue, interstitial and intraluminal 
macrophage density correlates with effector alloantibodies and clinical antibody mediated 
rejection [22]. Even more, histopathological staining’s for macrophages have been found to 
be positive prior to the onset of graft dysfunction indicating that macrophages can serve 
as potential diagnostic markers for transplant rejection [18]. Intravascular macrophages in 
the capillaries of endomyocardial tissue are shown to be a distinguishing feature of ABMR 
and are considered as one of the important histopathological diagnostic criteria in cardiac 
transplantation [22, 23]. 
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
119118
7
A recent study showed that the severity of macrophage infiltration during ACR with 
arteritis is associated with impaired kidney function as measured by creatinine values up 
to 36 months post transplantation [19]. Importantly, Oberbarnscheidt et al. showed that 
monocyte recognition of allogeneic non-self persists over time, long after acute surgical 
inflammation has been subsided, indicating the important role of monocytes in the principle 
of long-term graft failure [24]. Recently, the presence of smooth muscle like-precursor cells 
within the non-classical monocyte subset has been described in kidney transplant patients. 
Characterization of non-classical monocytes in peripheral blood of kidney transplant 
patients undergoing chronic transplant dysfunction showed lower numbers compared to 
patients without chronic transplant dysfunction. Within the total living cell percentages of 
CD14+ monocytes there was no change observed, suggesting a shift within different subsets. 
Non-classical monocytes being reduced in transplant recipients with chronic transplant 
dysfunction may indicate a vital role in interstitial and vascular remodelling [25]. 
In stable kidney transplant recipients, a skewed balance towards pro-inflammatory CD16+ 
monocytes was shown at the time of kidney transplantation and during the first 6 months 
post-transplant. These monocytes were able to produce IFNγ, which acts as an important 
bridge between innate and adaptive immunity [26, 27].
In summary, the currently available knowledge concerning the immunobiology of 
specialized monocyte–macrophage subsets, their pathogenic role in rejection, and the still 
unmet clinical need to specifically prevent alloimmunity justify research on strategies for 
monocyte-macrophage directed therapeutics. In this review, we aim to discuss the relevant 
knowledge on monocyte-macrophage immunobiology. Briefly, to elaborate on the effects of 
currently available immunosuppressive drugs in relation to monocyte/macrophage lineage 
cells mainly focussed within, but also outside of the SOT field (Table 1), and eventually touch 
upon the future challenges and developments.
Table 1. Immunosuppressive drugs and the monocyte/macrophage lineage
Drug type Effects on monocytes/macrophages Key references
Ba
si
lix
im
ab
 &
 A
TG
• Basliximab targets the CD25 molecule (the IL-2 receptor) on activated 
T cells
• ATG binds to multiple T-cell specific antigens and causes cell death via 
complement mediated cytotoxicity 
• Reduced number of monocytes in vivo
• Upregulation of the anti-inflammatory M2 macrophage subset CD14+ 
CD163+ in vivo
Sekerkova et al, 2014
A
le
m
tu
zu
m
ab • Targets CD52 on B cells, T cells, NK cells, dendritic cells and monocytes
• Less effective in depleting monocytes than depleting T cells 
• Leads to a relative high expression of co-stimulatory molecules, IL-6 and 
NFκB 
Hale et al, 1990
Kirk et al, 2003
Fabian et al, 1993
Rao et al, 2012
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Drug type Effects on monocytes/macrophages Key references
Ca
lc
in
eu
ri
n 
in
hi
bi
to
rs
(t
ac
ro
lim
us
 &
 c
yc
lo
sp
or
in
)
• No inhibitory effect on p38MAPK phosphorylation, but reduce cytokine 
production via ERK phosphorylation
• Downregulate production of IL-6 and TNF-α after TLR stimulation in vitro
• Impaired phagocytosis function and promotion of infection (CsA) 
Escolano et al, 2014
Howell et al, 2013
Tourneur et al, 2013
M
yc
op
he
no
la
te
 
m
of
eti
l
• Diminished the production of IL-1β, IL-10 and TNF-α and decreased 
expression of TNF-receptor 1 on monocytes
• Reduced monocyte migration through lower expression of adhesion 
molecules
Alisson et al, 2000
Weimer et al, 2003
G
lu
co
co
rti
co
id
s
• Lower CD14+CD16++monocyte counts 
• Lower expression of B7 molecules leading to disturbed co-stimulation
• Induction of anti-inflammatory response via increased IL-10 production
• Impaired phagocytosis function 
Rogacev et al, 2015
Girndt et al, 1998
Hodge et al, 2005
Blotta et al, 1997
Rinehart et al, 1974
m
To
r 
in
hi
bi
to
rs • Decreased chemokine and cytokine production
• Combination therapy with steroids increased pro-inflammatory cytokine 
production
Lin et al, 2014
Oliveira et al, 2002
Weichhart et al, 2011
Be
la
ta
ce
pt
/
ab
at
ac
ep
t
• Block CD80/86 molecules on antigen-presenting cells and inhibit co-
stimulatory function 
• Lower migration and adhesion capacity
• Decreased expression of the pro-inflammatory cytokines IL-12 and 
TNF-α
Latek et al, 2009
Bonelli et al, 2013
Wenink et al, 2011
Ex
pe
ri
m
en
ta
l d
ru
gs
• Canakinumab inhibits IL-1β production by monocytes
• Sinomenine is associated with less monocyte migration, differentiation 
and maturation 
• 15-deoxyspergualin decreases monocyte proliferation, TNF-α 
production, phagocytosis and antigen presentation
• Simvastatin and salsalate are associated with less monocyte activation 
and inhibition of IL-6 and IL-8 production in diabetes patients
• Tocilizumab inhibits IL-6 production by monocytes
• BET inhibitors are involved in epigenetic control of monocytes thereby 
preventing inflammation
• Fish oils are associated with lower numbers of macrophages in obesitas 
patients and a reduced secretion of TNF-α in vitro
Hoffman et al, 1993
Ou Y et al, 2009
Wang et al, 2011
Perenyei et al, 2014
Donath et al, 2011
McCarty et al, 2010
Tono et al, 2015
Chan et al, 2015
Spencer et al, 2013
Zhao et al, 2013
Jialal et al. 2007
ATG anti-thymocyte globulin; IL interleukin; NFκB nuclear factor kappa-light-chain-enhancer of activated B cells; 
MAPK; mitogen-activated protein kinases; ERK extracellular signal–regulated kinase; CsA Cyclosporin A; TNF tumor 
necrosis factor; BET bromodomain and extra-terminal motif
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Monocyte immunobiology
Monocytes and macrophages are mononuclear phagocytes with crucial and distinct roles 
in transplant immunity. Monocytes display a remarkable plasticity in response to signals 
from the microenvironment, enabling them to differentiate into various cell types. Several 
pro-inflammatory, metabolic and immune stimuli all increase the attraction of monocytes 
towards tissue [7]. Based on the expression of CD14 (LPS co-receptor) and CD16 (Fcγ receptor 
III), three phenotypically and functionally distinct human monocyte subsets: CD14++CD16- 
(classical), CD14++CD16+ (intermediate), and CD14+CD16++ (non-classical) monocytes can 
be defined [28-31]. Monocytes arise from myeloid precursor cells in primary and secondary 
lymphoid organs, such as liver and bone marrow. In humans, monocytes represent 
respectively 10% of the nucleated cells in peripheral blood, with 2 major reservoirs: the 
spleen and lungs that can mobilize monocytes on demand [32, 33]. Classical monocytes are 
able to start proliferating in the bone marrow in response to infection or tissue damage, 
and subsequently be released into the circulation in a CCR2 dependent manner (Figure 1) 
[34]. Intermediate and non-classical monocytes are thought to be descendants of classical 
monocytes that have been under control of transcription factor Nur77 (NR4A1) returned 
to the bone marrow [35]. Non-classical monocytes show a patrolling, distinct motility and 
crawling pattern [36]. Interestingly, intermediate monocytes show higher expression of 
major histocompatibility (MHC) class II molecules and thereby more related to non-classical 
monocytes [37, 38]. CD14+ monocytes can be recruited to the site of inflammation or areas 
of tissue injury where they can differentiate into macrophages and dendritic cells [39]. In 
steady state, circulating monocytes have minimal contribution to the maintenance of tissue 
resident macrophages [40, 41]. Depending on the microenvironment, activation stimuli 
and cross talk with other immunological effector cells, activation of macrophages alters 
their cytokine profile and co-stimulatory molecule expression. Monocyte differentiation 
to tissue macrophages is Colony Stimulating Factor 1 Receptor (CSF1R) dependent. Most 
tissue macrophages are seeded before birth in embryonic state, with varying contributions 
of primitive-derived and definitive-derived cells. Monocytic input to tissue macrophage 
compartments seems to be restricted to inflammatory settings, such as infection and acute 
graft rejection [39]. Monocyte chemotactic peptide-1 (MCP-1) is an important regulator 
of macrophage recruitment and was shown to be highly expressed in the kidney allograft, 
supporting the concept of recruitment of monocytes from the circulation [42]. 
Macrophages can be subdivided in ‘classically activated’ or ‘alternatively activated’. 
Classically activated macrophages are described as M1 macrophages, which are developed 
upon response to IFNγ, LPS or TNF-α. M1 macrophages express surface markers: MHCII, 
CD40, CD80, CD86 and CD11b. They can produce inflammatory cytokines such as: TNF-α, IL-
1, IL-6, IL-8, IL-12, CCL2, CXCL9 and CXCL10. M1 macrophages are linked to the Th1 response 
and are mainly considered as pro-inflammatory macrophages whereas M2 are considered 
as mainly anti-inflammatory. M2 macrophages can be subdivided in M2a, M2b and M2c. 
M2a macrophages are generated on response to IL-4 and IL-13. Immune complexes and 
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TLR/IL-1R ligands activate M2b macrophages whereas M2c macrophages are activated by 
IL-10, TGF-β and glucocorticoids. M2 macrophages express surface markers: CD163, CD206 
and CD209. M2 macrophages produce IL-10 and TGF-β mainly leading to tissue repair and 
scar formation. M2 macrophages are linked to Th2 response and show immune-modulatory 
functions [7, 39, 43]. Human regulatory macrophages (Mregs) are in a specific state of 
differentiation with a robust phenotype and potent T-cell suppressor function. These Mregs 
arise from CD14+ peripheral blood monocytes during 7-day culture exposed to M-CSF and 
activation by IFNγ [44]. Mregs express several molecules such as MHCII, FCγR, IFNγR, TLR-4 
and PD-L1 as shown in Figure 1 [45]. Shifting the balance between regulatory macrophages 
and/or monocytes on the one hand, and the effector macrophages and proinflammatory 
monocytes on the other hand could theoretically result in dampening the immune 
response against the graft and the immunological tolerance, or to aggravation of graft 
rejection. To date, two clinical trials investigated the feasibility of regulatory macrophages 
in promoting allograft acceptance with promising results [46, 47]. Moreover, recently, a 
new homogeneous monocyte subpopulation of human G-CSF induced CD34+ monocytes 
with powerful immunosuppressive properties upon human allogeneic T-cell activation was 
described. Such tolerogenic monocytes could be used for novel immune-regulatory or 
cellular therapy development [48].
Recently, an adaptive feature of innate immunity has been described as “trained immunity”. 
Trained immunity is defined as a nonspecific immunological memory resulting from rewiring 
the epigenetic program and the functional state of the innate immunity [49]. Twenty naïve 
patients were vaccinated for bacille Calmette-Guérin (BCG) to investigate mechanisms of 
the enhanced immune function. Interestingly, these authors identified trained monocytes 
in the circulation of BCG-vaccinated individuals for at least 3 months suggesting that 
reprogramming takes place at the level of progenitor cells in the bone marrow [50]. 
Recent evidence emerged to indicate that innate immune memory could be transferred 
via hematopoietic stem and progenitor cells. In vitro studies showed effects lasting for days 
[51, 52], whereas other reports showed memory effects for weeks [53]. These interesting 
observations might be explained by alterations in epigenetic (de)methylation profiles 
after antigenic stimulation. Altering the epigenetic program by pharmacological means 
leading to behavioral changes of monocytes could be a promising method to restore or 
modify the healthy gene/protein expression in the pro-inflammatory microenvironment. 
The phenomenon of trained immunity in alloreactivity and transplantation may be a very 
interesting area of future research: i.e. innate memory towards donor antigens resulting 
from cross-reactivity with other microbial and/or viral agents. 
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Figure 1. Monocyte immunobiology
Monocytes arise from myeloid precursor cells in primary lymphoid organs, including liver and bone marrow. In 
the peripheral blood, monocytes can be subdivided in three disti nct subsets according to their CD14 and CD16 
expression profi le. Monocytes can undergo transendothelial migrati on through α4β1 integrin interacti on with 
VCAM-1. Acti vati on of monocytes is followed by the polarizati on of macrophages to acquire proinfl ammatory 
phenotype (M1), anti -infl ammatory phenotype (M2) or the regulatory phenotype (Mreg). The secreti on of 
disti nct pro- or anti -infl ammatory cytokines, next to expression patt erns of surface molecules characterizes each 
phenotype.
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rATG and basiliximab and monocyte/macrophage cell lineage
Rabbit Anti-thymocyte globulin (rATG) is a polyclonal antibody with mainly T cell depleting 
capacities. rATG can also induce B cell apoptosis, and stimulates Treg and NKT cell generation 
[54]. After rATG treatment, cytokine dependent homeostatic proliferation of T cells is 
initiated [55]. Basiliximab (anti CD25 monoclonal antibody) blocks the CD25 receptor on 
the surface of activated T cells. Studies on the effects of basiliximab or rATG on monocytes/
macrophages are scarce. However, one report showed a reduction in the percentage of 
CD14+CD16+ monocytes when PBMC were cultured in vitro in the presence of rATG [56]. 
In contrast, this cell type was not affected by basiliximab, although low expression levels of 
CD25 on stimulated monocytes and macrophages are described [57, 58]. These authors also 
reported a reduction of circulating CD14+CD16+ monocytes in kidney transplant patients 
treated with rATG during the first week after transplantation, while this was not seen for 
basiliximab induction therapy. Another part of the same study showed an upregulation of 
the percentage of CD14+CD163+ monocytes in either basiliximab or rATG -treated kidney 
transplant recipients, which could be detected for a longer time period in the circulation 
than in patients without induction therapy. CD14+CD163+ monocytes are precursors 
for M2 macrophages and these cells are well known for their anti-inflammatory effect, 
suggesting that the upregulation of CD14+CD163+ cells may contribute to a better outcome 
after transplantation. However, this study only described the changes in the CD14+CD16+ 
monocyte subset after rATG or basiliximab therapy, while the effect on other subsets such 
as the classical CD14++CD16- monocytes remains unknown. Therefore, it is unclear whether 
the pro-inflammatory immune response by monocytes is changed in the presence of rATG 
or basiliximab.  
Alemtuzumab and monocyte/macrophage cell lineage
The humanized monoclonal antibody alemtuzumab targets the CD52 molecule which is 
expressed at different levels on B cells, T cells, NK cells, dendritic cells and monocytes. The 
CD52 molecule, also known as CAMPATH-1 antigen, is a glycoprotein of which the precise 
function is unclear, although it might be involved in T-cell migration and co-stimulation [59]. 
However, monocytes are known to be less sensitive for the depleting effects of alemtuzumab 
than lymphocytes, despite their high CD52 expression [60-63]. For example, in acute cellular 
rejection dominated by monocytes, alemtuzumab treatment did not show depletion 
of monocytes in tissue, confirming the low sensitivity of monocytes to alemtuzumab 
treatment [64]. An explanation for this low susceptibility could be the high expression levels 
of complement inhibitory proteins, which protect monocytes from complement mediated 
lysis [63]. Another study showed repopulation of monocytes within 3 months after 
alemtuzumab therapy, while the recovery of T and B cells takes usually more than 1 year. 
Consequently, the low susceptibility of monocytes for alemtuzumab is thought to be one of 
the reasons for renal graft dysfunction after induction therapy with alemtuzumab, such as 
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reperfusion and rejection [65]. So far, this low susceptibility of monocytes to alemtuzumab 
therapy could be partially explained by the high expression of complementary inhibitory 
proteins that protect monocytes from getting lysed after alemtuzumab treatment [63]. 
After alemtuzumab treatment, tissue monocytes in the rejecting graft showed an increased 
expression of the co-stimulatory molecules CD80 and CD86, a higher intracellular expression 
of NFκB and stronger production of IL-6 compared to patients without alemtuzumab therapy 
[61]. Moreover, this pro-inflammatory cytokine production could facilitate kidney allograft 
rejection after alemtuzumab therapy, although other cell types, such as NK cells, could also 
contribute to rejection processes after alemtuzumab therapy [66]. 
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Figure 2. Monocyte and macrophage lineage cell and the effect of immunosuppressive drugs. 
The effect of currently prescribed immunosuppressive drugs with several inhibition spots on and in monocyte/
macrophage lineage cells.
Calcineurin inhibitors and monocyte/macrophage cell lineage
Tacrolimus and cyclosporine A inhibit the calcineurin pathway in T cells, which is also present 
in other cell types. As a consequence, the activation of the Nuclear Factor of Activated T 
cells (NFAT) is blocked, leading to a reduced production of IL-2 and IFN-γ by T cells [67, 
68]. Calcineurin inhibitors (CNI) also have an effect on the MAPK signalling pathway via the 
inhibition of p38MAPK phosphorylation and consequently, reduced production of cytokines, 
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such as IL-2, IL-10, TNF-α and IFN-γ [69]. The calcineurin and MAPK pathway are also present 
in macrophages, although the inhibitory effects of CNIs on T cells and macrophages are 
different [70]. In more detail, tacrolimus was found to have no inhibitory effect on p38MAPK 
phosphorylation at low (5 ng/ml) and high (50 ng/ml) concentrations in LPS-activated 
monocytic THP-1 leukaemia cells [71]. However, another member of the MAPK pathway, 
ERK, did show less phosphorylation in the presence of a high concentration (50 ng/ml) of 
tacrolimus in monocytes as measured by western blotting, leading to a lower production 
of TNF-α. Kang et al. reported that monocyte signalling pathways were activated instead 
of inhibited by CNI via the inhibition of the calcineurin pathway and, as a consequence, the 
activation of the NFκB signalling pathway [70]. However, the concentrations of CNIs used in 
this study were supratherapeutic. Therefore, the observed induction in cytokine production, 
shown in this study, could also be explained by toxic lysis of the monocytes [72]. Overall, 
these studies suggest that CNIs cannot supress the activation of monocytes to the same 
degree as in T-cells.  
Recognition of damage-associated molecular patterns (DAMP’s) by toll like receptors (TLR) 
on the surface of monocytes leads to the activation of these cells and plays an important 
pathogenic role during transplant rejection [73-75]. Both tacrolimus and cyclosporine can 
inhibit TLR signaling of PBMC in liver transplant patients, as shown by decreased production 
of IL-6 and TNF-α after TLR stimulation [72]. CNIs act differently in suppressing the cytokine 
production upon TLR activation. For example, cyclosporine inhibits the production of TNF-α 
mediated by TLR7/8 and the production of IL-6 mediated by TLR2 and TLR7/8 signalling 
significantly more than tacrolimus [72]. Moreover, monocytes from renal transplant 
recipients treated with tacrolimus showed an increased production of IL-1β, TNF-α, IL-6, IL-
10 after stimulation with LPS, in comparison to cyclosporine treated patients [76]. Thus, the 
effect of CNIs on monocytes differs between tacrolimus and cyclosporine. 
 The different outcomes of tacrolimus and cyclosporine on cytokine production concerns 
only one of the monocyte/macrophage functions. Bacterial infections can have a significant 
impact on the graft after transplantation. Cyclosporine inhibits the phagocytosis of bacteria 
by macrophages via the alteration of NOD-1 expression. The NOD-1 expression depends on 
the activation of the transcription factor NFAT, which is the main target of CNI [77]. Thus, 
cyclosporine can promote bacterial infections after transplantation by altering phagocytic 
capacity of macrophages more rigorously.
Mycophenolate mofetil and monocyte/macrophage cell lineage
Mycophenolate mofetil (MMF) has led to significantly reduced rejection rate as compared 
to its counterpart azathioprine [78-80]. The active metabolite mycophenolic acid (MPA) 
reduces the synthesis of guanosine nucleotides via the inhibition of inosine monophosphate 
dehydrogenase, which is a more specific metabolic pathway for T and B cells than for other 
cell types [81, 82] . 
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Circulating monocytes of kidney transplant recipients suffering from chronic rejection who 
were treated with MMF showed a decreased capacity to produce IL-1β, IL-10 and TNF-α 
as compared to circulating monocytes of chronic rejection patients who were not treated 
with MMF. Cytokine production capacity was measured by flow cytometry and confirmed 
by PCR on gene expression level [83]. Moreover, the expression of the TNF-receptor 1 was 
decreased in the MMF treated group, suggesting a favourable effect in patients with chronic 
rejection [83]. Furthermore, MMF reduced the expression of the adhesion molecules; 
intercellular adhesion molecule (ICAM)-1 and MHC II on isolated human monocytes [84].
Glucocorticoids and monocyte/macrophage cell lineage
The immunosuppressive and anti-inflammatory effects of glucocorticoids are redundant and 
cover different stages of alloreactivity triggered by activation of donor-specific T cells after 
transplantation. Steroids can bind via passive diffusion to the intracellular glucocorticoid 
receptor. After translocation to the nucleus, steroids bind to the glucocorticoid response 
elements (GRE’s) that have a connection with promotors of different genes. The anti-
inflammatory effect of glucocorticoids is based on the transrepression of inflammatory 
gene transcription, such as the inhibition of the transcription factors AP-1 and NFκB, and 
the transactivation of anti-inflammatory genes, including tyrosine aminotransferase (TAT) 
and the induction of IκB [85-88]. In this way, glucocorticoids control antigen presentation, 
cytokine production and proliferation of lymphocytes. 
In monocytes, glucocorticoids specially affect the heterogeneity of monocyte subsets [89-
91]. Flow cytometric analysis revealed that steroid treatment of stable kidney transplant 
patients for more than 12 months is associated with an increased absolute number of 
CD14++CD16- and CD14++CD16+ monocyte subsets compared to patients without steroid 
intake. As a consequence, the counts for the non-classical CD14+CD16++ monocyte subset, 
were significantly lower [89]. Furthermore, glucocorticoids inhibit the upregulation of B7 
molecules on the surface of human monocytes, which can negatively affect the antigen 
presenting function of the cell [92, 93]. The B7 family consists of many peripheral membrane 
proteins, including CD80 and CD86, which are all involved in the co-stimulatory signal 
needed for T cell activation. This suggests that glucocorticoid therapy in combination with 
belatacept therapy (blocking CD80/CD86) could theoretically block the immune response by 
T cells induced via antigen presenting monocytes after transplantation.
The production of the anti-inflammatory cytokine IL-10 by monocytes is increased under 
treatment with methylprednisolone while the production of the pro-inflammatory cytokines 
IL-12, IL-1 and TNF-α are down-regulated in the presence of glucocorticoids [94, 95]. 
Addition of 16 μg/ml of glucocorticoids in vitro leads to a decreased uptake of bacteria by 
monocytes, indicating that the phagocytosis of bacteria by monocytes is downregulated [96]. 
Glucocorticoids are also known to drive the polarization of macrophages to a M2 phenotype 
[43, 97]. This indicates that glucocorticoids drive the cytokine production by monocyte to 
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a more anti-inflammatory phenotype and inhibits the phagocytic function of monocytes. 
Glucocorticoids enhance the uptake of apoptotic cells by macrophages trough the 
induction of Mer-Tk (MER proto-oncogene tyrosine kinase), thereby inducing macrophage 
reprogramming toward a regulatory phenotype, also called Meff, for macrophages 
performing efferocytosis [98-100]. This approach has been evaluated in the treatment of 
collagen-induced arthritis (Bonnefoy F et al., Arthritis Res Ther. 2016 Aug 11;18(1):184), 
as well as acute graft rejection (Wang Z et al., Am J Transplant. 2006 Jun;6(6):1297-311.) 
justifying further exploration in the field of transplantation.
Inhibitors of the mammalian target of rapamycin (mTOR) and monocyte/macrophage 
cell lineage
The mammalian target of rapamycin (mTOR) signalling pathway is involved in the activation, 
proliferation, differentiation and translocation of T cells. Inhibitors of mTOR, such as 
everolimus and sirolimus, are therefore very useful after transplantation [101]. The same 
mTOR inhibitors do also have an inhibitory effect on human monocytes by suppressing the 
production of the chemokines MCP-1, RANTES, IL-8, MIP-1α and MIP-1β [102]. Furthermore, 
the downstream effects of rapamycin therapy are characterized by a decreased production 
of the monocyte-derived cytokine IL-6 and an increase of TGF-beta production in comparison 
to MMF, as it was shown by fine-needle biopsy cultures from kidney transplant patients 
treated with either a cyclosporine-rapamycin-prednisone or a cyclosporine-MMF-prednisone 
therapy one week after transplantation [103]. This resulted in a more tolerogenic effect of 
the monocytes and less graft rejection during the first 6 months after transplantation in 
comparison to a MMF based drug therapy. Moreover, combined therapy of mTOR inhibitors 
and glucocorticoid therapy increased the production of the pro-inflammatory cytokines IL-
12, TNF-α and IL-1β [104]. Altogether, mTOR inhibitors can inhibit cytokine production by 
monocytes shortly after transplantation, although a combination therapy with prednisone 
should be regarded with caution. 
Belatacept and monocyte/macrophage cell lineage
Belatacept, a fusion-protein consisting of the extracellular domain of the human cytotoxic 
T-lymphocyte antigen (CTLA)-4 antigen linked to a Fc-fragment of immunoglobulin G1 
(IgG1), inhibits the co-stimulatory signal between the CD80/CD86 molecules on antigen 
presenting cells and the CD28 molecule on T cells, thereby preventing T cell activation [105]. 
Monocytes express CD80/CD86 molecules and, as a consequence, the antigen presenting 
function of monocytes is blocked by belatacept [106-108]. This suggests that belatacept 
inhibits the antigen presenting function of monocytes/macrophages. In one case of acute 
rejection within 3 months after transplantation, the blockade of CD80/CD86 was incomplete 
under belatacept treatment, suggesting the importance of higher belatacept tissue 
concentrations needed to completely block monocyte antigen presentation function [106]. 
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Thus belatacept, in controlled dosages, blocks the expression of CD80/CD86 on monocytes, 
thereby inhibiting their antigen presenting function and activation of T cells.
The older variant of belatacept, abatacept (CTLA-4Ig), is frequently used in the treatment of 
patients with rheumatoid arthritis (RA) [109]. After treatment with abatacept, the number 
of circulating monocytes was increased, and the phenotype of these cells was significantly 
changed, due to down regulation of actin fibers. For example, the capability of monocyte 
migration was negatively changed even as the number of adhesion molecules in vitro. Data 
were verified with monocytes from healthy controls. The reduced number of adhesion 
molecules and migration capacity could be a reason for the increased number of monocytes 
in the peripheral blood that cannot pass endothelial barriers, whereby it is no longer possible 
for the monocyte to contribute in inflammation. 
Binding of abatacept to the CD80/CD86 receptor on macrophages from healthy blood 
donors is associated with decreased production of the pro-inflammatory cytokines IL-12 and 
TNF-α, suggesting again a role for abatacept/belatacept in changing the pro-inflammatory 
environment via macrophages after transplantation [110].
Other experimental drugs and monocyte/macrophage cell lineage
Although no monocyte specific drugs as such exist now, multiple experimental and less 
known drugs do influence monocyte functions. Looking outside the box of currently used 
immunosuppressive drugs in solid organ transplantation, there are a few compounds 
with immune-inhibitory effects, which theoretically could be interesting in combating 
alloimmunity. For example, the human monoclonal antibody canakinumab, originally 
designed as an interleukin-beta (IL-1β) inhibitor for the repression of inflammation in 
autoimmune diseases, can also inhibit the IL-1β production by monocytes [111]. A high 
expression of IL-1β is noticed in the most severe liver transplant rejection episodes and at 
the time of kidney transplantation, suggesting the importance of blocking its production by 
monocytes [112, 113]. However, treatment of kidney transplant recipients with canakinumab 
can inhibit IL-1β secretion in many other cell types, leading to undesirable side effects [114]. 
Infliximab, originally used in the treatment of autoimmune diseases, is another monoclonal 
antibody targeting monocyte TNF-α production. Monocytes and macrophages are main 
producers of TNF-α, suggesting the importance of infliximab for targeting monocytes [115]. 
Beside the effect on TNF-α production, monocytes from Crohn’s disease patients treated 
with therapeutic concentrations of infliximab showed also increased apoptosis via the 
activation of caspase-3, 8 and 9 [116].
Furthermore, the herbal medicine sinomenine was found to reduce migration of activated 
human monocyte cells and inhibits human monocytes-derived DC differentiation and 
maturation [71, 117]. In addition, peripheral blood monocytes from healthy donors cultured 
for 60 hours in the presence of different concentrations of sinomenine showed an enhanced 
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production of IL-6 and a decreased expression of IL-8, which is important for cell migration 
[118]. This would suggest a positive effect of sinomenine on monocyte infiltration and 
migration, although there is still an increased production of pro-inflammatory cytokines. 
However, this research was performed using monocytic THP-1 cell-line, and isolated 
peripheral blood monocytes from healthy donors, so that possible effects with regard to 
transplantation are still unknown. 
15-deoxyspergualin or gusperimus is a relatively long known immunosuppressive drug with 
an inhibitory effect on monocyte proliferation, TNF-α production and phagocytotic functions 
of monocytes. More recently, it was been suggested that gusperimus can also be effective 
in suppressing the antigen presentation function of monocytes in transplantation [119]. 
Another member of the spergualin family is LF15-0195. This drug is known for its inhibitory 
effect on monocyte accumulation in the tubulo-interstitial compartment of rat kidneys and 
was shown to have beneficial effects in the treatment of glomerulonephritis [120]. 
In diabetes mellitus, macrophage accumulation and activation play a central role in disease 
progression. Research on simvastatin, a drug to lower elevated lipid levels, has been 
shown to effectively lower IL-6, IL-8, TNF cytokine and superoxide anion production by 
monocytes isolated from human blood samples of patients with diabetes mellitus type 1 
[121]. In addition, simvastatin reduces the NFκB activity in monocytes with approximately 
60%, which causes the inhibition of IL-6 and IL-8 production. Treatment of IgA nephropathy 
with the drug atorvastatin showed a reduction of monocyte proliferation [122]. In diabetes 
mellitus type 2 patients this drug lowers the TNF-alpha production by monocytes [123]. 
Other studies in diabetes mellitus patients have shown potential effects of salsalate on 
macrophages activation. Salsalate, a prodrug of salicylic acid, is also known for the inhibition 
of the NFκB pathway in macrophages [124, 125]. This suggests a working mechanism for 
salsalate that is similar to simvastatin. Both drugs can be promising compounds to inhibit 
monocyte and macrophage activation.
In RA, research on therapeutic drugs to target monocytes and macrophages is more common 
because of the important role of monocytes in developing this disease. In addition, TNF-α 
is a key player known to cause inflammation in RA and is mainly produced by monocytes 
[126]. Some of the drugs used to suppress inflammation in RA could also have a potential in 
transplantation. For example, a decreased number of CD14+ CD16+ monocytes was found 
after treatment of RA patients with tocilizumab, an IL-6 receptor blocker [127]. In addition, 
production of IL-6 by monocytes from healthy donors was reduced when tocilizumab was 
added in vitro. The drug also induces the apoptosis of SEB (staphylococcal enterotoxin B)-
activated monocytes [128]. These results suggest that tocilizumab could theoretically impair 
the monocyte responses after transplantation. Furthermore, bromodomain and extra 
terminal (BET) inhibitors are developed to control the intracellular chromatin regulation 
responsible for the activation of monocytes, thereby inhibiting inflammation processes 
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induced by monocytes. In more detail, CD14+ monocytes were isolated from blood samples 
of healthy volunteers and cultured in the presence of BET inhibitors and IFN-β, IFN-γ, IL-4 
and IL-10 stimuli, where after the intracellular activation cytokine response were suppressed 
[129]. In RA patients this epigenetic control by BET inhibitors could suppress the production 
of pro-inflammatory cytokines and chemokines such as CXCL10. This would indicate that 
BET inhibitors could also inhibit monocyte activation after transplantation, although this is 
very speculative and require more research.
Fish oil based drugs, such as lovaza, are used to lower triglyceride levels in obesity. These 
fish oil compounds demonstrated a reduction in the number of macrophages and reduced 
MCP-1 blood levels [130]. Eicosapentaenoic acid, one of the major fatty acids in fish oil, 
reduces the secretion of TNF-α by human monocytic THP-1 cells, via the inhibition of the 
intracellular NFκB activation [131]. This suggests also a suppressing role for fatty acids in 
monocyte activation that could have a potential effect in transplantation as well.
Future challenges and developments 
Therapies targeting monocytes and macrophages in (SOT) could intervene at different 
points with monocyte actions and their subsequent functions (Figure 3). First, the activation 
and function of the cells can be inhibited at multiple stages: Signaling pathway activation, 
antigen presentation and cytokine production. Blockade of the intracellular signaling 
pathways inhibits the activation of monocytes and macrophages. For example, the use 
of specific MAPK inhibitors, such as SB203580, blocks the activation of monocytes [132]. 
However, these drugs will also block the activation of many other cell types. Targeting antigen 
presentation is even more difficult than targeting signaling pathways. It is known that the 
Fcγ-receptor on monocytes is involved in the recognition and processing of donor antigen 
specific antibodies [133, 134]. Blocking this receptor with specific antibodies could inhibit 
the antigen presentation function of monocytes. Furthermore, already existing drugs that 
reduce the cytokine production by monocytes and macrophages, for example canakinumab, 
infliximab and tocilizumab, mainly target the inhibition of one single cytokine. To be more 
effective, monocyte specific drugs should be developed to inhibit the production or the 
effects of multiple cytokines at once, thereby reducing side effects. 
Second, delivering any potential new drug to the target cell, in this case, monocytes and 
macrophages, is a major point of intervention, which could lower the side effects. One can 
envision a delivery system using the phagocytosis function of the monocyte/macrophage, 
whereby macrophages can ingest immunosuppressive drug loaded-inactivated bacteria or 
liposomes carrying the potential new drug [135]. However, the monocyte is not the only cell 
type with a phagocytic system. Therefore the surface of these bacteria or liposomes should 
be modified to facilitate the specific recognition by the monocyte/macrophage in order to 
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overcome side effects. Another approach to target monocytes and macrophages via their 
phagocytotic function is to use apoptotic cells through a process that is known as efferocytosis 
[99, 100]. Phagocytosis of these apoptotic cells by monocytes and macrophages will induce 
an anti-inflammatory response at the tissue level and may induce immunological tolerance. 
Furthermore, ex vivo experiments showed a decrease in CD11b expression on macrophages 
[136], suggesting that treatment with apoptotic cells induces the generation of Mregs. As 
mentioned above (paragraph “Glucocorticoids and monocyte/macrophage cell lineage”), the 
uptake of apoptotic cells can be enhanced by treatment with glucocorticoids [100].
The third point of therapeutic efficacy would be the manipulation of the nature of these 
cells. The future of in vivo manipulation of macrophages is intriguing; phenotypes could be 
changed by transfection with adenovirus, modulation of nuclear transcription factor NR4A1 
(Nur77) or by modulation of local microenvironment with cytokines to polarize macrophages 
to reparative phenotype [35]. Targeting all monocytes and macrophages indiscriminately 
could also be a disadvantage as regulatory and effector macrophages also have beneficial 
effects including the control of infections and the induction of regulatory cells [137]. 
Moreover, inhibition of all macrophages will also affect the number of Mregs, which are 
important for inducing tolerance after transplantation [138]. Too much inhibition of effector 
macrophages or Mregs could lead to graft rejection or complications, such as atherosclerosis 
and cardiovascular diseases. Furthermore, currently pre-scribed immunosuppressive drugs 
might miss the power to upregulate Mregs efficiently. In experimental mouse models, Mregs 
have demonstrated anti-inflammatory and T-cell suppressing effects (Other beneficial effects 
of Mregs are described in the paragraph “Monocyte immunobiology” [139, 140]. A more 
specific upregulation of these cells could be an approach to beneficially shift the balance 
towards macrophages controlling immune responses including those in organ transplant 
patients. Ideally, after SOT, the balance of macrophage subsets should be in favour of 
macrophages that control the anti-donor response, while the accumulation of macrophages 
with pro-inflammatory and antigen presentation characteristics should be decreased [141, 
142]. For example reduced function of the detrimental functions of macrophages involved 
in alloreactivity might be a useful therapy, although more research is needed to find a 
specific approach. Another way to differentiate between effector and controlling functions 
of macrophages could be by polarizing cells into M1 and M2 subsets. 
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Figure 3. Future challenges and developments: Strategies to target monocytes/macrophages. 
New therapies targeti ng monocytes and macrophages could intervene at three levels with monocyte acti ons and 
their subsequent functi ons as depicted, and described in manuscript body.
Targeti ng specifi c signaling pathways involved in this polarizati on process like the Notch 
signaling pathway could change the nature of these cells to an more anti -infl ammatory 
phenotype [143]. NFκB signaling, controlled by the Notch pathway, is associated with pro-
infl ammatory macrophage responses, while a more anti -infl ammatory phenotype is induced 
via the ERK pathway [143, 144]. Targeti ng these pathways with specifi c sti muli may change 
the phenotype of macrophages. Sti muli that induce macrophage polarizati on towards a M1 
phenotype are GM-CSF, IFN-γ and LPS, while IL-4, IL-13 and IL-10 enhance a M2 macrophage 
phenotype [145]. Future insight and research are necessary to investi gate the eff ect of these 
manipulated macrophages on healthy and diseased ti ssue.
Ideally, a potenti al new drug inhibiti ng monocytes-macrophages at these three levels would 
change the spectrum of not only rejecti on treatment or preventi on aft er (SOT) but also 
the course of many autoimmune mediated diseases. Either alone or in combinati on with 
other existi ng immunosuppressive drugs, this fi eld consti tutes a challenging area of future 
therapeuti c research. 
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
135134
7
Author Contributions
NMK and TPP contributed in the process of writing/design and discussing, DAH contributed 
in the process of discussion and reviewing, CCB contributed in the process of writing/design/
discussing and reviewing, ATR contributed in the process of writing/design/discussing and 
reviewing.
Disclosure
The authors of this manuscript have no conflicts of interest to disclose as described by 
Frontiers in Immunology.
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
135134
7
References
1. Koo, E.H., et al., The impact of early and late acute rejection on graft survival in renal transplantation. Kidney. 
Res. Clin. Pract., 2015. 34(3): p. 160-164.
2. Sellares, J., et al., Understanding the causes of kidney transplant failure: the dominant role of antibody-
mediated rejection and nonadherence. Am. J. Transplant., 2012. 12(2): p. 388-99.
3. Einecke, G., et al., Antibody-mediated microcirculation injury is the major cause of late kidney transplant 
failure. Am. J. Transplant., 2009. 9(11): p. 2520-31.
4. Meier-Kriesche, H.U., et al., Lack of improvement in renal allograft survival despite a marked decrease in 
acute rejection rates over the most recent era. Am. J. Transplant., 2004. 4(3): p. 378-83.
5. Nankivell, B.J. and S.I. Alexander, Rejection of the kidney allograft. N. Engl. J. Med., 2010. 363(15): p. 1451-62.
6. Mannon, R.B., Macrophages: Contributors to Allograft Dysfunction, Repair or Innocent Bystanders? Curr. 
Opin. Organ. Transplant., 2012. 17(1): p. 20-25.
7. Rowshani, A.T. and E.J.F. Vereyken, The Role of Macrophage Lineage Cells in Kidney Graft Rejection and 
Survival. Transplantation, 2012. 94(4): p. 309-318.
8. Girlanda, R., et al., Monocyte Infiltration and Kidney Allograft Dysfunction During Acute Rejection. Am. J. 
Transplant., 2008. 8(3): p. 600.
9. van Kooten, C. and M.R. Daha, Cytokine cross-talk between tubular epithelial cells and interstitial 
immunocompetent cells. Curr. Opin. Nephrol. Hypertens., 2001. 10(1): p. 55-59.
10. Moreau, A., et al., Effector Mechanisms of Rejection. Cold. Spring. Harb. Perspect. Med., 2013. 3(11).
11. Toki, D., et al., The Role of Macrophages in the Development of Human Renal Allograft Fibrosis in the First 
Year After Transplantation. Am. J. Transplant., 2014. 14(9): p. 2126-2136.
12. Sentís, A., et al., The prognostic significance of glomerular infiltrating leukocytes during acute renal allograft 
rejection. Transpl. Immunol., 2015. 33(3): p. 168-175.
13. Kwan, T., H. Wu, and S.J. Chadban, Macrophages in renal transplantation: Roles and therapeutic implications. 
Cell. Immunol., 2014. 291(1–2): p. 58-64.
14. Kozakowski, N., et al., Monocytes/macrophages in kidney allograft intimal arteritis: no association with 
markers of humoral rejection or with inferior outcome. Nephrol. Dial. Transplant., 2009. 24(6): p. 1979-1986.
15. Tinckam, K.J., O. Djurdjev, and A.B. Magil, Glomerular monocytes predict worse outcomes after acute renal 
allograft rejection independent of C4d status. Kidney Int., 2005. 68(4): p. 1866-1874.
16. Fahim, T., et al., The Cellular Lesion of Humoral Rejection: Predominant Recruitment of Monocytes to 
Peritubular and Glomerular Capillaries. Am. J. Transplant., 2007. 7(2): p. 385-393.
17. Özdemir, B.H., B. Demirhan, and Y. Güngen, The Presence and Prognostic Importance of Glomerular 
Macrophage Infiltration in Renal Allografts. Nephron, 2002. 90(4): p. 442-446.
18. Grimm, P.C., et al., Clinical Rejection Is Distinguished from Subclinical Rejection by Increased Infiltration by a 
Population of Activated Macrophages. Clin. J. Am. Soc. Nephrol., 1999. 10(7): p. 1582-1589.
19. Bergler, T., et al., Infiltration of Macrophages Correlates with Severity of Allograft Rejection and Outcome in 
Human Kidney Transplantation. PLoS One, 2016. 11(6): p. e0156900.
20. Om A, B.A., Raja R, Kim P, Bannett AD., The prognostic significance of the presence of monocytes in glomeruli 
of renal transplant allografts. Transplant. Proc., 1987. 19(1): p. 1618-22.
21. Copin, M.C., et al., Diagnostic and predictive value of an immunohistochemical profile in asymptomatic acute 
rejection of renal allografts. Transpl. Immunol., 1995. 3(3): p. 229-239.
22. Xu, L., et al., Increased macrophage density of cardiac allograft biopsies is associated with antibody-mediated 
rejection and alloantibodies to HLA antigens. Clin. Transplant., 2014. 28(5): p. 554-560.
23. Fishbein, G.A. and M.C. Fishbein, Morphologic and immunohistochemical findings in antibody-mediated 
rejection of the cardiac allograft. Hum. Immunol., 2012. 73(12): p. 1213-1217.
24. Oberbarnscheidt, M.H., et al., Non-self recognition by monocytes initiates allograft rejection. J. Clin. Invest., 
2014. 124(8): p. 3579-3589.
25. Boersema, M., et al., CD16+ monocytes with smooth muscle cell characteristics are reduced in human renal 
chronic transplant dysfunction. Immunobiology, 2015(0).
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
137136
7
26. Vereyken, E.J.F., et al., A Shift towards Pro-Inflammatory CD16+ Monocyte Subsets with Preserved Cytokine 
Production Potential after Kidney Transplantation. PLoS One, 2013. 8(7): p. e70152.
27. Kraaij, M.D., et al., Human monocytes produce interferon-gamma upon stimulation with LPS. Cytokine, 2014. 
67(1): p. 7-12.
28. Ziegler-Heitbrock, L., Blood monocytes and their subsets: established features and open questions. Front. 
Immunol., 2015. 6.
29. Ziegler-Heitbrock, L., Monocyte subsets in man and other species. Cell. Immunol., 2014. 289(1–2): p. 135-
139.
30. Ziegler-Heitbrock, L. and T.P. Hofer, Toward a refined definition of monocyte subsets. Front. Immunol., 2013. 
4: p. 23.
31. Wong, K.L., et al., The three human monocyte subsets: implications for health and disease. Immunol. Res., 
2012. 53(1-3): p. 41-57.
32. van Furth, R. and W. Sluiter, Distribution of blood monocytes between a marginating and a circulating pool. 
J. Exp. Med., 1986. 163(2): p. 474-479.
33. Swirski, F.K., et al., Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites. 
Science, 2009. 325(5940): p. 612-616.
34. Terry, R.L. and S.D. Miller, Molecular control of monocyte development. Cell. Immunol., 2014. 291(1–2): p. 
16-21.
35. Hanna, R.N., et al., The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the 
survival of Ly6C- monocytes. Nat. Immunol., 2011. 12(8): p. 778-785.
36. Ghattas, A., et al., Monocytes in Coronary Artery Disease and Atherosclerosis: Where Are We Now? J. Am. 
Coll. Cardiol., 2013. 62(17): p. 1541-1551.
37. Frankenberger, M., et al., Transcript profiling of CD16-positive monocytes reveals a unique molecular 
fingerprint. Eur. J. Immunol., 2012. 42(4): p. 957-974.
38. Brooks, C.F. and M. Moore, Differential MHC class II expression on human peripheral blood monocytes and 
dendritic cells. Immunology, 1988. 63(2): p. 303-11.
39. Ginhoux, F. and S. Jung, Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. 
Rev. Immunol., 2014. 14(6): p. 392-404.
40. Yona, S., et al., Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under 
Homeostasis. Immunity, 2013. 38(1): p. 79-91.
41. Hashimoto, D., et al., Tissue-Resident Macrophages Self-Maintain Locally throughout Adult Life with Minimal 
Contribution from Circulating Monocytes. Immunity, 2013. 38(4): p. 792-804.
42. W. Prodjosudjadi, M.R.D., J. S. J. Gerritsma, K. W. Florijn, J. N. M. Barendregt , J. A.Bruijn, F.J. van der Woude 
and L.A. van Es, Increased urinary excretion of monocyte ehemoattractant protein-1 during acute renal 
allograft rejection. Nephrol. Dial. Transplant., 1996. 11: p. 7.
43. Martinez, F.O. and S. Gordon, The M1 and M2 paradigm of macrophage activation: time for reassessment. 
F1000Prime Rep., 2014. 6: p. 13.
44. Hutchinson, J.A., et al., Cutting Edge: Immunological Consequences and Trafficking of Human Regulatory 
Macrophages Administered to Renal Transplant Recipients. J. Immunol., 2011. 187(5): p. 2072-2078.
45. Fleming, B.D. and D.M. Mosser, Regulatory macrophages: Setting the Threshold for Therapy. Eur. J. Immunol., 
2011. 41(9): p. 2498-2502.
46. Hutchinson, J.A., et al., Transplant acceptance-inducing cells as an immune-conditioning therapy in renal 
transplantation. Transpl. Int., 2008. 21(8): p. 728-741.
47. Hutchinson, J.A., et al., A cell-based approach to the minimization of immunosuppression in renal 
transplantation. Transpl. Int., 2008. 21(8): p. 742-754.
48. D’Aveni, M., et al., G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease. Sci. 
Transl. Med., 2015. 7(281): p. 281ra42-281ra42.
49. Netea, M.G., et al., Trained immunity: A program of innate immune memory in health and disease. Science, 
2016. 352(6284).
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
137136
7
50. Kleinnijenhuis, J., et al., Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from 
reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. U S A, 2012. 109(43): p. 17537-
17542.
51. Ostuni, R., et al., Latent Enhancers Activated by Stimulation in Differentiated Cells. Cell, 2013. 152(1–2): p. 
157-171.
52. Quintin, J., et al., Candida albicans Infection Affords Protection against Reinfection via Functional 
Reprogramming of Monocytes. Cell Host & Microbe, 2012. 12(2): p. 223-232.
53. Yoshida, K. and S. Ishii, Innate immune memory via ATF7-dependent epigenetic changes. Cell Cycle, 2016. 
15(1): p. 3-4.
54. Mohty, M., Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia, 2007. 
21(7): p. 1387-1394.
55. Bouvy, A.P., et al., Kinetics of homeostatic proliferation and thymopoiesis after rATG induction therapy in 
kidney transplant patients. Transplantation, 2013. 96(10): p. 904-13.
56. Sekerkova, A., et al., CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft 
transplantation. BMC Immunol., 2014. 15: p. 4-4.
57. Bosco, M.C., et al., Regulation by interleukin-2 (IL-2) and interferon gamma of IL-2 receptor gamma chain 
gene expression in human monocytes. Blood, 1994. 83(10): p. 2995.
58. Valitutti, S., et al., The expression of functional IL-2 receptor on activated macrophages depends on the 
stimulus applied. Immunology, 1989. 67(1): p. 44-50.
59. Hu, Y., et al., Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse 
model. Immunology, 2009. 128(2): p. 260-70.
60. Hale, G., et al., The CAMPATH-1 antigen (CDw52). Tissue Antigens, 1990. 35(3): p. 118-127.
61. Kirk, A.D., et al., Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific 
monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation, 2003. 76(1): p. 120-129.
62. Fabian, I., et al., Effects of CAMPATH-1 antibodies on the functional activity of monocytes and 
polymorphonuclear neutrophils. Exp. Hematol., 1993. 21(12): p. 1522-7.
63. Rao, S.P., et al., Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels 
and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis. PLoS One, 2012. 7(6): p. e39416.
64. Zhang, P.L., et al., Acute cellular rejection predominated by monocytes is a severe form of rejection in human 
renal recipients with or without Campath-1H (alemtuzumab) induction therapy. Am. J. Transplant., 2005. 
5(3): p. 604-7.
65. Bloom, D., et al., BAFF Is Increased in Renal Transplant Patients Following Treatment with Alemtuzumab. Am. 
J. Transplant., 2009. 9(8): p. 1835-1845.
66. Lenihan, C.R., J.C. Tan, and N. Kambham, Acute transplant glomerulopathy with monocyte rich infiltrate. 
Transpl. Immunol., 2013. 29(1–4): p. 114-117.
67. Liu, J., et al., Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 
1991. 66(4): p. 807-15.
68. Fruman, D.A., et al., Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin 
A. Proc. Natl. Acad. Sci. U S A, 1992. 89(9): p. 3686-90.
69. Vafadari, R., et al., Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney 
transplant recipients measured by whole-blood phosphospecific flow cytometry. Transplantation, 2012. 
93(12): p. 1245-51.
70. Kang, Y.J., et al., Calcineurin Negatively Regulates TLR-Mediated Activation Pathways. J. Immunol., 2007. 
179(7): p. 4598-4607.
71. Ou, Y.-q., et al., Sinomenine influences capacity for invasion and migration in activated human monocytic 
THP-1 cells by inhibiting the expression of MMP-2, MMP-9, and CD147. Acta Pharmacol. Sin., 2009. 30(4): p. 
435-441.
72. Howell, J., et al., Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver 
transplantation. Liver Transpl., 2013. 19(10): p. 1099-1107.
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
139138
7
73. Zhuang, Q. and F.G. Lakkis, Dendritic cells and innate immunity in kidney transplantation. Kidney Int., 2015. 
87(4): p. 712-8.
74. Rao, D.A. and J.S. Pober, Endothelial injury, alarmins, and allograft rejection. Crit. Rev. Immunol., 2008. 28(3): 
p. 229-48.
75. Kono, H. and K.L. Rock, How dying cells alert the immune system to danger. Nat. Rev. Immunol., 2008. 8(4): 
p. 279-89.
76. Weimer, R., et al., Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, 
and monokine responses. Hum. Immunol., 2000. 61(9): p. 884-97.
77. Tourneur, E., et al., Cyclosporine A Impairs Nucleotide Binding Oligomerization Domain (Nod1)-Mediated 
Innate Antibacterial Renal Defenses in Mice and Human Transplant Recipients. PLoS Pathog., 2013. 9(1): p. 
e1003152.
78. Zuckermann, A., et al., Comparison between mycophenolate mofetil- and azathioprine-based 
immunosuppressions in clinical lung transplantation. J. Heart. Lung. Transplant., 1999. 18(5): p. 432-40.
79. Rigotti, P., et al., Mycophenolate mofetil (MMF) versus azathioprine (AZA) in pancreas transplantation: a 
single-center experience. Clin. Nephrol., 2000. 53(4): p. suppl 52-4.
80. van Gelder, T. and D.A. Hesselink, Mycophenolate revisited. Transpl. Int., 2015. 28(5): p. 508-15.
81. Allison, A.C. and E.M. Eugui, Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 
2000. 47(2–3): p. 85-118.
82. Allison, A.C. and E.M. Eugui, Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, 
mycophenolate mofetil. Immunol. Rev., 1993. 136: p. 5-28.
83. Weimer, R.M., Joannis; Feustel, Andreas; Preiss, Astrid; Daniel, Volker; Grimm, Helmut; Wiesel, Manfred; 
Opelz, Gerhard, Mycophenolate mofetil-based immunosuppression and cytokine genotypes: effects on 
monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation, 2003. 
75(12): p. 2090-2099.
84. Glomsda, B.A., R.A. Blaheta, and N.P. Hailer, Inhibition of monocyte//endothelial cell interactions and 
monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord, 
2003. 41(11): p. 610-619.
85. Newton, R. and N.S. Holden, Separating transrepression and transactivation: a distressing divorce for the 
glucocorticoid receptor? Mol. Pharmacol., 2007. 72(4): p. 799-809.
86. Jantzen, H.M., et al., Cooperativity of glucocorticoid response elements located far upstream of the tyrosine 
aminotransferase gene. Cell, 1987. 49(1): p. 29-38.
87. Rigaud, G., et al., In vivo footprinting of rat TAT gene: dynamic interplay between the glucocorticoid receptor 
and a liver-specific factor. Cell, 1991. 67(5): p. 977-86.
88. Cato, A.C. and E. Wade, Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays, 
1996. 18(5): p. 371-8.
89. Rogacev, K.S., et al., Immunosuppression and monocyte subsets. Nephrol. Dial. Transplant., 2015. 30(1): p. 
143-153.
90. Orii, M., et al., Circulating CD14++CD16+ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect 
of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis. Circ. J., 2015. 79(7): p. 1585-92.
91. Sumegi, A., et al., Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding 
and activation of monocytes in patients suffering from systemic lupus erythematosus. Clin. Immunol., 2005. 
117(3): p. 271-9.
92. Girndt, M., et al., Glucocorticoids inhibit activation-dependent expression of costimulatory molecule B7-1 in 
human monocytes. Transplantation, 1998. 66(3): p. 370-375.
93. Jirapongsananuruk, O. and D.Y. Leung, The modulation of B7.2 and B7.1 on B cells by immunosuppressive 
agents. Clin. Exp. Immunol., 1999. 118(1): p. 1-8.
94. Hodge, G., et al., Up-regulation of Interleukin-8, Interleukin-10, Monocyte Chemotactic Protein-1, and 
Monocyte Chemotactic Protein-3 in Peripheral Blood Monocytes in Stable Lung Transplant Recipients: Are 
Immunosuppression Regimens Working? Transplantation, 2005. 79(4): p. 387-391.
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
139138
7
95. Blotta, M.H., R.H. DeKruyff, and D.T. Umetsu, Corticosteroids inhibit IL-12 production in human monocytes 
and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J. Immunol., 1997. 158(12): p. 5589-
95.
96. Rinehart, J.J., et al., Effects of corticosteroids on human monocyte function. J. Clin. Invest., 1974. 54(6): p. 
1337-43.
97. Italiani, P. and D. Boraschi, From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional 
Differentiation. Front Immunol, 2014. 5: p. 514.
98. Schif-Zuck, S., et al., Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by 
resolvins and glucocorticoids. Eur J Immunol, 2011. 41(2): p. 366-79.
99. Saas, P., E. Daguindau, and S. Perruche, Concise Review: Apoptotic Cell-Based Therapies-Rationale, Preclinical 
Results and Future Clinical Developments. Stem Cells, 2016. 34(6): p. 1464-73.
100. Poon, I.K., et al., Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol, 2014. 
14(3): p. 166-80.
101. Shipkova, M., et al., Therapeutic Drug Monitoring of Everolimus: A Consensus Report. Ther. Drug. Monit., 
2016. 38(2): p. 143-69.
102. Lin, H.Y.-H., et al., Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines. BMC 
Immunol., 2014. 15(1): p. 1-9.
103. Oliveira, J.G.G., et al., Compared to mycophenolate mofetil, rapamycin induces significant changes on growth 
factors and growth factor receptors in the early days postkidney transplantation1. Transplantation, 2002. 
73(6): p. 915-920.
104. Weichhart, T., et al., Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid 
immune cells. Blood, 2011. 117(16): p. 4273-4283.
105. Graav, G.N.d., et al., Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation. Ther. Drug. 
Monit., 2015. 37(5): p. 560-7.
106. Graav, G.N.d., et al., An Acute Cellular Rejection With Detrimental Outcome Occurring Under Belatacept-
Based Immunosuppressive Therapy: An Immunological Analysis. Transplantation, 2015. Online First.
107. Latek, R., et al., Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-
Receptor Saturation. Transplantation, 2009. 87(6): p. 926-933.
108. Ford, M.L., A.B. Adams, and T.C. Pearson, Targeting co-stimulatory pathways: transplantation and 
autoimmunity. Nat. Rev. Nephrol., 2014. 10(1): p. 14-24.
109. Bonelli, M., et al., Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients 
with rheumatoid arthritis. Arthritis Rheum., 2013. 65(3): p. 599-607.
110. Wenink, M.H., et al., Abatacept modulates proinflammatory macrophage responses upon cytokine-activated 
T cell and Toll-like receptor ligand stimulation. Ann. Rheum. Dis., 2011.
111. Dhimolea, E., Canakinumab. mAbs, 2010. 2(1): p. 3-13.
112. Hoffmann, M.W., et al., Production of cytokines (TNF-alpha, IL-1-beta) and endothelial cell activation in 
human liver allograft rejection. Transplantation, 1993. 55(2): p. 329-35.
113. Vereyken, E.J., et al., A shift towards pro-inflammatory CD16+ monocyte subsets with preserved cytokine 
production potential after kidney transplantation. PLoS One, 2013. 8(7): p. e70152.
114. Wanderer, A.A., Rationale and timeliness for IL-1β-targeted therapy to reduce allogeneic organ injury at 
procurement and to diminish risk of rejection after transplantation. Clin. Transplant., 2010. 24(3): p. 307-311.
115. Ebert, E.C., Infliximab and the TNF-α system. Am. J. Physiol. Gastrointest. Liver. Physiol., 2009. 296(3): p. 
G612-G620.
116. Lugering, A., et al., Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's 
disease by using a caspase-dependent pathway. Gastroenterology, 2001. 121(5): p. 1145-57.
117. Wang, Q. and X.-K. Li, Immunosuppressive and anti-inflammatory activities of sinomenine. Int. 
Immunopharmacol., 2011. 11(3): p. 373-376.
118. Shenghao, T., H. Yonghong, and L. Fu’er, Effect of sinomenine on IL-8, IL-6, IL-2 produced by peripheral blood 
mononuclear cells. J. Tongji Med. Univ., 1999. 19(4): p. 257-259.
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
141140
7
119. Perenyei, M., D.R. Jayne, and O. Flossmann, Gusperimus: immunological mechanism and clinical applications. 
Rheumatology, 2014. 53(10): p. 1732-41.
120. Tesch, G.H., et al., LF15-0195 prevents the induction and inhibits the progression of rat anti-GBM disease. 
Kidney Int, 2001. 60(4): p. 1354-65.
121. Jialal, I., et al., Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation 
with low-dose simvastatin therapy in patients with type 1 diabetes. J. Clin. Endocrinol. Metab., 2007. 92(8): 
p. 3136-40.
122. Lundberg, S., et al., Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with 
IgA nephropathy: a chronic inflammatory kidney disease. Clin. Nephrol., 2010. 73(3): p. 221-8.
123. Mandosi, E., et al., Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha 
levels in type 2 diabetes. J. Atheroscler. Thromb., 2010. 17(6): p. 539-45.
124. Donath, M.Y. and S.E. Shoelson, Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol., 2011. 11(2): 
p. 98-107.
125. McCarty, M.F., Salsalate may have broad utility in the prevention and treatment of vascular disorders and the 
metabolic syndrome. Med. Hypotheses, 2010. 75(3): p. 276-81.
126. Davignon, J.-L., et al., Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. 
Rheumatology, 2012.
127. Kikuchi, J., et al., Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased 
by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with 
clinical response. Arthritis Res. Ther., 2015. 17: p. 10.
128. Tono, T., et al., Effects of anti-IL-6 receptor antibody on human monocytes. Mod. Rheumatol., 2015. 25(1): p. 
79-84.
129. Chan, C.H., et al., BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT 
signaling in a gene-specific manner in human monocytes. Eur. J. Immunol., 2015. 45(1): p. 287-97.
130. Spencer, M., et al., Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin 
resistance. Diabetes, 2013. 62(5): p. 1709-17.
131. Zhao, Y., et al., Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB 
activation. J. Am. Coll. Nutr., 2004. 23(1): p. 71-8.
132. Kaminska, B., MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular 
mechanisms to therapeutic benefits. Biochim. Biophys. Acta, 2005. 1754(1-2): p. 253-62.
133. Gosselin, J., et al., Modulatory effects of Epstein-Barr, herpes simplex, and human herpes-6 viral infections 
and coinfections on cytokine synthesis. A comparative study. J. Immunol., 1992. 149(1): p. 181-7.
134. Castro-Dopico, T. and M.R. Clatworthy, Fcγ Receptors in Solid Organ Transplantation. Curr. Transplant. Rep., 
2016: p. 1-10.
135. Kelly, C., C. Jefferies, and S.-A. Cryan, Targeted Liposomal Drug Delivery to Monocytes and Macrophages. J. 
Drug. Deliv., 2011. 2011: p. 11.
136. Pashover-Schallinger, E., et al., The atypical chemokine receptor D6 controls macrophage efferocytosis and 
cytokine secretion during the resolution of inflammation. Faseb J, 2012. 26(9): p. 3891-900.
137. Murray, P.J. and T.A. Wynn, Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol, 
2011. 11(11): p. 723-37.
138. Zhang, C., et al., The Crosstalk between Myeloid Derived Suppressor Cells and Immune Cells: To Establish 
Immune Tolerance in Transplantation. J Immunol Res, 2016. 2016: p. 4986797.
139. Brem-Exner, B.G., et al., Macrophages driven to a novel state of activation have anti-inflammatory properties 
in mice. J Immunol, 2008. 180(1): p. 335-49.
140. Kraaij, M.D., et al., Dexamethasone increases ROS production and T cell suppressive capacity by anti-
inflammatory macrophages. Mol Immunol, 2011. 49(3): p. 549-57.
141. Conde, P., et al., DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance. Immunity, 
2015. 42(6): p. 1143-58.
142. Scalea, J.R., et al., Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms. Front Immunol, 
2016. 7: p. 87.
Chapter 7 Targeting monocyte-macrophage lineage cells in SOT
141140
7
143. Quillard, T. and B. Charreau, Impact of notch signaling on inflammatory responses in cardiovascular disorders. 
Int J Mol Sci, 2013. 14(4): p. 6863-88.
144. Zhang, Q., et al., Notch signal suppresses Toll-like receptor-triggered inflammatory responses in macrophages 
by inhibiting extracellular signal-regulated kinase 1/2-mediated nuclear factor kappaB activation. J Biol 
Chem, 2012. 287(9): p. 6208-17.
145. Wang, N., H. Liang, and K. Zen, Molecular mechanisms that influence the macrophage m1-m2 polarization 
balance. Front Immunol, 2014. 5: p. 614.

Chapter 8
Summary and Discussion
Chapter 8 Summary and Discussion
145144
8 8
Summary 
In the last decade it became apparent that apart from cells of the adaptive immune system 
such as the well-known T and B lymphocytes also cells of the innate immune system i.e., 
NK cells, DC and monocytes actively contribute to the rejection response after organ 
transplantation. In this response DC and monocytes present antigen, secrete pro- and 
anti-inflammatory cytokines, proliferate, differentiate while NK cells secrete cytokines 
and are cytolytic. The central aim of this thesis is to examine the role of monocytes and 
macrophages in various types of rejection and in fibrotic processes in immunosuppressed 
kidney and heart transplant recipients.
 In chapter 2, we aimed to identify and correlate monocyte – macrophage profiles in tissue 
(endomyocardial biopsies) and corresponding blood samples both prior and during an 
acute cellular rejection episode in heart transplant recipients. At tissue level, striking CD16+ 
monocyte infiltration was observed during rejection. An interesting observation was done 
for the infiltrating macrophages. During acute rejection significantly more CD68+CD163+ 
M2 macrophages were present in the allograft than in specimens without histological signs 
of rejection. Moreover, acute rejection was associated with severe fibrosis in 1-year biopsies 
(p < 0.001). In the peripheral blood lower frequencies of CD16+ monocytes were found in 
patients compared to healthy individuals. At the time of rejection, significantly increased 
CD54 (adhesion molecule) and HLA-DR (activation marker) expression levels were found on 
peripheral CD16+ monocytes with retained cytokine production potential. The association 
of acute rejection with development of fibrosis at later stages after transplantation links the 
consequences of tissue injury with development of more chronic, fibrotic processes which 
might lead to failure of the allograft at later stages. 
The elucidation of the molecular mechanisms underlying the observed cellular shifts in both 
peripheral blood and allograft may enable the timely adjustment of immunosuppressive 
drugs aiming to improve outcome after transplantation. In addition, it may lead to the 
discovery of molecular biomarkers that are also helpful in finding molecular targets for 
specific immunosuppressive therapy.
In chapter 3, we hypothesized that there are significant compartmental differences in 
monocyte – macrophage infiltration between different types of rejection that affect the 
outcome of kidney transplants. To address this hypothesis, we studied 48 kidney transplant 
rejection biopsies diagnosed according to the latest Banff 2015 by staining for monocyte 
and macrophage subtypes. Next, we correlated the histopathological findings with other 
rejection-associated variables in time up to 12 months after the biopsy procedure using 
multivariate analysis. We found that CD163+CD68+ M2 type macrophages were associated 
with clinical diagnoses of rejection, regardless of Banff category. Importantly, we found that 
CD163+CD68+ macrophages were associated with worse kidney graft function in the long-
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term. Compartmental infiltration analysis showed that glomerular and perivascular infiltration 
of monocyte subtypes and tubulointerstitial infiltration of mainly CD16+ monocytes were 
associated with rejection. Furthermore, we learnt that there are significant compartmental 
differences in the distribution of different macrophage and monocyte subtypes between 
c-aABMR vs. a-aABMR, and a-aABMR vs. TCMR II/ I. Compartmental infiltration showed 
potential diagnostic patterns as shown by glomerular monocyte infiltration during c-aABMR, 
prominent perivascular presence of CD68+ CD163+ in a-aABMR and TCMRII, and high 
perivascular CD16+ monocyte infiltration during TCMR II. Comparing a-aABMR to TCMR I/II; 
glomerular CD16+ monocyte infiltration hallmarked TCMR I, while perivascular infiltration 
of mainly CD16+ monocytes and CD68+CD163 + macrophages signified TCMR II. Glomerular 
CD68+ CD163+ macrophage infiltration was significantly higher in a/a ABMR. Comparing 
a-aABMR with c-aABMR; we found that a prominent glomerular infiltration by all monocyte 
subsets in c-aABMR, also significantly more CD14+ perivascular monocyte distribution was 
observed in c-aABMR. In this study, perivascular infiltration by CD68+CD163+ macrophages 
signified a-aABMR. Further research to the underlying compartmental mechanisms of 
specific patterns together with larger validation studies will set a benchmark about the role 
of monocytes-macrophages in rejection processes. 
In chapter 4, we questioned if differences in monocyte subset composition of the 
pretransplantation blood samples associated with rejection after kidney transplantation. 
Recipients who developed an acute rejection response had higher absolute numbers of 
CD16+ monocytes at the time of transplantation than patients who remained free from this 
complication. Higher absolute numbers of classical CD14+ monocytes were associated with 
lower rejection risk. In a pilot-case-control study, we studied 6 kidney transplant rejection 
biopsies and timely matched kidney transplant control biopsies without rejection showing 
normal transplant tissue. We found higher numbers of tissue resident CD16+ monocytes in 
rejection biopsies. In parallel, we observed a clear decrease in circulating CD16+ monocytes 
indicating the migration of these proinflammatory monocytes from the circulations towards 
rejecting kidney transplant tissue. Altogether, our data show that higher pretransplant 
numbers of CD16+ monocytes are associated with a significantly higher rejection risk, shorter 
rejection free survival, and may serve as an early biomarker to predict acute rejection after 
kidney transplantation. 
In chapter 5, we focused on tissue expression of micro(mi)RNAs in 32 kidney rejection 
biopsies and if these profiles discriminate between the different Banff rejection categories. 
We compared microRNAs expression profiles between a-aABMR vs. aTCMR and a-aABMR 
vs. c-aABMR, and performed pathway analyses to search for the target proteins and the 
contributions of specific miRNAs in the rejection process. We identified 55 differentially 
expressed microRNAs between a-aABMR and aTCMR. MicroRNA-100-5p was identified as 
one of the most differentially expressed miRNA’s. From the literature it is known that this 
microRNA-100-5p controls the expression of CD209 (DC-SIGN) which is expressed by both 
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macrophages and dendritic cells and contribute to the rejection process by subverting the 
alloimmune response [1]. The microRNAs found in this study are all part of immune and 
inflammation pathways which again shows the dominant role of these pathways in the 
anti-donor response. This pathways are enriched with immune cells such as lymphocytes, 
monocytes – macrophages, NK cells and dendritic cells. These cells are all involved during 
rejection of the allograft. Nevertheless, it is clear that more studies are warranted in larger 
cohorts also including samples showing no signs of rejection i. to validate our findings, and 
ii. to determine the association of specific miRNAs with either a-aABMR or aTCMR.
Because IFN-γ plays a pivotal role in both innate and adaptive immunity we studied in 
chapter 6, the ability of monocytes to produce this cytokine. For these studies we used 
peripheral blood samples of healthy individuals and immunosuppressed kidney transplant 
recipients. Upon LPS stimulation increased IFN-γ mRNA and protein levels were produced by 
CD14+ monocytes from both controls and patients. Interestingly, we noticed that stimulation 
of freshly isolated CD14+ monocytes of healthy individuals and transplant patients by LPS 
alone or in combination with IFN-γ, lead to a significant increase in the percentage of TNF-α 
and IFN-γ producing monocytes. Thus, monocytes do have the capacity to produce IFN-γ, an 
important mediator in the rejection process. 
In chapter 7, we discussed the effects of currently given immunosuppressive drugs on the 
monocyte – macrophage functions as well as future opportunities for the development 
of novel immunosuppressive drugs for transplantation. After reviewing the literature, 
it was clear that surprisingly little is known about the impact of immunosuppression on 
monocyte-macrophages functions. There is some first evidence that immunosuppressant’s 
such as MMF and mTOR inhibitors have limited inhibitory effects. Also CNIs do suppress 
the activation of monocytes but not to the same degree as in T-cells, described effects 
of immunosuppressive drugs on monocytes-macrophage functions include: inhibition of 
cytokine transcription and subsequent production, and inhibition of migration of these cells 
to the site of rejection. In addition to the literature focusing on these immunosuppressive 
drugs, we speculate that future studies targeting the monocyte-macrophages should be 
designed aiming to i: inhibit monocyte activation and function, ii: develop specific delivery 
systems via lipid vesicles and iii. manipulate the nature of monocytes and macrophages by 
modulation of Nur77 or modulation of the microenvironment and polarize them towards 
reparative and anti-inflammatory phenotypes. Ideally, new immunosuppressive drugs 
should inhibit the monocyte/macrophage at all these levels, which might prevent and also 
can be used to treat rejection. 
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Discussion 
The overall aim of this thesis is to improve our understanding about the role of monocytes – 
macrophages in rejection responses after transplantation required to achieve improved graft 
outcomes. Presence of high numbers of monocyte-macrophages has been associated with 
poor allograft function and survival [2-4]. Here, we analyzed whether specific monocyte-
macrophages profiles in grafted tissue and circulation are associated with biopsy proven 
rejection in heart transplant recipients [2-4]. The decreased CD16+ monocytes and increased 
CD16- monocytes frequencies in the peripheral blood suggest transendothelial migration of 
pro-inflammatory CD16+ monocytes to the allograft tissue at the time of rejection [5, 6]. 
In addition, presence of CD16+ monocytes in the allograft was associated with advanced 
vascular dysfunction in patients who develop early coronary artery disease [7]. In line 
with these findings we also found a shift in the balance between CD14+ CD16+ monocyte 
subsets and M1-M2 macrophages that were associated with the presence of fibrosis after 
rejection in heart patients. CD16+ monocytes and M2 macrophages secrete cytokines 
and growth factors known for their involvement in fibrotic processes such as TGF-β and 
Galactin-3 a protein associated with cardiac fibrosis and atrial fibrillation [8]. Also after heart 
transplantation these factors secreted by the infiltrated monocytes – macrophages might 
contribute to fibrosis of the damaged heart transplant [9, 10].   
Also in kidney transplantation the role of monocytes-macrophages in allogeneic responses 
has been recognized. Our observation that higher pretransplant numbers of CD16+ 
monocytes were associated with a significantly higher rejection risk and shorter rejection 
free survival shows importance of this cell population in anti-donor reactivity. This potential 
role of CD16+ monocytes makes this cell population an interesting marker to further 
develop as a biomarker for rejection. However, high numbers of circulating monocytes 
might be influenced by the underlying kidney disease and/or renal replacement therapy. 
For example, studies reporting data of patients on dialysis showed increased levels of 
circulating CD16+ monocytes that produced high levels of the pro-inflammatory cytokines 
IL-1β, TNF-α and IL-6 [11]. Another study reported that patients on hemodialysis have a 
temporary absence of their circulating monocytes that recover after the dialysis procedure 
and reappear in the circulation as highly activated CD16+ monocytes [12]. Our studies show 
promising results but need validation in other cohorts of kidney transplant patients. This will 
confirm that absolute number of CD16+ monocytes can be used as to identify patients at 
risk for rejection.  
Diagnosis of rejection is made by histological examination of the kidney biopsy in combination 
with the clinical parameters of rejection. Histopathological lesions are non-specific and the 
diagnosis depends on the pathologist’s evaluation with limited reproducibility between 
pathologists [13-16]. As described in the introduction of this thesis, the BANFF criteria have 
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led to improvement of diagnostic accuracy of different types of rejection in kidney transplant 
recipients [17-19]. We here report that M2 type macrophages are significantly associated 
with clinical rejection regardless of Banff category. The large number of M2 macrophages and 
their active state could lead to the continuous production of TGF-β and several other growth 
factors that promote proliferation of myofibroblasts, activation of epithelial-mesenchymal 
transition/endothelial-mesenchymal transition and extra cellular matrix deposition [20]. 
Interestingly, the compartmental differences between subtypes of rejection indicate that 
these cells could accumulate in specific compartments of the kidney. Hoffmann et al. 
reported that high numbers of activated CX3CR1+CD68+ macrophages are present in acute 
tubulointerstitial and acute vascular rejection [21]. A recent study by Bergler et al. showed 
that glomerular CD68+ macrophage infiltration with active expression of Ki67 (proliferation 
marker) could be a surrogate for ABMR, indicating that infiltrating macrophages act as active 
triggers of alloimmune inflammation and severe graft injury [22]. Moreover, cases with 
severe glomerular endothelial injury associated with monocyte-macrophage infiltration in 
patients on alemtuzumab anti-rejection therapy have been described [23-26]. 
In view of rapid advances in our knowledge of human genome and microRNAs, also the field 
of transplantation immunology will take advantage of these new insights [27-31]. In order 
to better define differences in distinct alloimmune inflammatory responses, which give rise 
to different types of rejection, a molecular approach could be used. In our study, we found 
significant differences between a-aABMR and TCMR, whereas less differences were found 
between a-aABMR and c-aABMR. The latter might be due to a small sample size. Particularly 
the expression of microRNA-100-5p was different between a-aABMR and aTCMR. It is known 
that this microRNA is indirectly involved with adhesion molecule CD209 (DC-SIGN) and 
functional studies should demonstrate the functional interaction between microRNAs-100-
5p and CD209 [32, 33]. The majority of the infiltrated myeloid dendritic cells express CD209. 
This molecule stimulates T-cells [33]. Also microRNA-145-5p, controlled by TGF-β1, interacts 
with many cellular functions such as cell growth, cell proliferation, cell differentiation and 
apoptosis [34-36]. MicroRNA-145-5 is expressed by CD4+ and CD8+T-cells, and CD19+ 
B-cells [37]. Our data provide interesting new data but also clearly shows the limitations of 
miRNA studies which requires further studies before conclusions can be drawn that impact 
diagnostic decisions. Specificity and interpretation of kidney biopsy derived microRNAs is 
a hurdle to be taken. For example many different cell types of the kidney contain a broad 
range of miRNAs, all with their unique targets and functions. Therefore, a limitation of 
biopsy studies is that the cellular source expressing a particular miRNA is unknown. Also 
miRNAs can interact with multiple genes. To determine the biological impact of a particular 
miRNA also mRNA expression should be studied. This will lead to a better understanding of 
the cells and pathways involved in rejection processes. Another limitation is that the present 
microRNA library is being constantly updated as more validated targets are incomplete or 
due to ongoing experiments [31].  
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Looking outside the box of currently used immunosuppressive drugs in solid organ 
transplantation; there are other compounds with immune-inhibitory effects that are 
of interest for the organ transplantation field. First, the human monoclonal antibody 
canakinumab, originally designed as an IL-1β inhibitor for the repression of inflammation 
in autoimmune diseases, might also inhibit the IL-1β production by monocytes involved in 
allogeneic reactions after transplantation [38]. A high expression of IL-1β is noticed in the 
most severe liver transplant rejection episodes and at the time of kidney transplantation, 
suggesting the importance of blocking its production by monocytes [39, 40]. Second, 
infliximab, originally used in the treatment of autoimmune diseases, is a monoclonal 
antibody targeting TNF-α production, a cytokine produced in high amounts by activated 
monocytes and macrophages. Therefore, infliximab could also target monocyte functions 
during rejection [41]. Besides the effect on TNF-α production, monocytes from Crohn’s 
disease patients treated with therapeutic concentrations of infliximab also showed increased 
apoptosis via the activation of caspase-3, 8 and 9 [42]. A first study in kidney transplantation 
by the Berlin group reported excellent 5-year outcome [43]. Third, production of IL-6 by 
activated monocytes obtained from healthy donors was reduced when tocilizumab was 
added in vitro. The drug also induced apoptotic cell death of SEB (staphylococcal enterotoxin 
B)-activated monocytes [44]. These results support the hypothesis that tocilizumab 
inhibits monocyte responses after transplantation [45-47]. Recently, it was demonstrated 
that tocilizumab can suppress TNF-α production in monocytes during in vitro antibody-
dependent cellular cytotoxicity assay suggesting a role of IL-6 pathway in TNF- α monocyte 
activation [48]. 
After reviewing the literature about the effects of immunosuppressive drugs on monocyte 
and macrophage functions it is obvious that the current clinically used immunosuppressive 
drugs do not specifically target this cell population. Looking into the future, several recently 
developed immunosuppressive drugs that are used in autoimmunity are of interest for 
the clinical transplantation field. The necessity of implementation of these agents and 
translation of developments in preclinical models targeting monocytic cells to the clinic is 
clear. These agents might also inhibit acute and chronic alloimmune responses, which will 
lead to improved outcomes.
Conclusions
The described research in this thesis aimed to investigate the role of monocytes and 
macrophages in rejection processes after kidney and heart transplantation. It was 
concluded that there are clear shifts of monocyte subset composition in both peripheral 
blood and transplanted organ during rejection after heart transplantation. A predominant 
presence of CD16+ monocytes and M2 type macrophages in the allograft was found which 
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was associated with an increased risk for the development of fibrosis detectable in 1-year 
post-transplant biopsies. In rejectors after kidney transplantation, high absolute numbers 
of CD16+ monocytes were measured in their subsequent pretransplantation blood sample. 
These first findings should be further explored for validation as well as the mechanisms 
involved. Only then this could be further developed as a predictive marker for rejection. 
Tissue infiltration with CD68+CD163+ macrophages was significantly associated with worse 
transplant function after rejection. The presence of glomerular and perivascular monocytes 
and CD68+CD163+ macrophages in the rejecting graft tissue can serve as a hallmark of clinical 
rejection independent of histopathological Banff assignment. Compartemental infiltration 
showed potential specific diagnostic patterns with possible clinical implementation in typing 
and grading of rejection in relation to graft outcome.
Overall, this thesis provides novel insights about the role of monocytes - macrophages in the 
allograft rejection process. Our data show that these cells play pivotal roles in both TCMR 
and ABMR. Given our findings, we postulate that based on monocyte features i. diagnostic 
tests should be developed to better identify patients at risk for rejection and ii. that 
immunosuppression therapy should be applied also targeting monocytes – macrophages 
actions. 
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Samenvatting
Bij patiënten met eindstadium nier- of hartfalen is transplantatie de enige mogelijkheid voor 
een betere kwaliteit van leven en levensverwachting. Deze kwaliteit van leven kan nooit 
helemaal gelijk zijn aan die van gezonde personen omdat transplantatie patiënten hun leven 
lang medicijnen zullen moeten blijven slikken die ervoor zorgen dat het getransplanteerde 
orgaan niet kan worden afgestoten. 
De nieren zijn belangrijke organen in het menselijk lichaam en hebben verschillende 
functies zoals het verwijderen van afvalstoffen, regulatie van vocht en zouten, regulatie 
van de bloeddruk en de productie van hormonen die aanmaak van rode bloedcellen 
stimuleren. De nieren kunnen beschadigd raken door verschillende oorzaken zoals hoge 
bloedruk, diabetes, medicijn gebruik en auto-immuunziektes. Patiënten bij wie de nieren 
steeds slechter functioneren zijn uiteindelijk aangewezen op dialyse totdat er een donornier 
beschikbaar komt. Transplantatie van een nier is de beste oplossing om de nierfunctie voor 
de patiënt te vervangen. 
Een klein deel van patiënten met eindstadium hartfalen als gevolg van uitgebreide coronair 
ziekte, hartspierziekte zoals cardiomyopathie of een aangeboren hartafwijking ondergaan 
een harttransplantatie wanneer andere medische of chirurgische behandelingen niet meer 
mogelijk of afdoende zijn. Het probleem na transplantatie is dat het lichaamsvreemde 
orgaan wordt aangevallen door het afweersysteem van de patiënt. Om dit te voorkomen 
dan wel te onderdrukken krijgen nier- en harttransplantatiepatiënten afweerremmende 
geneesmiddelen genaamd immunosuppressiva voorgeschreven. Er zijn verschillende afweer 
onderdrukkende medicijnen maar desalniettemin kan er een acute afstotingsreactie bij 
nier- en harttransplantatiepatiënten plaats vinden waarvoor zij dan extra geneesmiddelen 
moeten krijgen. In het eerste jaar na niertransplantatie gebeurd dit bij ongeveer 15% van de 
patiënten en na harttransplantatie bij 25% van de patiënten. 
Er zijn verschillende soorten van afstoting, meest voorkomend in de eerste 6 maanden na 
transplantatie is de acute afstoting (TCMR) waarbij de afweercellen genaamd T- cellen van 
de patiënt worden geactiveerd tegen de eiwitten (antigenen) van de donornier. Ook is er 
een chronische vorm (ABMR) van afstoting. Bij deze vorm van afstoting spelen antilichamen 
en complement factoren een belangrijke rol. Bij deze afstotingsreacties zijn verschillende 
typen cellen van het aangeboren en verworven afweersysteem betrokken. Onderzoek heeft 
laten zien dat naast cellen van het verworven immuunsysteem zoals de T- en B-cellen ook 
cellen van het aangeboren immuunsysteem zoals “natural killer cells” (NK cellen), “dendritic 
cells” (DC cellen) en monocyten/macrofagen, aan de afstotingsreactie bijdragen. Echter, er 
is nog maar weinig bekend over wat precies de rol en bijdrage van deze monocyten en 
macrofagen in de diverse typen van afstoting is. 
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Monocyten en macrofagen kun je onderverdelen in verschillende subsets. Monocyten 
bestaan uit 3 subtypes: klassieke monocyten (CD14++CD16-), intermediaire monocyten 
(CD14++CD16+) en niet-klassieke monocyten (CD14+CD16++). De CD16+ monocyten staan 
er om bekend dat ze na stimulatie met antigeen hoge hoeveelheden van pro-inflammatoire 
cytokinen kunnen produceren. Macrofagen kun je ook onderverdelen in verschillende 
subtypes: M1 macrofagen (CD68+CD80+) die bekend staan als pro-inflammatoire cellen 
die hoge hoeveelheid cytokines maken, en M2 macrofagen (CD68+CD163+) die bekend 
staan als anti-inflammatoire cellen die voornamelijk betrokken zijn bij de opruimreactie 
(bindweefselvorming) na een ontsteking.
In dit proefschrift onderzoeken wij de rol alsmede de bijdrage van monocyten-macrofagen 
in afstotingsreacties maar ook in productie van ongewenste bindweefselvorming in 
getransplanteerde nieren en harten. 
In hoofdstuk 2 onderzochten wij de bijdrage van verschillende typen monocyten en 
macrofagen in het afstotingsproces in hartweefsels en bloedsamples van dezelfde patiënten 
zowel voor, als tijdens en na een acute cellulaire afstoting na harttransplantatie. We 
vonden veel geïnfiltreerde CD16+ monocyten in het getransplanteerde hart tijdens de 
acute afstotingsreactie. Opvallend daarbij was dat er tijdens de acute afstoting een groot 
aantal CD68+CD163+ M2 type macrofagen werd gevonden in het weefsel in vergelijking 
tot het hartweefsel zonder histologische afstoting. Acute afstoting was tevens geassocieerd 
met fibrosevorming tot 1 jaar na de afstotingsreactie. In het bloed van deze patiënten 
werden er lagere frequenties van CD16+ monocyten gemeten in vergelijking met gezonde 
individuen. Tijdens een afstotingsreactie vonden we ook een verhoogde concentratie van 
allerlei moleculen zoals CD54 en HLA-DR op de CD16+ monocyten die uiteindelijk cytokine 
productie stimuleren. De belangrijkste bevinding was dat schade opgedaan tijdens de 
afstoting, 1 jaar na afstoting nog meer chronische schade zal veroorzaken en daarbij een 
belangrijke rol meespeelt in het uiteindelijk falen van het harttransplantaat. 
In hoofdstuk 3 toetsten we de hypothese of er in de verschillende compartimenten van 
getransplanteerde nieren er verschillen zijn in aantal en type infiltrerende monocyten en 
macrofagen. Daarnaast hebben we de relatie tussen aanwezigheid van deze cellen met 
de histopathologische diagnoses onderzocht. Om de hypothese te testen hebben wij 48 
niertransplantatie biopten die gediagnosticeerd zijn met de laatste Banff 2015 classificatie 
immunohistochemisch gekleurd voor markers die voorkomen op monocyten en macrofagen. 
Daarnaast werden de histopathologische bevindingen gecorreleerd met afstoting 
gerelateerde variabelen in de tijd tot 12 maanden na biopsie, daarbij gebruikmakend van 
multivariate analyse. Wij vonden dat M2-type macrofagen geassocieerd waren met de 
klinische diagnose van afstoting, onafhankelijk van de Banff categorie. Bovendien was een 
belangrijke bevinding dat M2 macrofagen geassocieerd waren met een slechtere nierfunctie 
op de langere termijn. We zagen dat veel infiltrerende CD16+ monocyten in de glomerulaire 
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ruimtes, langs en in de bloedvaten en in de tubulointerstitiële ruimte infiltreerden. Er bleken 
significante verschillen te bestaan tussen c-aABMR versus a-aABMR, en a-aABMR versus 
TCMR I/II in deze compartimenten. De patronen van compartiment infiltratie correleert met 
diagnostische categorieën. Zo zagen wij glomerulaire infiltratie tijdens c-aABMR, prominente 
aanwezigheid van M2-macrofagen bij de vaten in a-aABMR en hoge infiltratie van CD16+ 
monocyten in de vaten tijdens TCMR II. Glomerulaire infiltratie van CD16+ monocyten in 
TCMR I terwijl er hoge infiltratie van CD16+ monocyten en M2 macrofagen bij de vaten tijdens 
TCMR II werd gevonden behoren tot de belangrijke bevindingen. Vergelijking van a-aABMR 
met c-aABMR leerde ons dat een hoog aantal infiltrerende monocyten van alle subtypes 
in de glomeruli tijdens c-aABMR met daarbij ook significant meer CD14+ monocyten bij 
de vaten werden gevonden. In deze studie vonden wij dat perivasculaire infiltratie van M2 
macrofagen op a-aABMR duidt. Verder onderzoek naar de onderliggende mechanismen 
van deze specifieke compartiment verdeling in een grotere cohort zal een duidelijker beeld 
verschaffen over de rol van monocyten en macrofagen tijdens het afstotingsproces. 
In hoofdstuk 4 onderzochten wij of voorafgaand aan de transplantatie procedure er 
al verschil aantoonbaar was in bepaalde subpopulaties van monocyten in het bloed van 
niertransplantatiepatiënten en of deze geassocieerd zijn met afstoting. Wij vonden een 
hoger aantal CD16+ monocyten op het pretranplantatie tijdspunt in patiënten die een 
acute afstoting ontwikkelden in vergelijking tot niertransplantatiepatiënten bij wie geen 
afstoting optrad. Een hoog aantal van CD14+ monocyten in het bloed was geassocieerd 
met een lager risico op het optreden van afstoting. In een pilot-case-control studie hebben 
wij 6 nierbiopten met afstoting vergeleken met controle biopten zonder afstoting. In de 
afstotingsbiopten waren veel infiltrerende CD16+ monocyten aanwezig. Deze bevindingen 
duiden erop dat circulerende CD16+ monocyten naar de afstotingsreactie van de 
getransplanteerde nier migreren. Onze data laat zien dat een hoog aantal absoluut CD16+ 
monocyten in de circulatie van de transplantatie patiënt significant geassocieerd is met 
hoger risico op afstoting, kortere afstotingsvrije overleving en mogelijk kan dienen als een 
vroege biomarker om afstoting te voorspellen na transplantatie. 
In hoofdstuk 5 toetsten we of de expressie van bepaalde microRNAs onderscheid kan 
maken tussen de verschillende vormen van afstoting. Hiertoe zijn microRNA profielen van 
31 nierbiopten vergeleken met de a-aABMR versus aTCMR status en de a-aABMR versus 
c-aABMR status. Tevens is er een pathway analyse uitgevoerd om inzicht te krijgen in de 
betrokken eiwitten die gereguleerd worden door specifieke microRNAs welke een rol 
kunnen spelen in het afstotingsproces. Tussen a-aABMR en aTCMR werden er 55 significant 
verschillende microRNAs gevonden. Hierbij werd microRNA-100-5p geïdentificeerd als de 
meest significante en dus als belangrijkste. Vanuit de literatuur is bekend dat microRNA-
100-5p de expressie van CD209 (DC-SIGN) reguleert; dit eiwit komt tot expressie in zowel 
macrofagen als dendritische cellen en welke beide bijdragen aan het afstotingsproces. De 
microRNAs die wij in deze studie hebben gevonden zijn allen betrokken bij immuun en/
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of ontstekingsprocessen, en dus compatibel met hun betrokkenheid bij de anti-donor 
response. De microRNAs hebben uiteindelijk via regulatie van productie en functie van 
eiwitten allen een rol in de communicatie tussen verschillende typen immuun cellen zoals 
lymfocyten, macrofagen, NK cellen en dendritische cellen. Er zijn zeker nog meer studies 
nodig om in andere cohorten en met name ook in biopten zonder tekenen van afstoting 
onze eerste bevindingen te valideren. Daarnaast natuurlijk ook om te bestuderen of er 
specifieke microRNAs geassocieerd zijn met het optreden van a-aABMR of aTCMR welke 
een toegevoegde waarde kan hebben bij de afstotingsdiagnostiek.
Omdat interferon-gamma een belangrijke rol speelt in de aangeboren en verworven immuniteit 
hebben wij in hoofdstuk 6 onderzocht of monocyten deze cytokine kunnen produceren. 
Voor deze studie hebben wij bloed van gezonde personen en niertransplantatiepatiënten 
die immunosuppressiva gebruiken, bestudeerd. Wanneer de CD14+ monocyten werden 
gestimuleerd met LPS (lipopolysachariden) werden de mRNA niveaus van IFNγ eiwit maar 
ook het eiwit zelf verhoogd tot expressie gebracht in monocyten van gezonde personen 
en van de transplantatiepatiënten. Deze resultaten laten zien dat monocyten de capaciteit 
hebben om IFNγ te produceren.
In hoofdstuk 7, bediscussiëren wij de effecten van de op dit moment voorgeschreven 
afweerremmende geneesmiddelen op monocyten en macrofagen alsmede de ontwikkeling 
van nieuwe immunosuppressiva voor de transplantatiegeneeskunde. Na het lezen van de 
literatuur werd duidelijk dat er weinig bekend is over het effect van immunosuppressiva op 
monocyten – macrofagen functies. Er is bewijs dat de afweerremmende geneesmiddelen 
zoals mycofeno-laat-mofetil (MMF) en mechanistic target of rapamycin (mTOR) remmers 
in beperkte mate een remmend effect hebben op monocyten functies. Ook calcineurine 
remmers (CNIs) remmen de activiteit van monocyten, maar minder sterk dan die van T 
cellen. De effecten van immunosuppressiva op monocyten – macrofagen functies zijn onder 
andere remming van cytokine transcriptie en productie en remming van de migratie van 
deze cellen naar de plek van afstoting/ontsteking. Voorstellen voor nieuwe studies worden 
besproken die betrekking hebben op het gebruik van geneesmiddelen die monocyten 
en macrofagen remmen. Idealiter, deze nieuwe geneesmiddelen moeten de functie 
van monocyten en macrofagen beter onderdrukken dan de huidige medicatie. Ook het 
ontwikkelen van een specifiek afleveringssysteem met behulp van lipide vesicles en het 
manipuleren van het micromilieu en polarisatie van monocyten tot een anti-ontsteking 
fenotype zijn bediscussieerd. Het meest ideale scenario zou de ontwikkeling van een 
nieuw immunosuppressivum zijn die op meerdere punten in de activatie cascade de voor 
afstotingsreactie verantwoordelijke afweercellen kan remmen en daarmee afstoting kan 
voorkomen dan wel genezen. 
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Conclusies
De beschreven onderzoeken in deze dissertatie tonen aan dat monocyten en macrofagen 
een belangrijke rol spelen in zowel TCMR als ABMR. Zo hebben wij aangetoond dat M2 
macrofagen en CD16+ monocyten betrokken zijn bij acute afstoting van het harttransplantaat, 
en dat dit mogelijk leidt tot blijvende schade welke 1-jaar na afstoting terug werd gevonden. 
Tevens vonden wij in de niertransplantatie patiënten dat een hoog aantal circulerende 
CD16+ monocyten een grotere kans op afstoting kan voorspellen. Zo ook de infiltratie 
van deze CD16+ monocyten naar de afstotende nier tezamen met de aanwezigheid van 
M2 macrofagen in specifieke compartimenten een indicatie kunnen geven van het soort 
afstoting. Tevens toonden wij aan dat de huidige afweerremmende middelen niet goed de 
monocyten – macrofagen functies kunnen onderdrukken. 
Onze belangrijkste bevinding uit al deze studies is dat CD16+ monocyten en hun verder 
gedifferentieerde vorm M2 macrofagen een belangrijke rol (als zowel pro-inflammatoir als 
mede anti-inflammatoir) spelen in het afstotingsmechanisme. Gezien deze bevindingen, 
moeten wij: testen ontwikkelen gebaseerd op de functies van monocyten – macrofagen welke 
de afstotingsdiagnostiek kunnen ondersteunen. Dit moet leiden tot het eerder traceren van 
patiënten met een hoog risico op afstoting. Deze patiënten moeten afstotingsremmende 
geneesmiddelen voorgeschreven krijgen die juist de functies monocyten en macrofagen 
beter kunnen onderdrukken waarmee de afstotingsreactie kan worden voorkomen. 
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